WO2005087710A1 - アミノフェニルプロパン酸誘導体 - Google Patents
アミノフェニルプロパン酸誘導体 Download PDFInfo
- Publication number
- WO2005087710A1 WO2005087710A1 PCT/JP2005/004872 JP2005004872W WO2005087710A1 WO 2005087710 A1 WO2005087710 A1 WO 2005087710A1 JP 2005004872 W JP2005004872 W JP 2005004872W WO 2005087710 A1 WO2005087710 A1 WO 2005087710A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- optionally substituted
- compound
- ring
- hydrogen atom
- Prior art date
Links
- HTCSFFGLRQDZDE-UHFFFAOYSA-N 2-azaniumyl-2-phenylpropanoate Chemical class OC(=O)C(N)(C)C1=CC=CC=C1 HTCSFFGLRQDZDE-UHFFFAOYSA-N 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 475
- 239000003814 drug Substances 0.000 claims abstract description 63
- 150000003839 salts Chemical class 0.000 claims abstract description 48
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 31
- 102100026148 Free fatty acid receptor 1 Human genes 0.000 claims abstract description 27
- 101000912510 Homo sapiens Free fatty acid receptor 1 Proteins 0.000 claims abstract description 27
- 229940002612 prodrug Drugs 0.000 claims abstract description 25
- 239000000651 prodrug Substances 0.000 claims abstract description 25
- -1 {2 ', 6'-Dimethyl-4'-[3- (2-oxopyrrolidine-1-yl) propoxy] biphenyl-3-yl) methyl Chemical group 0.000 claims description 276
- 125000000217 alkyl group Chemical group 0.000 claims description 139
- 125000003545 alkoxy group Chemical group 0.000 claims description 110
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 104
- 125000001424 substituent group Chemical group 0.000 claims description 89
- 125000005843 halogen group Chemical group 0.000 claims description 77
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 73
- 238000000034 method Methods 0.000 claims description 64
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 60
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 55
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 55
- 125000003277 amino group Chemical group 0.000 claims description 45
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 40
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 30
- 235000019260 propionic acid Nutrition 0.000 claims description 21
- 125000004429 atom Chemical group 0.000 claims description 20
- 229910052760 oxygen Inorganic materials 0.000 claims description 19
- 125000002252 acyl group Chemical group 0.000 claims description 18
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 18
- 125000002947 alkylene group Chemical group 0.000 claims description 17
- 241000124008 Mammalia Species 0.000 claims description 13
- 125000000335 thiazolyl group Chemical group 0.000 claims description 13
- 229940122199 Insulin secretagogue Drugs 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 11
- 125000004122 cyclic group Chemical group 0.000 claims description 11
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 11
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical group C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 claims description 10
- 230000003914 insulin secretion Effects 0.000 claims description 10
- 125000006850 spacer group Chemical group 0.000 claims description 10
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 claims description 9
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 9
- 230000001105 regulatory effect Effects 0.000 claims description 8
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 7
- 125000001041 indolyl group Chemical group 0.000 claims description 7
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 claims description 7
- 125000001624 naphthyl group Chemical group 0.000 claims description 7
- 125000005750 substituted cyclic group Chemical group 0.000 claims description 7
- 102000005962 receptors Human genes 0.000 claims description 6
- 108020003175 receptors Proteins 0.000 claims description 6
- 125000005044 dihydroquinolinyl group Chemical group N1(CC=CC2=CC=CC=C12)* 0.000 claims description 5
- 230000036961 partial effect Effects 0.000 claims description 4
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical group C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 3
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 3
- 125000006125 ethylsulfonyl group Chemical group 0.000 claims description 3
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 claims description 3
- 229940017219 methyl propionate Drugs 0.000 claims description 2
- 230000011987 methylation Effects 0.000 claims description 2
- 238000007069 methylation reaction Methods 0.000 claims description 2
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 34
- 229940124597 therapeutic agent Drugs 0.000 abstract description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
- 201000010099 disease Diseases 0.000 abstract description 9
- 230000003449 preventive effect Effects 0.000 abstract description 6
- 230000001575 pathological effect Effects 0.000 abstract description 2
- 230000001270 agonistic effect Effects 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 434
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 272
- 239000000243 solution Substances 0.000 description 161
- 238000006243 chemical reaction Methods 0.000 description 158
- 239000000203 mixture Substances 0.000 description 125
- 230000002829 reductive effect Effects 0.000 description 100
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 90
- 238000001819 mass spectrum Methods 0.000 description 88
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 82
- 238000010898 silica gel chromatography Methods 0.000 description 76
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 73
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 72
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 71
- 239000003921 oil Substances 0.000 description 71
- 235000019198 oils Nutrition 0.000 description 71
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 54
- 239000013078 crystal Substances 0.000 description 54
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 51
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 51
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 50
- 235000002639 sodium chloride Nutrition 0.000 description 48
- 239000002904 solvent Substances 0.000 description 48
- 239000012230 colorless oil Substances 0.000 description 47
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 43
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 42
- 125000000623 heterocyclic group Chemical group 0.000 description 34
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 33
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 32
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 32
- 229910052757 nitrogen Inorganic materials 0.000 description 31
- 239000000706 filtrate Substances 0.000 description 30
- 239000002585 base Substances 0.000 description 29
- 239000011541 reaction mixture Substances 0.000 description 29
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 28
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 28
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 28
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 27
- 238000001816 cooling Methods 0.000 description 26
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 24
- 238000001914 filtration Methods 0.000 description 24
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 23
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 22
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 22
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- 229910000027 potassium carbonate Inorganic materials 0.000 description 21
- 235000011181 potassium carbonates Nutrition 0.000 description 21
- 238000003756 stirring Methods 0.000 description 21
- 238000002360 preparation method Methods 0.000 description 20
- 235000011054 acetic acid Nutrition 0.000 description 19
- 239000002253 acid Substances 0.000 description 19
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 18
- 125000004414 alkyl thio group Chemical group 0.000 description 18
- 239000003054 catalyst Substances 0.000 description 18
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 18
- 229940095102 methyl benzoate Drugs 0.000 description 17
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 16
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 16
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 16
- 239000008103 glucose Substances 0.000 description 16
- 229910052751 metal Inorganic materials 0.000 description 16
- 239000002184 metal Substances 0.000 description 16
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 15
- 125000000753 cycloalkyl group Chemical group 0.000 description 15
- 125000004433 nitrogen atom Chemical group N* 0.000 description 15
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 14
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 13
- 239000007864 aqueous solution Substances 0.000 description 13
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 13
- 239000012044 organic layer Substances 0.000 description 13
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 13
- 229920006395 saturated elastomer Polymers 0.000 description 13
- 239000012312 sodium hydride Substances 0.000 description 13
- 229910000104 sodium hydride Inorganic materials 0.000 description 13
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 12
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 12
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 12
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 12
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
- 229910052783 alkali metal Inorganic materials 0.000 description 12
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 12
- 125000004432 carbon atom Chemical group C* 0.000 description 12
- 229910052739 hydrogen Inorganic materials 0.000 description 12
- 239000001257 hydrogen Substances 0.000 description 12
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 12
- 229910000029 sodium carbonate Inorganic materials 0.000 description 12
- 229910052717 sulfur Inorganic materials 0.000 description 12
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- 206010056997 Impaired fasting glucose Diseases 0.000 description 11
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 11
- 229910052799 carbon Inorganic materials 0.000 description 11
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 230000035484 reaction time Effects 0.000 description 11
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 11
- 235000017557 sodium bicarbonate Nutrition 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 10
- 238000005984 hydrogenation reaction Methods 0.000 description 10
- 238000006722 reduction reaction Methods 0.000 description 10
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 10
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 9
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 9
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 9
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 9
- 150000004945 aromatic hydrocarbons Chemical group 0.000 description 9
- 229930195733 hydrocarbon Natural products 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- 239000012299 nitrogen atmosphere Substances 0.000 description 9
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 9
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 9
- 125000004434 sulfur atom Chemical group 0.000 description 9
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 8
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 8
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 8
- 239000012300 argon atmosphere Substances 0.000 description 8
- 229910052785 arsenic Inorganic materials 0.000 description 8
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 125000005842 heteroatom Chemical group 0.000 description 8
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 8
- 125000004076 pyridyl group Chemical group 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 8
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 7
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 7
- 150000001408 amides Chemical class 0.000 description 7
- 235000019270 ammonium chloride Nutrition 0.000 description 7
- 229910052786 argon Inorganic materials 0.000 description 7
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 7
- 239000012267 brine Substances 0.000 description 7
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- 125000002541 furyl group Chemical group 0.000 description 7
- 229910052736 halogen Inorganic materials 0.000 description 7
- 150000002367 halogens Chemical class 0.000 description 7
- 239000012280 lithium aluminium hydride Substances 0.000 description 7
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 7
- 125000002950 monocyclic group Chemical group 0.000 description 7
- 125000004430 oxygen atom Chemical group O* 0.000 description 7
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- 235000011121 sodium hydroxide Nutrition 0.000 description 7
- 125000004149 thio group Chemical group *S* 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 6
- 208000002705 Glucose Intolerance Diseases 0.000 description 6
- 208000031226 Hyperlipidaemia Diseases 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 6
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 125000003710 aryl alkyl group Chemical group 0.000 description 6
- 239000012298 atmosphere Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 6
- DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 6
- 150000001721 carbon Chemical group 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 238000006460 hydrolysis reaction Methods 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 239000002198 insoluble material Substances 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 229910052744 lithium Inorganic materials 0.000 description 6
- 150000007524 organic acids Chemical class 0.000 description 6
- 125000002971 oxazolyl group Chemical group 0.000 description 6
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 201000009104 prediabetes syndrome Diseases 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000012279 sodium borohydride Substances 0.000 description 6
- 229910000033 sodium borohydride Inorganic materials 0.000 description 6
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 5
- GPTVQTPMFOLLOA-UHFFFAOYSA-N 1-chloro-2-ethoxyethane Chemical compound CCOCCCl GPTVQTPMFOLLOA-UHFFFAOYSA-N 0.000 description 5
- 239000004215 Carbon black (E152) Substances 0.000 description 5
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 5
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 5
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 5
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 5
- 229910052782 aluminium Inorganic materials 0.000 description 5
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 5
- 229910052794 bromium Inorganic materials 0.000 description 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000003638 chemical reducing agent Substances 0.000 description 5
- 230000032050 esterification Effects 0.000 description 5
- 238000005886 esterification reaction Methods 0.000 description 5
- 150000008282 halocarbons Chemical class 0.000 description 5
- 150000002430 hydrocarbons Chemical group 0.000 description 5
- 125000000842 isoxazolyl group Chemical group 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 5
- 125000006574 non-aromatic ring group Chemical group 0.000 description 5
- 150000007530 organic bases Chemical class 0.000 description 5
- 229910052763 palladium Inorganic materials 0.000 description 5
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 5
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 5
- 239000011591 potassium Substances 0.000 description 5
- 229910052700 potassium Inorganic materials 0.000 description 5
- 229960003975 potassium Drugs 0.000 description 5
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 125000003396 thiol group Chemical group [H]S* 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 4
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 4
- NXXYKOUNUYWIHA-UHFFFAOYSA-N 2,6-Dimethylphenol Chemical compound CC1=CC=CC(C)=C1O NXXYKOUNUYWIHA-UHFFFAOYSA-N 0.000 description 4
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 4
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 4
- UOTMHAOCAJROQF-UHFFFAOYSA-N 3-bromo-4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1Br UOTMHAOCAJROQF-UHFFFAOYSA-N 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 4
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N Methyl ethyl ketone Natural products CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 4
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 4
- 229940100389 Sulfonylurea Drugs 0.000 description 4
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 4
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 4
- 150000008041 alkali metal carbonates Chemical class 0.000 description 4
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 4
- 235000019445 benzyl alcohol Nutrition 0.000 description 4
- 229960004217 benzyl alcohol Drugs 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 125000004093 cyano group Chemical group *C#N 0.000 description 4
- 150000001925 cycloalkenes Chemical class 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 150000002170 ethers Chemical class 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 4
- 229940093915 gynecological organic acid Drugs 0.000 description 4
- 230000002140 halogenating effect Effects 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 125000001786 isothiazolyl group Chemical group 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- 229910000103 lithium hydride Inorganic materials 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 4
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 4
- 150000007522 mineralic acids Chemical class 0.000 description 4
- 235000005985 organic acids Nutrition 0.000 description 4
- 238000002953 preparative HPLC Methods 0.000 description 4
- 238000010926 purge Methods 0.000 description 4
- 125000005554 pyridyloxy group Chemical group 0.000 description 4
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 4
- 229940044601 receptor agonist Drugs 0.000 description 4
- 239000000018 receptor agonist Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 159000000000 sodium salts Chemical class 0.000 description 4
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 4
- 150000003462 sulfoxides Chemical class 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 229930192474 thiophene Natural products 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 4
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 4
- 229910052725 zinc Inorganic materials 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 3
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 3
- OXBLVCZKDOZZOJ-UHFFFAOYSA-N 2,3-Dihydrothiophene Chemical compound C1CC=CS1 OXBLVCZKDOZZOJ-UHFFFAOYSA-N 0.000 description 3
- CKSCMRNFDBWFND-UHFFFAOYSA-N 4-hydroxy-2,3-dihydroinden-1-one Chemical compound OC1=CC=CC2=C1CCC2=O CKSCMRNFDBWFND-UHFFFAOYSA-N 0.000 description 3
- 125000003341 7 membered heterocyclic group Chemical group 0.000 description 3
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 3
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 3
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 3
- OGALXJIOJZXBBP-UHFFFAOYSA-N [4-(chloromethyl)phenyl]methanol Chemical compound OCC1=CC=C(CCl)C=C1 OGALXJIOJZXBBP-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000000883 anti-obesity agent Substances 0.000 description 3
- 239000003472 antidiabetic agent Substances 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229940125710 antiobesity agent Drugs 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 3
- 125000005604 azodicarboxylate group Chemical group 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 3
- 239000000920 calcium hydroxide Substances 0.000 description 3
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 150000001924 cycloalkanes Chemical class 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 3
- 229910052808 lithium carbonate Inorganic materials 0.000 description 3
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 3
- 239000000347 magnesium hydroxide Substances 0.000 description 3
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229910052987 metal hydride Inorganic materials 0.000 description 3
- 150000004681 metal hydrides Chemical class 0.000 description 3
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 3
- FBZUARPUEPDXQU-UHFFFAOYSA-N methyl 4-(bromomethyl)-3-propan-2-yloxybenzoate Chemical compound COC(=O)C1=CC=C(CBr)C(OC(C)C)=C1 FBZUARPUEPDXQU-UHFFFAOYSA-N 0.000 description 3
- NLWBJPPMPLPZIE-UHFFFAOYSA-N methyl 4-(bromomethyl)benzoate Chemical compound COC(=O)C1=CC=C(CBr)C=C1 NLWBJPPMPLPZIE-UHFFFAOYSA-N 0.000 description 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 125000006518 morpholino carbonyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])N(C(*)=O)C1([H])[H] 0.000 description 3
- 125000002757 morpholinyl group Chemical group 0.000 description 3
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 3
- 229960000698 nateglinide Drugs 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 125000003566 oxetanyl group Chemical group 0.000 description 3
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 3
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 3
- 238000006268 reductive amination reaction Methods 0.000 description 3
- 229930195734 saturated hydrocarbon Natural products 0.000 description 3
- 235000009518 sodium iodide Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 3
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 239000003451 thiazide diuretic agent Substances 0.000 description 3
- 150000003573 thiols Chemical class 0.000 description 3
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- ATFFDSGLYMTUGH-UHFFFAOYSA-N (1-oxo-2,3-dihydroinden-4-yl) trifluoromethanesulfonate Chemical compound FC(F)(F)S(=O)(=O)OC1=CC=CC2=C1CCC2=O ATFFDSGLYMTUGH-UHFFFAOYSA-N 0.000 description 2
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 2
- HJBGZJMKTOMQRR-UHFFFAOYSA-N (3-formylphenyl)boronic acid Chemical compound OB(O)C1=CC=CC(C=O)=C1 HJBGZJMKTOMQRR-UHFFFAOYSA-N 0.000 description 2
- HFAYFIJQCXYQFG-DUXPYHPUSA-N (E)-3-(4-amino-2-fluorophenyl)prop-2-enoic acid Chemical compound NC1=CC=C(\C=C\C(O)=O)C(F)=C1 HFAYFIJQCXYQFG-DUXPYHPUSA-N 0.000 description 2
- KZKRRZFCAYOXQE-UHFFFAOYSA-N 1$l^{2}-azinane Chemical group C1CC[N]CC1 KZKRRZFCAYOXQE-UHFFFAOYSA-N 0.000 description 2
- FTDIXCPTGXEVPL-UHFFFAOYSA-N 1-(2-ethoxyethylsulfanyl)-3,5-dimethylbenzene Chemical compound CCOCCSC1=CC(C)=CC(C)=C1 FTDIXCPTGXEVPL-UHFFFAOYSA-N 0.000 description 2
- AVFZOVWCLRSYKC-UHFFFAOYSA-N 1-methylpyrrolidine Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 2
- IBXNCJKFFQIKKY-UHFFFAOYSA-N 1-pentyne Chemical compound CCCC#C IBXNCJKFFQIKKY-UHFFFAOYSA-N 0.000 description 2
- KLAQSPUVCDBEGF-UHFFFAOYSA-N 2,3,5,6-tetramethylphenol Chemical compound CC1=CC(C)=C(C)C(O)=C1C KLAQSPUVCDBEGF-UHFFFAOYSA-N 0.000 description 2
- OGRAOKJKVGDSFR-UHFFFAOYSA-N 2,3,5-trimethylphenol Chemical compound CC1=CC(C)=C(C)C(O)=C1 OGRAOKJKVGDSFR-UHFFFAOYSA-N 0.000 description 2
- FPZWZCWUIYYYBU-UHFFFAOYSA-N 2-(2-ethoxyethoxy)ethyl acetate Chemical group CCOCCOCCOC(C)=O FPZWZCWUIYYYBU-UHFFFAOYSA-N 0.000 description 2
- RTIBXWDANRAAJR-UHFFFAOYSA-N 2-(4-bromo-3,5-dimethylphenoxy)-6-methoxypyridine Chemical compound COC1=CC=CC(OC=2C=C(C)C(Br)=C(C)C=2)=N1 RTIBXWDANRAAJR-UHFFFAOYSA-N 0.000 description 2
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 2
- XNMQEEKYCVKGBD-UHFFFAOYSA-N 2-butyne Chemical compound CC#CC XNMQEEKYCVKGBD-UHFFFAOYSA-N 0.000 description 2
- BHNHHSOHWZKFOX-UHFFFAOYSA-N 2-methyl-1H-indole Chemical compound C1=CC=C2NC(C)=CC2=C1 BHNHHSOHWZKFOX-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- JXHKUYQCEJILEI-UHFFFAOYSA-N 3,5-diphenyl-1h-pyrazole Chemical compound C=1C(C=2C=CC=CC=2)=NNC=1C1=CC=CC=C1 JXHKUYQCEJILEI-UHFFFAOYSA-N 0.000 description 2
- UEQDCVLVDQENIN-UHFFFAOYSA-N 3,5-ditert-butyl-1h-pyrazole Chemical compound CC(C)(C)C=1C=C(C(C)(C)C)NN=1 UEQDCVLVDQENIN-UHFFFAOYSA-N 0.000 description 2
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 2
- RGTRSFUXNGBZKU-UHFFFAOYSA-N 3-(4-hydroxy-2,6-dimethylphenyl)benzaldehyde Chemical compound CC1=CC(O)=CC(C)=C1C1=CC=CC(C=O)=C1 RGTRSFUXNGBZKU-UHFFFAOYSA-N 0.000 description 2
- GHYVEVIEZLCMLC-UHFFFAOYSA-N 3-[2-fluoro-4-[[4-[[3-methylbutyl-[4-[4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]amino]methyl]phenyl]methylamino]phenyl]propanoic acid Chemical compound N=1C(C=2C=CC(=CC=2)C(F)(F)F)=CSC=1N(CCC(C)C)CC(C=C1)=CC=C1CNC1=CC=C(CCC(O)=O)C(F)=C1 GHYVEVIEZLCMLC-UHFFFAOYSA-N 0.000 description 2
- DGENZVKCTGIDRZ-UHFFFAOYSA-N 3-[4-[(3-phenoxyphenyl)methylamino]phenyl]propanoic acid Chemical compound C1=CC(CCC(=O)O)=CC=C1NCC1=CC=CC(OC=2C=CC=CC=2)=C1 DGENZVKCTGIDRZ-UHFFFAOYSA-N 0.000 description 2
- WZFZJEPHYDDFCT-UHFFFAOYSA-N 3-chloro-2-methyl-n-[4-[2-(3-oxomorpholin-4-yl)ethyl]-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound CC1=C(Cl)C=CC=C1S(=O)(=O)NC1=NC(CCN2C(COCC2)=O)=CS1 WZFZJEPHYDDFCT-UHFFFAOYSA-N 0.000 description 2
- RZDALYRWHLEJRP-UHFFFAOYSA-N 4-(2,6-dimethylphenyl)-2,3-dihydroinden-1-one Chemical compound CC1=CC=CC(C)=C1C1=CC=CC2=C1CCC2=O RZDALYRWHLEJRP-UHFFFAOYSA-N 0.000 description 2
- QBQLYIISSRXYKL-UHFFFAOYSA-N 4-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-1,2-oxazolidine-3,5-dione Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CCOC(C=C1)=CC=C1CC1C(=O)NOC1=O QBQLYIISSRXYKL-UHFFFAOYSA-N 0.000 description 2
- WMUWDPLTTLJNPE-UHFFFAOYSA-N 4-bromo-3,5-dimethylphenol Chemical compound CC1=CC(O)=CC(C)=C1Br WMUWDPLTTLJNPE-UHFFFAOYSA-N 0.000 description 2
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 description 2
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 208000010444 Acidosis Diseases 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229910015900 BF3 Inorganic materials 0.000 description 2
- 125000005914 C6-C14 aryloxy group Chemical group 0.000 description 2
- IKXBNYZGUJZOGU-UHFFFAOYSA-N CC(C)(C)C1=NN(CC2=CC=C(COCOC)C=C2)C(C(O)=O)=C1 Chemical compound CC(C)(C)C1=NN(CC2=CC=C(COCOC)C=C2)C(C(O)=O)=C1 IKXBNYZGUJZOGU-UHFFFAOYSA-N 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 2
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 239000005749 Copper compound Substances 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
- 206010012655 Diabetic complications Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 108010011459 Exenatide Proteins 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 229940125827 GPR40 agonist Drugs 0.000 description 2
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- SFBODOKJTYAUCM-UHFFFAOYSA-N Ipriflavone Chemical compound C=1C(OC(C)C)=CC=C(C2=O)C=1OC=C2C1=CC=CC=C1 SFBODOKJTYAUCM-UHFFFAOYSA-N 0.000 description 2
- 208000007976 Ketosis Diseases 0.000 description 2
- 208000020358 Learning disease Diseases 0.000 description 2
- 239000002841 Lewis acid Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 208000001344 Macular Edema Diseases 0.000 description 2
- 206010025415 Macular oedema Diseases 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 241000269799 Perca fluviatilis Species 0.000 description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- 201000001880 Sexual dysfunction Diseases 0.000 description 2
- 102000000070 Sodium-Glucose Transport Proteins Human genes 0.000 description 2
- 108010080361 Sodium-Glucose Transport Proteins Proteins 0.000 description 2
- 229940123051 Somatostatin receptor agonist Drugs 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 206010046543 Urinary incontinence Diseases 0.000 description 2
- LXGQHDUCNDGTDB-PAMNCVQHSA-N [2-[(8s,9r,10s,13s,14s,16s,17r)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate;[2-[(8s,9r,10s,13s,14s,16s,17r)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11, Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]1(C)CC2O.C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COP(O)(O)=O)(O)[C@@]1(C)CC2O LXGQHDUCNDGTDB-PAMNCVQHSA-N 0.000 description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 2
- WJGAPUXHSQQWQF-UHFFFAOYSA-N acetic acid;hydrochloride Chemical compound Cl.CC(O)=O WJGAPUXHSQQWQF-UHFFFAOYSA-N 0.000 description 2
- 230000007950 acidosis Effects 0.000 description 2
- 208000026545 acidosis disease Diseases 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 description 2
- 229960002535 alfacalcidol Drugs 0.000 description 2
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 2
- 150000008046 alkali metal hydrides Chemical class 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 2
- 125000005153 alkyl sulfamoyl group Chemical group 0.000 description 2
- 229960003318 alteplase Drugs 0.000 description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 229940005524 anti-dementia drug Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940030600 antihypertensive agent Drugs 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 229960004676 antithrombotic agent Drugs 0.000 description 2
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 2
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 2
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 2
- 229910001863 barium hydroxide Inorganic materials 0.000 description 2
- 125000005605 benzo group Chemical group 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 229960002890 beraprost Drugs 0.000 description 2
- YTCZZXIRLARSET-VJRSQJMHSA-M beraprost sodium Chemical compound [Na+].O([C@H]1C[C@@H](O)[C@@H]([C@@H]21)/C=C/[C@@H](O)C(C)CC#CC)C1=C2C=CC=C1CCCC([O-])=O YTCZZXIRLARSET-VJRSQJMHSA-M 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000006268 biphenyl-3-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C([H])C(*)=C([H])C([H])=C1[H] 0.000 description 2
- YXVFYQXJAXKLAK-UHFFFAOYSA-N biphenyl-4-ol Chemical compound C1=CC(O)=CC=C1C1=CC=CC=C1 YXVFYQXJAXKLAK-UHFFFAOYSA-N 0.000 description 2
- UORVGPXVDQYIDP-BJUDXGSMSA-N borane Chemical class [10BH3] UORVGPXVDQYIDP-BJUDXGSMSA-N 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- ZQNPDAVSHFGLIQ-UHFFFAOYSA-N calcium;hydrate Chemical compound O.[Ca] ZQNPDAVSHFGLIQ-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 230000006315 carbonylation Effects 0.000 description 2
- 238000005810 carbonylation reaction Methods 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 150000001880 copper compounds Chemical class 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 208000033679 diabetic kidney disease Diseases 0.000 description 2
- 150000005690 diesters Chemical class 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- HPYNZHMRTTWQTB-UHFFFAOYSA-N dimethylpyridine Natural products CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 2
- 229960001348 estriol Drugs 0.000 description 2
- 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 2
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000000446 fuel Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 2
- 229960004346 glimepiride Drugs 0.000 description 2
- 230000026030 halogenation Effects 0.000 description 2
- 238000005658 halogenation reaction Methods 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 2
- 150000004678 hydrides Chemical class 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 229960005431 ipriflavone Drugs 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 230000004140 ketosis Effects 0.000 description 2
- 201000003723 learning disability Diseases 0.000 description 2
- 150000007517 lewis acids Chemical class 0.000 description 2
- AFRJJFRNGGLMDW-UHFFFAOYSA-N lithium amide Chemical class [Li+].[NH2-] AFRJJFRNGGLMDW-UHFFFAOYSA-N 0.000 description 2
- WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 201000010230 macular retinal edema Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 238000010576 medium-pressure preparative liquid chromatography Methods 0.000 description 2
- 229910000000 metal hydroxide Inorganic materials 0.000 description 2
- 150000004692 metal hydroxides Chemical class 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- LXHNQRGWWMORLQ-UHFFFAOYSA-N methyl 3-(4-aminophenyl)propanoate Chemical compound COC(=O)CCC1=CC=C(N)C=C1 LXHNQRGWWMORLQ-UHFFFAOYSA-N 0.000 description 2
- GCSINTLJUNXLLU-UHFFFAOYSA-N methyl 3-hydroxy-4-methylbenzoate Chemical compound COC(=O)C1=CC=C(C)C(O)=C1 GCSINTLJUNXLLU-UHFFFAOYSA-N 0.000 description 2
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- WPGGHFDDFPHPOB-BBWFWOEESA-N mitiglinide Chemical compound C([C@@H](CC(=O)N1C[C@@H]2CCCC[C@@H]2C1)C(=O)O)C1=CC=CC=C1 WPGGHFDDFPHPOB-BBWFWOEESA-N 0.000 description 2
- 229960003365 mitiglinide Drugs 0.000 description 2
- 108010075698 monteplase Proteins 0.000 description 2
- 229950005805 monteplase Drugs 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- OQJBFFCUFALWQL-UHFFFAOYSA-N n-(piperidine-1-carbonylimino)piperidine-1-carboxamide Chemical compound C1CCCCN1C(=O)N=NC(=O)N1CCCCC1 OQJBFFCUFALWQL-UHFFFAOYSA-N 0.000 description 2
- 125000005029 naphthylthio group Chemical group C1(=CC=CC2=CC=CC=C12)S* 0.000 description 2
- 229950002774 nateplase Drugs 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- PKWDZWYVIHVNKS-UHFFFAOYSA-N netoglitazone Chemical compound FC1=CC=CC=C1COC1=CC=C(C=C(CC2C(NC(=O)S2)=O)C=C2)C2=C1 PKWDZWYVIHVNKS-UHFFFAOYSA-N 0.000 description 2
- 150000002816 nickel compounds Chemical class 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 238000007410 oral glucose tolerance test Methods 0.000 description 2
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 150000002941 palladium compounds Chemical class 0.000 description 2
- 108010085108 pamiteplase Proteins 0.000 description 2
- 229950003603 pamiteplase Drugs 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 2
- 150000003003 phosphines Chemical class 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 2
- 229910000105 potassium hydride Inorganic materials 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 2
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 229960002354 repaglinide Drugs 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 231100000872 sexual dysfunction Toxicity 0.000 description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 2
- WMOVHXAZOJBABW-UHFFFAOYSA-N tert-butyl acetate Chemical compound CC(=O)OC(C)(C)C WMOVHXAZOJBABW-UHFFFAOYSA-N 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- CXGTZJYQWSUFET-IBGZPJMESA-N tesaglitazar Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCCC1=CC=C(OS(C)(=O)=O)C=C1 CXGTZJYQWSUFET-IBGZPJMESA-N 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 2
- 229910052718 tin Inorganic materials 0.000 description 2
- 125000004665 trialkylsilyl group Chemical group 0.000 description 2
- LMJSLTNSBFUCMU-UHFFFAOYSA-N trichlormethiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC(C(Cl)Cl)NS2(=O)=O LMJSLTNSBFUCMU-UHFFFAOYSA-N 0.000 description 2
- 229960004813 trichlormethiazide Drugs 0.000 description 2
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 2
- 125000005951 trifluoromethanesulfonyloxy group Chemical group 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- 229940061639 zonegran Drugs 0.000 description 2
- UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- WYRSGXAIHNMKOL-UHFFFAOYSA-N $l^{1}-sulfanylethane Chemical compound CC[S] WYRSGXAIHNMKOL-UHFFFAOYSA-N 0.000 description 1
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- KYLUAQBYONVMCP-UHFFFAOYSA-N (2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P KYLUAQBYONVMCP-UHFFFAOYSA-N 0.000 description 1
- NEQSWPCDHDQINX-MRXNPFEDSA-N (2R)-3-cyclopentyl-2-(4-methylsulfonylphenyl)-N-(2-thiazolyl)propanamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1[C@H](C(=O)NC=1SC=CN=1)CC1CCCC1 NEQSWPCDHDQINX-MRXNPFEDSA-N 0.000 description 1
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- KSDDQEGWVBODMD-OULINLAESA-N (2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-6-amino-2-[[(2S)-4-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-amino-3-sulfanylpropanoyl]amino]-4-carboxybutanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]hexanoyl]amino]-4-carboxybutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-4-oxobutanoyl]amino]-4-oxobutanoyl]amino]hexanoyl]amino]-3-hydroxybutanoyl]amino]-4-carboxybutanoyl]amino]hexanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CS)CC1=CC=CC=C1 KSDDQEGWVBODMD-OULINLAESA-N 0.000 description 1
- VLPIATFUUWWMKC-SNVBAGLBSA-N (2r)-1-(2,6-dimethylphenoxy)propan-2-amine Chemical compound C[C@@H](N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-SNVBAGLBSA-N 0.000 description 1
- WDQLRUYAYXDIFW-RWKIJVEZSA-N (2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 WDQLRUYAYXDIFW-RWKIJVEZSA-N 0.000 description 1
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 description 1
- KWSPYUOBNIMILB-SANMLTNESA-N (2s)-2-methyl-3-[4-[2-(5-methyl-2-thiophen-2-yl-1,3-oxazol-4-yl)ethoxy]phenyl]-2-phenoxypropanoic acid Chemical compound O([C@@](C)(CC1=CC=C(C=C1)OCCC=1N=C(OC=1C)C=1SC=CC=1)C(O)=O)C1=CC=CC=C1 KWSPYUOBNIMILB-SANMLTNESA-N 0.000 description 1
- WAAPEIZFCHNLKK-UFBFGSQYSA-N (2s,4s)-6-fluoro-2',5'-dioxospiro[2,3-dihydrochromene-4,4'-imidazolidine]-2-carboxamide Chemical compound C([C@H](OC1=CC=C(F)C=C11)C(=O)N)[C@@]21NC(=O)NC2=O WAAPEIZFCHNLKK-UFBFGSQYSA-N 0.000 description 1
- JUZCSXHYOWVCHI-UHFFFAOYSA-N (3-formylfuran-2-yl)boronic acid Chemical compound OB(O)C=1OC=CC=1C=O JUZCSXHYOWVCHI-UHFFFAOYSA-N 0.000 description 1
- AXKGIPZJYUNAIW-UHFFFAOYSA-N (4-aminophenyl)methanol Chemical compound NC1=CC=C(CO)C=C1 AXKGIPZJYUNAIW-UHFFFAOYSA-N 0.000 description 1
- COIQUVGFTILYGA-UHFFFAOYSA-N (4-hydroxyphenyl)boronic acid Chemical compound OB(O)C1=CC=C(O)C=C1 COIQUVGFTILYGA-UHFFFAOYSA-N 0.000 description 1
- ULVDFHLHKNJICZ-JVCXMKTPSA-N (4z)-4-[[4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]phenyl]methoxyimino]-4-phenylbutanoic acid Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1COC(C=C1)=CC=C1CO\N=C(\CCC(O)=O)C1=CC=CC=C1 ULVDFHLHKNJICZ-JVCXMKTPSA-N 0.000 description 1
- JRLCAABMCLNQKU-UHFFFAOYSA-N (5-methoxy-2-methylpyrazol-3-yl)methanol Chemical compound COC=1C=C(CO)N(C)N=1 JRLCAABMCLNQKU-UHFFFAOYSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 description 1
- IDFPQEHZYBXIFO-GFCCVEGCSA-N (R)-(4-fluoro-2-propylphenyl)-(1H-imidazol-2-yl)methanol Chemical compound CCCc1cc(F)ccc1[C@@H](O)c1ncc[nH]1 IDFPQEHZYBXIFO-GFCCVEGCSA-N 0.000 description 1
- SYTBZMRGLBWNTM-SNVBAGLBSA-N (R)-flurbiprofen Chemical compound FC1=CC([C@H](C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-SNVBAGLBSA-N 0.000 description 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- USVVENVKYJZFMW-ONEGZZNKSA-N (e)-carboxyiminocarbamic acid Chemical compound OC(=O)\N=N\C(O)=O USVVENVKYJZFMW-ONEGZZNKSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- FNQJDLTXOVEEFB-UHFFFAOYSA-N 1,2,3-benzothiadiazole Chemical compound C1=CC=C2SN=NC2=C1 FNQJDLTXOVEEFB-UHFFFAOYSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- FHGWEHGZBUBQKL-UHFFFAOYSA-N 1,2-benzothiazepine Chemical compound S1N=CC=CC2=CC=CC=C12 FHGWEHGZBUBQKL-UHFFFAOYSA-N 0.000 description 1
- QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 description 1
- YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 1
- WDCYWAQPCXBPJA-UHFFFAOYSA-N 1,3-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC([N+]([O-])=O)=C1 WDCYWAQPCXBPJA-UHFFFAOYSA-N 0.000 description 1
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical compound NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 description 1
- IHDKBHLTKNUCCW-UHFFFAOYSA-N 1,3-thiazole 1-oxide Chemical compound O=S1C=CN=C1 IHDKBHLTKNUCCW-UHFFFAOYSA-N 0.000 description 1
- SGUVLZREKBPKCE-UHFFFAOYSA-N 1,5-diazabicyclo[4.3.0]-non-5-ene Chemical compound C1CCN=C2CCCN21 SGUVLZREKBPKCE-UHFFFAOYSA-N 0.000 description 1
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 1
- KZEVSDGEBAJOTK-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[5-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CC=1OC(=NN=1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O KZEVSDGEBAJOTK-UHFFFAOYSA-N 0.000 description 1
- YIWGJFPJRAEKMK-UHFFFAOYSA-N 1-(2H-benzotriazol-5-yl)-3-methyl-8-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carbonyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound CN1C(=O)N(c2ccc3n[nH]nc3c2)C2(CCN(CC2)C(=O)c2cnc(NCc3cccc(OC(F)(F)F)c3)nc2)C1=O YIWGJFPJRAEKMK-UHFFFAOYSA-N 0.000 description 1
- WZRKSPFYXUXINF-UHFFFAOYSA-N 1-(bromomethyl)-4-methylbenzene Chemical compound CC1=CC=C(CBr)C=C1 WZRKSPFYXUXINF-UHFFFAOYSA-N 0.000 description 1
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- WSDSEIUBXJOEIQ-UHFFFAOYSA-N 1-[1-(3-ethoxyphenyl)-4-methylcyclohexyl]-4-phenylpiperazine;methanesulfonic acid Chemical compound CS(O)(=O)=O.CCOC1=CC=CC(C2(CCC(C)CC2)N2CCN(CC2)C=2C=CC=CC=2)=C1 WSDSEIUBXJOEIQ-UHFFFAOYSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- HHCLNZBCCQDVOQ-UHFFFAOYSA-N 1-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]pyrazol-3-yl]methyl]piperazin-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(N1CC2=C(CC1)NN=N2)=O)CN1C(CNCC1)=O HHCLNZBCCQDVOQ-UHFFFAOYSA-N 0.000 description 1
- CMIMBQIBIZZZHQ-UHFFFAOYSA-N 1-bromo-2-methylnaphthalene Chemical compound C1=CC=CC2=C(Br)C(C)=CC=C21 CMIMBQIBIZZZHQ-UHFFFAOYSA-N 0.000 description 1
- SVTSNKDDEXJEAM-UHFFFAOYSA-N 1-bromo-4-(2-ethoxyethoxy)-2,3,5,6-tetramethylbenzene Chemical compound CCOCCOC1=C(C)C(C)=C(Br)C(C)=C1C SVTSNKDDEXJEAM-UHFFFAOYSA-N 0.000 description 1
- CYNYIHKIEHGYOZ-UHFFFAOYSA-N 1-bromopropane Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 description 1
- RZTDESRVPFKCBH-UHFFFAOYSA-N 1-methyl-4-(4-methylphenyl)benzene Chemical group C1=CC(C)=CC=C1C1=CC=C(C)C=C1 RZTDESRVPFKCBH-UHFFFAOYSA-N 0.000 description 1
- QLAWAFBTLLCIIM-UHFFFAOYSA-N 1-naphthalen-1-ylsulfanylnaphthalene Chemical compound C1=CC=C2C(SC=3C4=CC=CC=C4C=CC=3)=CC=CC2=C1 QLAWAFBTLLCIIM-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- KMGXFPRSMVDSEC-UHFFFAOYSA-N 1-oxa-6-thiaspiro[2.5]octane Chemical compound C1OC11CCSCC1 KMGXFPRSMVDSEC-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- DUHQBKLTAVUXFF-FERBBOLQSA-N 192050-59-2 Chemical compound CS(O)(=O)=O.O=C1NC(=O)C2=C1C(C1=CC=CC=C11)=CN1CCO[C@H](CN(C)C)CCN1C3=CC=CC=C3C2=C1 DUHQBKLTAVUXFF-FERBBOLQSA-N 0.000 description 1
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 1
- ZKAMEFMDQNTDFK-UHFFFAOYSA-N 1h-imidazo[4,5-b]pyrazine Chemical compound C1=CN=C2NC=NC2=N1 ZKAMEFMDQNTDFK-UHFFFAOYSA-N 0.000 description 1
- UTQNKKSJPHTPBS-UHFFFAOYSA-N 2,2,2-trichloroethanone Chemical group ClC(Cl)(Cl)[C]=O UTQNKKSJPHTPBS-UHFFFAOYSA-N 0.000 description 1
- JWSUYSBONRNZRW-UHFFFAOYSA-N 2,2-dimethyl-1h-quinoline Chemical compound C1=CC=C2C=CC(C)(C)NC2=C1 JWSUYSBONRNZRW-UHFFFAOYSA-N 0.000 description 1
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 1
- YJUFGFXVASPYFQ-UHFFFAOYSA-N 2,3-dihydro-1-benzothiophene Chemical compound C1=CC=C2SCCC2=C1 YJUFGFXVASPYFQ-UHFFFAOYSA-N 0.000 description 1
- LWTIGYSPAXKMDG-UHFFFAOYSA-N 2,3-dihydro-1h-imidazole Chemical compound C1NC=CN1 LWTIGYSPAXKMDG-UHFFFAOYSA-N 0.000 description 1
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical group C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 1
- RLFNWAOMWYQWIJ-UHFFFAOYSA-N 2-(2,6-dimethylphenyl)propanoic acid Chemical compound OC(=O)C(C)C1=C(C)C=CC=C1C RLFNWAOMWYQWIJ-UHFFFAOYSA-N 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- JAJKJWPMIVZJAJ-UHFFFAOYSA-N 2-(4-bromo-3,5-dimethylphenoxy)-6-methylpyridine Chemical compound CC1=CC=CC(OC=2C=C(C)C(Br)=C(C)C=2)=N1 JAJKJWPMIVZJAJ-UHFFFAOYSA-N 0.000 description 1
- OTTZHAVKAVGASB-HYXAFXHYSA-N 2-Heptene Chemical compound CCCC\C=C/C OTTZHAVKAVGASB-HYXAFXHYSA-N 0.000 description 1
- IKOKHHBZFDFMJW-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-(2-morpholin-4-ylethoxy)pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)OCCN1CCOCC1 IKOKHHBZFDFMJW-UHFFFAOYSA-N 0.000 description 1
- WWSJZGAPAVMETJ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-ethoxypyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)OCC WWSJZGAPAVMETJ-UHFFFAOYSA-N 0.000 description 1
- ZYPDJSJJXZWZJJ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-piperidin-4-yloxypyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)OC1CCNCC1 ZYPDJSJJXZWZJJ-UHFFFAOYSA-N 0.000 description 1
- JQMFQLVAJGZSQS-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JQMFQLVAJGZSQS-UHFFFAOYSA-N 0.000 description 1
- JVKRKMWZYMKVTQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JVKRKMWZYMKVTQ-UHFFFAOYSA-N 0.000 description 1
- YGZFYDFBHIDIBH-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]icosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCC(CO)N(CCO)CCO YGZFYDFBHIDIBH-UHFFFAOYSA-N 0.000 description 1
- BJBCSGQLZQGGIQ-QGZVFWFLSA-N 2-acetamidoethyl (2r)-2-(4-chlorophenyl)-2-[3-(trifluoromethyl)phenoxy]acetate Chemical compound O([C@@H](C(=O)OCCNC(=O)C)C=1C=CC(Cl)=CC=1)C1=CC=CC(C(F)(F)F)=C1 BJBCSGQLZQGGIQ-QGZVFWFLSA-N 0.000 description 1
- IHIUEMIEYBSOJP-UHFFFAOYSA-N 2-bromo-5-(2-ethoxyethylsulfanyl)-1,3-dimethylbenzene Chemical compound CCOCCSC1=CC(C)=C(Br)C(C)=C1 IHIUEMIEYBSOJP-UHFFFAOYSA-N 0.000 description 1
- KMODISUYWZPVGV-UHFFFAOYSA-N 2-bromo-6-methoxypyridine Chemical compound COC1=CC=CC(Br)=N1 KMODISUYWZPVGV-UHFFFAOYSA-N 0.000 description 1
- SOHDPICLICFSOP-UHFFFAOYSA-N 2-bromo-6-methylpyridine Chemical compound CC1=CC=CC(Br)=N1 SOHDPICLICFSOP-UHFFFAOYSA-N 0.000 description 1
- ATEBGNALLCMSGS-UHFFFAOYSA-N 2-chloro-1,1-difluoroethane Chemical compound FC(F)CCl ATEBGNALLCMSGS-UHFFFAOYSA-N 0.000 description 1
- YMQRPXBBBOXHNZ-UHFFFAOYSA-N 2-chloro-1-morpholin-4-ylethanone Chemical compound ClCC(=O)N1CCOCC1 YMQRPXBBBOXHNZ-UHFFFAOYSA-N 0.000 description 1
- ROJNYKZWTOHRNU-UHFFFAOYSA-N 2-chloro-4,5-difluoro-n-[[2-methoxy-5-(methylcarbamoylamino)phenyl]carbamoyl]benzamide Chemical compound CNC(=O)NC1=CC=C(OC)C(NC(=O)NC(=O)C=2C(=CC(F)=C(F)C=2)Cl)=C1 ROJNYKZWTOHRNU-UHFFFAOYSA-N 0.000 description 1
- JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 description 1
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
- WOYWLLHHWAMFCB-UHFFFAOYSA-N 2-ethylhexyl acetate Chemical compound CCCCC(CC)COC(C)=O WOYWLLHHWAMFCB-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- OTTZHAVKAVGASB-UHFFFAOYSA-N 2-heptene Natural products CCCCC=CC OTTZHAVKAVGASB-UHFFFAOYSA-N 0.000 description 1
- JJKWHOSQTYYFAE-UHFFFAOYSA-N 2-methoxyacetyl chloride Chemical compound COCC(Cl)=O JJKWHOSQTYYFAE-UHFFFAOYSA-N 0.000 description 1
- JZICUKPOZUKZLL-UHFFFAOYSA-N 2-methyl-1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2NC(C)CCC2=C1 JZICUKPOZUKZLL-UHFFFAOYSA-N 0.000 description 1
- SDTMFDGELKWGFT-UHFFFAOYSA-N 2-methylpropan-2-olate Chemical compound CC(C)(C)[O-] SDTMFDGELKWGFT-UHFFFAOYSA-N 0.000 description 1
- VMPYFWTYGZZUMY-UHFFFAOYSA-N 2-morpholin-4-ylphenol Chemical compound OC1=CC=CC=C1N1CCOCC1 VMPYFWTYGZZUMY-UHFFFAOYSA-N 0.000 description 1
- UBVSIAHUTXHQTD-UHFFFAOYSA-N 2-n-(4-bromophenyl)-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(NC=2C=CC(Br)=CC=2)=N1 UBVSIAHUTXHQTD-UHFFFAOYSA-N 0.000 description 1
- GNDKYAWHEKZHPJ-UHFFFAOYSA-N 2-nitrobenzenesulfonimidic acid Chemical compound NS(=O)(=O)C1=CC=CC=C1[N+]([O-])=O GNDKYAWHEKZHPJ-UHFFFAOYSA-N 0.000 description 1
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 1
- WWPLDSOFBMZGIJ-UHFFFAOYSA-M 2-propan-2-yloxybenzoate Chemical compound CC(C)OC1=CC=CC=C1C([O-])=O WWPLDSOFBMZGIJ-UHFFFAOYSA-M 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- QQOMQLYQAXGHSU-UHFFFAOYSA-N 236TMPh Natural products CC1=CC=C(C)C(O)=C1C QQOMQLYQAXGHSU-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- HPOIPOPJGBKXIR-UHFFFAOYSA-N 3,6-dimethoxy-10-methyl-galantham-1-ene Natural products O1C(C(=CC=2)OC)=C3C=2CN(C)CCC23C1CC(OC)C=C2 HPOIPOPJGBKXIR-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- KUMHZYUUZFJMNG-UHFFFAOYSA-N 3-(2,6-dimethyl-4-phenylmethoxyphenyl)benzaldehyde Chemical compound C=1C(C)=C(C=2C=C(C=O)C=CC=2)C(C)=CC=1OCC1=CC=CC=C1 KUMHZYUUZFJMNG-UHFFFAOYSA-N 0.000 description 1
- SCADEVWRJSJBOM-UHFFFAOYSA-N 3-(2,6-dimethylphenyl)benzaldehyde Chemical compound CC1=CC=CC(C)=C1C1=CC=CC(C=O)=C1 SCADEVWRJSJBOM-UHFFFAOYSA-N 0.000 description 1
- MTELCJZDMIMFRY-UHFFFAOYSA-N 3-(2-methylnaphthalen-1-yl)benzaldehyde Chemical compound CC1=CC=C2C=CC=CC2=C1C1=CC=CC(C=O)=C1 MTELCJZDMIMFRY-UHFFFAOYSA-N 0.000 description 1
- HKLZNESHJCSQIG-UHFFFAOYSA-N 3-(4-hydroxy-2-methylphenyl)-2-methylbenzaldehyde Chemical compound CC1=CC(O)=CC=C1C1=CC=CC(C=O)=C1C HKLZNESHJCSQIG-UHFFFAOYSA-N 0.000 description 1
- RMNLMKOJDVKOHO-UHFFFAOYSA-N 3-(6-methyl-4,8-dioxo-1,3,6,2-dioxazaborocan-2-yl)benzonitrile Chemical compound O1C(=O)CN(C)CC(=O)OB1C1=CC=CC(C#N)=C1 RMNLMKOJDVKOHO-UHFFFAOYSA-N 0.000 description 1
- SZCJXVSQQYGHLN-UHFFFAOYSA-N 3-(chloromethyl)-4-(2-methylpropoxy)benzaldehyde Chemical compound CC(C)COC1=CC=C(C=O)C=C1CCl SZCJXVSQQYGHLN-UHFFFAOYSA-N 0.000 description 1
- AEDQNOLIADXSBB-UHFFFAOYSA-N 3-(dodecylazaniumyl)propanoate Chemical compound CCCCCCCCCCCCNCCC(O)=O AEDQNOLIADXSBB-UHFFFAOYSA-N 0.000 description 1
- ROJFLPMQQHJURI-UHFFFAOYSA-N 3-[(2,2-dimethylquinolin-1-yl)methyl]-4-(2-methylpropoxy)benzaldehyde Chemical compound CC(C)COC1=CC=C(C=O)C=C1CN1C(C)(C)C=CC2=CC=CC=C21 ROJFLPMQQHJURI-UHFFFAOYSA-N 0.000 description 1
- MDNVYYFFYSBPLH-UHFFFAOYSA-N 3-[(3,5-diphenylpyrazol-1-yl)methyl]-4-(2-methylpropoxy)benzaldehyde Chemical compound CC(C)COC1=CC=C(C=O)C=C1CN1C(C=2C=CC=CC=2)=CC(C=2C=CC=CC=2)=N1 MDNVYYFFYSBPLH-UHFFFAOYSA-N 0.000 description 1
- QRNLSMVPXNLSPR-UHFFFAOYSA-N 3-[(dibenzylamino)methyl]-4-(2-methylpropoxy)benzaldehyde Chemical compound CC(C)COC1=CC=C(C=O)C=C1CN(CC=1C=CC=CC=1)CC1=CC=CC=C1 QRNLSMVPXNLSPR-UHFFFAOYSA-N 0.000 description 1
- WJRJXMFNCHXCJK-UHFFFAOYSA-N 3-[4-[[4-[(3,5-diphenylpyrazol-1-yl)methyl]-3-propan-2-yloxyphenyl]methylamino]-2,6-difluorophenyl]propanoic acid Chemical compound C=1C=C(CN2C(=CC(=N2)C=2C=CC=CC=2)C=2C=CC=CC=2)C(OC(C)C)=CC=1CNC1=CC(F)=C(CCC(O)=O)C(F)=C1 WJRJXMFNCHXCJK-UHFFFAOYSA-N 0.000 description 1
- CWLKGDAVCFYWJK-UHFFFAOYSA-N 3-aminophenol Chemical compound NC1=CC=CC(O)=C1 CWLKGDAVCFYWJK-UHFFFAOYSA-N 0.000 description 1
- 229940018563 3-aminophenol Drugs 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- NWAYWNCTOHHMNV-UHFFFAOYSA-N 3-bromo-2-methyl-1h-indole Chemical compound C1=CC=C2C(Br)=C(C)NC2=C1 NWAYWNCTOHHMNV-UHFFFAOYSA-N 0.000 description 1
- VAGWLVWXXFXWIZ-UHFFFAOYSA-N 3-bromo-2-phenyl-1h-indole Chemical compound N1C2=CC=CC=C2C(Br)=C1C1=CC=CC=C1 VAGWLVWXXFXWIZ-UHFFFAOYSA-N 0.000 description 1
- QKKWLPJYKNZGRV-UHFFFAOYSA-N 3-bromo-4-propan-2-yloxybenzaldehyde Chemical compound CC(C)OC1=CC=C(C=O)C=C1Br QKKWLPJYKNZGRV-UHFFFAOYSA-N 0.000 description 1
- SUISZCALMBHJQX-UHFFFAOYSA-N 3-bromobenzaldehyde Chemical compound BrC1=CC=CC(C=O)=C1 SUISZCALMBHJQX-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 description 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- KFKSIUOALVIACE-UHFFFAOYSA-N 3-phenylbenzaldehyde Chemical compound O=CC1=CC=CC(C=2C=CC=CC=2)=C1 KFKSIUOALVIACE-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- BHRAZLYYXWCGPO-UHFFFAOYSA-N 3-sulfonyl-1,2-dihydropyrazole Chemical compound O=S(=O)=C1C=CNN1 BHRAZLYYXWCGPO-UHFFFAOYSA-N 0.000 description 1
- 239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 description 1
- ZXVONLUNISGICL-UHFFFAOYSA-N 4,6-dinitro-o-cresol Chemical group CC1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1O ZXVONLUNISGICL-UHFFFAOYSA-N 0.000 description 1
- VOWRUMIWLXRJMP-UHFFFAOYSA-N 4-(2,6-dimethylphenyl)-2,3-dihydro-1h-inden-1-ol Chemical compound CC1=CC=CC(C)=C1C1=CC=CC2=C1CCC2O VOWRUMIWLXRJMP-UHFFFAOYSA-N 0.000 description 1
- PWASYRSZCSTUIW-UHFFFAOYSA-N 4-(2-methylpropoxy)benzaldehyde Chemical compound CC(C)COC1=CC=C(C=O)C=C1 PWASYRSZCSTUIW-UHFFFAOYSA-N 0.000 description 1
- WWUOKYOLHOYJIC-UHFFFAOYSA-N 4-[(2,2-dimethylquinolin-1-yl)methyl]-3-propan-2-yloxybenzaldehyde Chemical compound CC(C)OC1=CC(C=O)=CC=C1CN1C(C)(C)C=CC2=CC=CC=C21 WWUOKYOLHOYJIC-UHFFFAOYSA-N 0.000 description 1
- HPDUFEHLRIVRLB-UHFFFAOYSA-N 4-[(2-methyl-3,4-dihydro-2h-quinolin-1-yl)methyl]-3-propan-2-yloxybenzaldehyde Chemical compound CC(C)OC1=CC(C=O)=CC=C1CN1C2=CC=CC=C2CCC1C HPDUFEHLRIVRLB-UHFFFAOYSA-N 0.000 description 1
- CBAQDLMGMPKLSV-UHFFFAOYSA-N 4-[[4-[3-(hydroxymethyl)phenyl]-3,5-dimethylphenoxy]methyl]thian-4-ol Chemical compound C=1C(C)=C(C=2C=C(CO)C=CC=2)C(C)=CC=1OCC1(O)CCSCC1 CBAQDLMGMPKLSV-UHFFFAOYSA-N 0.000 description 1
- FVOMYRSKSHADOX-UHFFFAOYSA-N 4-[[5-(2-phenylethyl)-3-[4-(trifluoromethyl)phenyl]pyrazol-1-yl]methyl]benzaldehyde Chemical compound C1=CC(C(F)(F)F)=CC=C1C1=NN(CC=2C=CC(C=O)=CC=2)C(CCC=2C=CC=CC=2)=C1 FVOMYRSKSHADOX-UHFFFAOYSA-N 0.000 description 1
- GPZFDGLFZRELGK-UHFFFAOYSA-N 4-[[5-tert-butyl-3-(2-phenylethyl)pyrazol-1-yl]methyl]benzaldehyde Chemical compound N=1N(CC=2C=CC(C=O)=CC=2)C(C(C)(C)C)=CC=1CCC1=CC=CC=C1 GPZFDGLFZRELGK-UHFFFAOYSA-N 0.000 description 1
- WXOHKMNWMKZMND-UHFFFAOYSA-N 4-aminohydrocinnamic acid Chemical compound NC1=CC=C(CCC(O)=O)C=C1 WXOHKMNWMKZMND-UHFFFAOYSA-N 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- MMEGELSFOYDPQW-UHFFFAOYSA-N 4-bromo-3-methylaniline Chemical compound CC1=CC(N)=CC=C1Br MMEGELSFOYDPQW-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- UWDMKTDPDJCJOP-UHFFFAOYSA-N 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-ium-4-carboxylate Chemical compound CC1(C)CC(O)(C(O)=O)CC(C)(C)N1 UWDMKTDPDJCJOP-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical class OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-M 4-nitrophenolate Chemical compound [O-]C1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-M 0.000 description 1
- DJWIXPPOXVIXSZ-UHFFFAOYSA-N 4-phenyl-1,3-thiazole-2-carbaldehyde Chemical compound S1C(C=O)=NC(C=2C=CC=CC=2)=C1 DJWIXPPOXVIXSZ-UHFFFAOYSA-N 0.000 description 1
- SHWDWAGEQXIWRK-UHFFFAOYSA-N 4-phenylmethoxy-2,3-dihydroinden-1-one Chemical compound O=C1CCC2=C1C=CC=C2OCC1=CC=CC=C1 SHWDWAGEQXIWRK-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- HXMUBKQVVIRKGD-UHFFFAOYSA-N 5-(2,6-dimethylphenyl)-2,3-dihydroinden-1-one Chemical compound CC1=CC=CC(C)=C1C1=CC=C(C(=O)CC2)C2=C1 HXMUBKQVVIRKGD-UHFFFAOYSA-N 0.000 description 1
- KDOBULPPDRXTKE-UHFFFAOYSA-N 5-(4-fluorophenyl)-1-methylpyrazole-4-carbaldehyde Chemical compound CN1N=CC(C=O)=C1C1=CC=C(F)C=C1 KDOBULPPDRXTKE-UHFFFAOYSA-N 0.000 description 1
- IETKPTYAGKZLKY-UHFFFAOYSA-N 5-[[4-[(3-methyl-4-oxoquinazolin-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound N=1C2=CC=CC=C2C(=O)N(C)C=1COC(C=C1)=CC=C1CC1SC(=O)NC1=O IETKPTYAGKZLKY-UHFFFAOYSA-N 0.000 description 1
- KSONICAHAPRCMV-UHFFFAOYSA-N 5-bromo-2,3-dihydroinden-1-one Chemical compound BrC1=CC=C2C(=O)CCC2=C1 KSONICAHAPRCMV-UHFFFAOYSA-N 0.000 description 1
- WGOLHUGPTDEKCF-UHFFFAOYSA-N 5-bromopyridin-2-amine Chemical compound NC1=CC=C(Br)C=N1 WGOLHUGPTDEKCF-UHFFFAOYSA-N 0.000 description 1
- ZRKQOVXGDIZYDS-UHFFFAOYSA-N 5-hydroxy-2,3-dihydroinden-1-one Chemical compound OC1=CC=C2C(=O)CCC2=C1 ZRKQOVXGDIZYDS-UHFFFAOYSA-N 0.000 description 1
- MPASMXLOYIBLFN-UHFFFAOYSA-N 5-phenoxy-2,3-dihydroinden-1-one Chemical compound C=1C=C2C(=O)CCC2=CC=1OC1=CC=CC=C1 MPASMXLOYIBLFN-UHFFFAOYSA-N 0.000 description 1
- LYTKODVZMLEVSA-UHFFFAOYSA-N 5-phenylmethoxy-2,3-dihydroinden-1-one Chemical compound C=1C=C2C(=O)CCC2=CC=1OCC1=CC=CC=C1 LYTKODVZMLEVSA-UHFFFAOYSA-N 0.000 description 1
- UAHDLZGBBMTCBN-UHFFFAOYSA-N 5-tert-butyl-1,2-dihydropyrazol-3-one Chemical compound CC(C)(C)C1=CC(=O)NN1 UAHDLZGBBMTCBN-UHFFFAOYSA-N 0.000 description 1
- UPKIRZZYJRVBSJ-UHFFFAOYSA-N 5-tert-butyl-1h-pyrazole-3-carbaldehyde Chemical compound CC(C)(C)C1=CC(C=O)=NN1 UPKIRZZYJRVBSJ-UHFFFAOYSA-N 0.000 description 1
- RQRWZFJMPKHYIC-UHFFFAOYSA-N 5-tert-butyl-1h-pyrazole-3-carboxylic acid Chemical compound CC(C)(C)C1=CC(C(O)=O)=NN1 RQRWZFJMPKHYIC-UHFFFAOYSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- DFGKGUXTPFWHIX-UHFFFAOYSA-N 6-[2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]acetyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)C1=CC2=C(NC(O2)=O)C=C1 DFGKGUXTPFWHIX-UHFFFAOYSA-N 0.000 description 1
- VFFZWMWTUSXDCB-ZDUSSCGKSA-N 6-[2-[[2-[(2s)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino]ethylamino]pyridine-3-carbonitrile Chemical compound N1([C@@H](CCC1)C#N)C(=O)CNCCNC1=CC=C(C#N)C=N1 VFFZWMWTUSXDCB-ZDUSSCGKSA-N 0.000 description 1
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- LLQHSBBZNDXTIV-UHFFFAOYSA-N 6-[5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-4,5-dihydro-1,2-oxazol-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC1CC(=NO1)C1=CC2=C(NC(O2)=O)C=C1 LLQHSBBZNDXTIV-UHFFFAOYSA-N 0.000 description 1
- PMTUQDMDLTXFLG-UHFFFAOYSA-N 6-thiaspiro[2.5]octane Chemical compound C1CC11CCSCC1 PMTUQDMDLTXFLG-UHFFFAOYSA-N 0.000 description 1
- ODPYDILFQYARBK-UHFFFAOYSA-N 7-thiabicyclo[4.1.0]hepta-1,3,5-triene Chemical compound C1=CC=C2SC2=C1 ODPYDILFQYARBK-UHFFFAOYSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 240000005020 Acaciella glauca Species 0.000 description 1
- 239000005964 Acibenzolar-S-methyl Substances 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 102100031786 Adiponectin Human genes 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- WLDHEUZGFKACJH-ZRUFZDNISA-K Amaranth Chemical compound [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1\N=N\C1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-ZRUFZDNISA-K 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- XFRYLRRQXPVHDK-UHFFFAOYSA-N B(O)O.C(=O)C=1C=C(C=CC1)O Chemical compound B(O)O.C(=O)C=1C=C(C=CC1)O XFRYLRRQXPVHDK-UHFFFAOYSA-N 0.000 description 1
- 108010028845 BIM 23190 Proteins 0.000 description 1
- 108700001281 BIM 51077 Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 206010004716 Binge eating Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- ZNSMNVMLTJELDZ-UHFFFAOYSA-N Bis(2-chloroethyl)ether Chemical compound ClCCOCCCl ZNSMNVMLTJELDZ-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 239000004135 Bone phosphate Substances 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- FIPWRIJSWJWJAI-UHFFFAOYSA-N Butyl carbitol 6-propylpiperonyl ether Chemical compound C1=C(CCC)C(COCCOCCOCCCC)=CC2=C1OCO2 FIPWRIJSWJWJAI-UHFFFAOYSA-N 0.000 description 1
- YWCISYBJUCBNSV-UHFFFAOYSA-N C(CCCCC)C(CCCCC)(PC1=C(C=CC=C1)C1=CC=CC=C1)CCCCCC Chemical group C(CCCCC)C(CCCCC)(PC1=C(C=CC=C1)C1=CC=CC=C1)CCCCCC YWCISYBJUCBNSV-UHFFFAOYSA-N 0.000 description 1
- 239000002080 C09CA02 - Eprosartan Substances 0.000 description 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
- 239000002081 C09CA05 - Tasosartan Substances 0.000 description 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 1
- JZGWJEGSRKUKKV-UHFFFAOYSA-N C1(=CC=CC2=CC=CC=C12)C1=CC=CC2=CC=CC=C12.C1(=CC=CC=C1)PC1=CC=CC=C1.C1(=CC=CC=C1)PC1=CC=CC=C1 Chemical group C1(=CC=CC2=CC=CC=C12)C1=CC=CC2=CC=CC=C12.C1(=CC=CC=C1)PC1=CC=CC=C1.C1(=CC=CC=C1)PC1=CC=CC=C1 JZGWJEGSRKUKKV-UHFFFAOYSA-N 0.000 description 1
- 108010055448 CJC 1131 Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229940122820 Cannabinoid receptor antagonist Drugs 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- LPCKPBWOSNVCEL-UHFFFAOYSA-N Chlidanthine Natural products O1C(C(=CC=2)O)=C3C=2CN(C)CCC23C1CC(OC)C=C2 LPCKPBWOSNVCEL-UHFFFAOYSA-N 0.000 description 1
- XJUZRXYOEPSWMB-UHFFFAOYSA-N Chloromethyl methyl ether Chemical compound COCCl XJUZRXYOEPSWMB-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- BMOVQUBVGICXQN-UHFFFAOYSA-N Clinofibrate Chemical compound C1=CC(OC(C)(CC)C(O)=O)=CC=C1C1(C=2C=CC(OC(C)(CC)C(O)=O)=CC=2)CCCCC1 BMOVQUBVGICXQN-UHFFFAOYSA-N 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000010970 Connexin Human genes 0.000 description 1
- 108050001175 Connexin Proteins 0.000 description 1
- QPLDLSVMHZLSFG-UHFFFAOYSA-N Copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 description 1
- 239000005751 Copper oxide Substances 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- 229940124186 Dehydrogenase inhibitor Drugs 0.000 description 1
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 description 1
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 description 1
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 229940118365 Endothelin receptor antagonist Drugs 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- VXLCNTLWWUDBSO-UHFFFAOYSA-N Ethiazide Chemical compound ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)NC(CC)NC2=C1 VXLCNTLWWUDBSO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102100023374 Forkhead box protein M1 Human genes 0.000 description 1
- PNKUSGQVOMIXLU-UHFFFAOYSA-N Formamidine Chemical compound NC=N PNKUSGQVOMIXLU-UHFFFAOYSA-N 0.000 description 1
- 102100033045 G-protein coupled receptor 4 Human genes 0.000 description 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101800001586 Ghrelin Proteins 0.000 description 1
- 102400000442 Ghrelin-28 Human genes 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 description 1
- 102000003638 Glucose-6-Phosphatase Human genes 0.000 description 1
- 108010086800 Glucose-6-Phosphatase Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 238000007341 Heck reaction Methods 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000907578 Homo sapiens Forkhead box protein M1 Proteins 0.000 description 1
- 101000871138 Homo sapiens G-protein coupled receptor 4 Proteins 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 101001055149 Homo sapiens Pro-interleukin-16 Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 239000003458 I kappa b kinase inhibitor Substances 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical compound CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- KLDXJTOLSGUMSJ-JGWLITMVSA-N Isosorbide Chemical compound O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 KLDXJTOLSGUMSJ-JGWLITMVSA-N 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- 229940127470 Lipase Inhibitors Drugs 0.000 description 1
- 206010024604 Lipoatrophy Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102000029828 Melanin-concentrating hormone receptor Human genes 0.000 description 1
- 108010047068 Melanin-concentrating hormone receptor Proteins 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- RJUFJBKOKNCXHH-UHFFFAOYSA-N Methyl propionate Chemical compound CCC(=O)OC RJUFJBKOKNCXHH-UHFFFAOYSA-N 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- GQWNECFJGBQMBO-UHFFFAOYSA-N Molindone hydrochloride Chemical compound Cl.O=C1C=2C(CC)=C(C)NC=2CCC1CN1CCOCC1 GQWNECFJGBQMBO-UHFFFAOYSA-N 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- IRLWJILLXJGJTD-UHFFFAOYSA-N Muraglitazar Chemical compound C1=CC(OC)=CC=C1OC(=O)N(CC(O)=O)CC(C=C1)=CC=C1OCCC1=C(C)OC(C=2C=CC=CC=2)=N1 IRLWJILLXJGJTD-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- SVYKKECYCPFKGB-UHFFFAOYSA-N N,N-dimethylcyclohexylamine Chemical compound CN(C)C1CCCCC1 SVYKKECYCPFKGB-UHFFFAOYSA-N 0.000 description 1
- PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 1
- 229930192627 Naphthoquinone Natural products 0.000 description 1
- 229930182559 Natural dye Natural products 0.000 description 1
- OKJHGOPITGTTIM-DEOSSOPVSA-N Naveglitazar Chemical compound C1=CC(C[C@H](OC)C(O)=O)=CC=C1OCCCOC(C=C1)=CC=C1OC1=CC=CC=C1 OKJHGOPITGTTIM-DEOSSOPVSA-N 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 108090000742 Neurotrophin 3 Proteins 0.000 description 1
- 102100029268 Neurotrophin-3 Human genes 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 239000005480 Olmesartan Substances 0.000 description 1
- 102000004140 Oncostatin M Human genes 0.000 description 1
- 108090000630 Oncostatin M Proteins 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 229940123973 Oxygen scavenger Drugs 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- CZYWHNTUXNGDGR-UHFFFAOYSA-L Pamidronate disodium Chemical compound O.O.O.O.O.[Na+].[Na+].NCCC(O)(P(O)([O-])=O)P(O)([O-])=O CZYWHNTUXNGDGR-UHFFFAOYSA-L 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- UJEWTUDSLQGTOA-UHFFFAOYSA-N Piretanide Chemical compound C=1C=CC=CC=1OC=1C(S(=O)(=O)N)=CC(C(O)=O)=CC=1N1CCCC1 UJEWTUDSLQGTOA-UHFFFAOYSA-N 0.000 description 1
- 206010036018 Pollakiuria Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- CYLWJCABXYDINA-UHFFFAOYSA-N Polythiazide Polymers ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CSCC(F)(F)F)NC2=C1 CYLWJCABXYDINA-UHFFFAOYSA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241001417524 Pomacanthidae Species 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 102100040918 Pro-glucagon Human genes 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010074268 Reproductive toxicity Diseases 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002305 Schizophyllan Polymers 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- JLRNKCZRCMIVKA-UHFFFAOYSA-N Simfibrate Chemical compound C=1C=C(Cl)C=CC=1OC(C)(C)C(=O)OCCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 JLRNKCZRCMIVKA-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 241000705989 Tetrax Species 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- BXNCIERBDJYIQT-PRDVQWLOSA-N [(2r,3s,4s,5r,6s)-6-[2-[3-(1-benzofuran-5-yl)propanoyl]-3-hydroxy-5-methylphenoxy]-3,4,5-trihydroxyoxan-2-yl]methyl methyl carbonate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)OC)O[C@H]1OC1=CC(C)=CC(O)=C1C(=O)CCC1=CC=C(OC=C2)C2=C1 BXNCIERBDJYIQT-PRDVQWLOSA-N 0.000 description 1
- FHKPLLOSJHHKNU-INIZCTEOSA-N [(3S)-3-[8-(1-ethyl-5-methylpyrazol-4-yl)-9-methylpurin-6-yl]oxypyrrolidin-1-yl]-(oxan-4-yl)methanone Chemical compound C(C)N1N=CC(=C1C)C=1N(C2=NC=NC(=C2N=1)O[C@@H]1CN(CC1)C(=O)C1CCOCC1)C FHKPLLOSJHHKNU-INIZCTEOSA-N 0.000 description 1
- QDPOOGQUCJJZAO-FCXRPNKRSA-N [(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate Chemical compound C1=C(O)C(O)=CC=C1\C=C\C(=O)OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QDPOOGQUCJJZAO-FCXRPNKRSA-N 0.000 description 1
- DTGJFMBEIIJAAM-UHFFFAOYSA-N [1-(2-methylphenyl)-5-(2-methylpropoxy)pyrazol-3-yl]methanol Chemical compound CC(C)COC1=CC(CO)=NN1C1=CC=CC=C1C DTGJFMBEIIJAAM-UHFFFAOYSA-N 0.000 description 1
- JYXPYSZKXALZDY-UHFFFAOYSA-N [3-(2-methylnaphthalen-1-yl)phenyl]methanol Chemical compound CC1=CC=C2C=CC=CC2=C1C1=CC=CC(CO)=C1 JYXPYSZKXALZDY-UHFFFAOYSA-N 0.000 description 1
- SJSUXYJMIWTUHM-UHFFFAOYSA-N [4-[(2,2-dimethylquinolin-1-yl)methyl]-3-propan-2-yloxyphenyl]methanol Chemical compound CC(C)OC1=CC(CO)=CC=C1CN1C(C)(C)C=CC2=CC=CC=C21 SJSUXYJMIWTUHM-UHFFFAOYSA-N 0.000 description 1
- NEKKZLRZIHEXDY-UHFFFAOYSA-N [4-[(2-methylindol-1-yl)methyl]-3-propan-2-yloxyphenyl]methanol Chemical compound CC(C)OC1=CC(CO)=CC=C1CN1C2=CC=CC=C2C=C1C NEKKZLRZIHEXDY-UHFFFAOYSA-N 0.000 description 1
- CSEJWUCHRFOSPQ-UHFFFAOYSA-N [4-[(3,5-ditert-butylpyrazol-1-yl)methyl]phenyl]methanol Chemical compound N1=C(C(C)(C)C)C=C(C(C)(C)C)N1CC1=CC=C(CO)C=C1 CSEJWUCHRFOSPQ-UHFFFAOYSA-N 0.000 description 1
- GHJMMZSKAIQNLV-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]-3-(2-methylprop-2-enyl)phenyl]methanol Chemical compound CC(=C)CC1=CC(CO)=CC=C1OCC1=CC=C(C)C=C1 GHJMMZSKAIQNLV-UHFFFAOYSA-N 0.000 description 1
- HABXVODZTDKRJS-UHFFFAOYSA-N [4-[[(4-phenyl-1,3-thiazol-2-yl)-propylamino]methyl]phenyl]methanol Chemical compound N=1C(C=2C=CC=CC=2)=CSC=1N(CCC)CC1=CC=C(CO)C=C1 HABXVODZTDKRJS-UHFFFAOYSA-N 0.000 description 1
- COYZOWWXINIJPM-UHFFFAOYSA-N [4-[[2-phenylethyl-(4-phenyl-1,3-thiazol-2-yl)amino]methyl]phenyl]methanol Chemical compound C1=CC(CO)=CC=C1CN(C=1SC=C(N=1)C=1C=CC=CC=1)CCC1=CC=CC=C1 COYZOWWXINIJPM-UHFFFAOYSA-N 0.000 description 1
- RPFCIBAUXCCWSF-UHFFFAOYSA-N [4-[[5-(4-fluorophenyl)-1-methylpyrazol-4-yl]methoxy]phenyl]methanol Chemical compound C=1C=C(F)C=CC=1C=1N(C)N=CC=1COC1=CC=C(CO)C=C1 RPFCIBAUXCCWSF-UHFFFAOYSA-N 0.000 description 1
- GZNPWWHZGHVUBP-UHFFFAOYSA-N [7-[4-(2-ethoxyethoxy)phenyl]-2,2-dimethyl-3h-1-benzofuran-5-yl]methanol Chemical compound C1=CC(OCCOCC)=CC=C1C1=CC(CO)=CC2=C1OC(C)(C)C2 GZNPWWHZGHVUBP-UHFFFAOYSA-N 0.000 description 1
- DBIUTSALHYGOMX-UHFFFAOYSA-N [Na].C(C)O[Na] Chemical compound [Na].C(C)O[Na] DBIUTSALHYGOMX-UHFFFAOYSA-N 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 125000004054 acenaphthylenyl group Chemical group C1(=CC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- PHENPABYBHPABM-UHFFFAOYSA-N acetic acid;octane Chemical compound CC(O)=O.CCCCCCCC PHENPABYBHPABM-UHFFFAOYSA-N 0.000 description 1
- HXGDTGSAIMULJN-UHFFFAOYSA-N acetnaphthylene Natural products C1=CC(C=C2)=C3C2=CC=CC3=C1 HXGDTGSAIMULJN-UHFFFAOYSA-N 0.000 description 1
- VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 description 1
- 229960001466 acetohexamide Drugs 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- MKOMESMZHZNBIZ-UHFFFAOYSA-M alagebrium Chemical compound [Cl-].CC1=C(C)SC=[N+]1CC(=O)C1=CC=CC=C1 MKOMESMZHZNBIZ-UHFFFAOYSA-M 0.000 description 1
- 239000003288 aldose reductase inhibitor Substances 0.000 description 1
- 229940090865 aldose reductase inhibitors used in diabetes Drugs 0.000 description 1
- 239000002170 aldosterone antagonist Substances 0.000 description 1
- DCSBSVSZJRSITC-UHFFFAOYSA-M alendronate sodium trihydrate Chemical compound O.O.O.[Na+].NCCCC(O)(P(O)(O)=O)P(O)([O-])=O DCSBSVSZJRSITC-UHFFFAOYSA-M 0.000 description 1
- 229960004343 alendronic acid Drugs 0.000 description 1
- 150000005325 alkali earth metal hydroxides Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 229910000287 alkaline earth metal oxide Inorganic materials 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000004645 aluminates Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000006295 amino methylene group Chemical group [H]N(*)C([H])([H])* 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001539 anorectic effect Effects 0.000 description 1
- 125000000748 anthracen-2-yl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C([H])=C([*])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 230000001887 anti-feedant effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 229940111121 antirheumatic drug quinolines Drugs 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 235000021229 appetite regulation Nutrition 0.000 description 1
- KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 description 1
- 229960003856 argatroban Drugs 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 229940000489 arsenate Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000001691 aryl alkyl amino group Chemical group 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- MOTJMGVDPWRKOC-QPVYNBJUSA-N atrasentan Chemical compound C1([C@H]2[C@@H]([C@H](CN2CC(=O)N(CCCC)CCCC)C=2C=C3OCOC3=CC=2)C(O)=O)=CC=C(OC)C=C1 MOTJMGVDPWRKOC-QPVYNBJUSA-N 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- IIOPLILENRZKRV-UHFFFAOYSA-N azosemide Chemical compound C=1C=CSC=1CNC=1C=C(Cl)C(S(=O)(=O)N)=CC=1C1=NN=N[N]1 IIOPLILENRZKRV-UHFFFAOYSA-N 0.000 description 1
- 229960004988 azosemide Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229950010663 balaglitazone Drugs 0.000 description 1
- 159000000009 barium salts Chemical class 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- YPAKZCPHSZUMCR-UHFFFAOYSA-N benzene;nitrobenzene Chemical compound C1=CC=CC=C1.[O-][N+](=O)C1=CC=CC=C1 YPAKZCPHSZUMCR-UHFFFAOYSA-N 0.000 description 1
- DALDUXIBIKGWTK-UHFFFAOYSA-N benzene;toluene Chemical compound C1=CC=CC=C1.CC1=CC=CC=C1 DALDUXIBIKGWTK-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- BMWITAUNXBHIPO-OZZZDHQUSA-N benzenesulfonic acid;(2s,4s)-4-fluoro-1-[2-[(1-hydroxy-2-methylpropan-2-yl)amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound OS(=O)(=O)C1=CC=CC=C1.OCC(C)(C)NCC(=O)N1C[C@@H](F)C[C@H]1C#N BMWITAUNXBHIPO-OZZZDHQUSA-N 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- UENWRTRMUIOCKN-UHFFFAOYSA-N benzyl thiol Chemical compound SCC1=CC=CC=C1 UENWRTRMUIOCKN-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WTEPWWCRWNCUNA-UHFFFAOYSA-M benzyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)CC1=CC=CC=C1 WTEPWWCRWNCUNA-UHFFFAOYSA-M 0.000 description 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960000516 bezafibrate Drugs 0.000 description 1
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- GPRLTFBKWDERLU-UHFFFAOYSA-N bicyclo[2.2.2]octane Chemical compound C1CC2CCC1CC2 GPRLTFBKWDERLU-UHFFFAOYSA-N 0.000 description 1
- LPCWKMYWISGVSK-UHFFFAOYSA-N bicyclo[3.2.1]octane Chemical compound C1C2CCC1CCC2 LPCWKMYWISGVSK-UHFFFAOYSA-N 0.000 description 1
- GNTFBMAGLFYMMZ-UHFFFAOYSA-N bicyclo[3.2.2]nonane Chemical compound C1CC2CCC1CCC2 GNTFBMAGLFYMMZ-UHFFFAOYSA-N 0.000 description 1
- WNTGVOIBBXFMLR-UHFFFAOYSA-N bicyclo[3.3.1]nonane Chemical compound C1CCC2CCCC1C2 WNTGVOIBBXFMLR-UHFFFAOYSA-N 0.000 description 1
- QEGGPUAKCVWNOT-UHFFFAOYSA-N bicyclo[4.3.1]decane Chemical compound C1C2CCCC1CCCC2 QEGGPUAKCVWNOT-UHFFFAOYSA-N 0.000 description 1
- 208000014679 binge eating disease Diseases 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- KZIBQYUFIVUOHY-UHFFFAOYSA-N bis(2-methylpropyl)alumane toluene Chemical compound Cc1ccccc1.[H][Al](CC(C)C)CC(C)C KZIBQYUFIVUOHY-UHFFFAOYSA-N 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 description 1
- 125000006251 butylcarbonyl group Chemical group 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960003773 calcitonin (salmon synthetic) Drugs 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- 229960005084 calcitriol Drugs 0.000 description 1
- 235000020964 calcitriol Nutrition 0.000 description 1
- 239000011612 calcitriol Substances 0.000 description 1
- 150000001669 calcium Chemical class 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- GDDSFMMICZTVCA-UHFFFAOYSA-L calcium;2-carboxyphenolate;3,7-dimethylpurine-2,6-dione Chemical compound [Ca+2].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O.CN1C(=O)NC(=O)C2=C1N=CN2C GDDSFMMICZTVCA-UHFFFAOYSA-L 0.000 description 1
- 239000003536 cannabinoid receptor antagonist Substances 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- HFNQLYDPNAZRCH-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O.OC(O)=O HFNQLYDPNAZRCH-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- MVCQKIKWYUURMU-UHFFFAOYSA-N cetilistat Chemical compound C1=C(C)C=C2C(=O)OC(OCCCCCCCCCCCCCCCC)=NC2=C1 MVCQKIKWYUURMU-UHFFFAOYSA-N 0.000 description 1
- 229950002397 cetilistat Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 1
- DDPFHDCZUJFNAT-PZPWKVFESA-N chembl2104402 Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CCCCCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 DDPFHDCZUJFNAT-PZPWKVFESA-N 0.000 description 1
- 239000007806 chemical reaction intermediate Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229940061627 chloromethyl methyl ether Drugs 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 229960001523 chlortalidone Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 229960004588 cilostazol Drugs 0.000 description 1
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229950003072 clinofibrate Drugs 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 150000001869 cobalt compounds Chemical class 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910000431 copper oxide Inorganic materials 0.000 description 1
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 150000001907 coumarones Chemical class 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- CFBGXYDUODCMNS-UHFFFAOYSA-N cyclobutene Chemical compound C1CC=C1 CFBGXYDUODCMNS-UHFFFAOYSA-N 0.000 description 1
- HXCKCCRKGXHOBK-UHFFFAOYSA-N cycloheptane Chemical compound [CH]1CCCCCC1 HXCKCCRKGXHOBK-UHFFFAOYSA-N 0.000 description 1
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 1
- UVJHQYIOXKWHFD-UHFFFAOYSA-N cyclohexa-1,4-diene Chemical compound C1C=CCC=C1 UVJHQYIOXKWHFD-UHFFFAOYSA-N 0.000 description 1
- 125000004956 cyclohexylene group Chemical group 0.000 description 1
- NQOJWOIPQBVKKX-UHFFFAOYSA-N cyclooctane Chemical compound [CH]1CCCCCCC1 NQOJWOIPQBVKKX-UHFFFAOYSA-N 0.000 description 1
- 239000004914 cyclooctane Substances 0.000 description 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N cyclopentadiene Chemical compound C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229940018872 dalteparin sodium Drugs 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 125000006612 decyloxy group Chemical group 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- WOUOLAUOZXOLJQ-MBSDFSHPSA-N delapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 WOUOLAUOZXOLJQ-MBSDFSHPSA-N 0.000 description 1
- 229960005227 delapril Drugs 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- RZHIALGQQJESEK-UHFFFAOYSA-L dichloronickel;triethylphosphane Chemical compound Cl[Ni]Cl.CCP(CC)CC.CCP(CC)CC RZHIALGQQJESEK-UHFFFAOYSA-L 0.000 description 1
- LCSNDSFWVKMJCT-UHFFFAOYSA-N dicyclohexyl-(2-phenylphenyl)phosphane Chemical group C1CCCCC1P(C=1C(=CC=CC=1)C=1C=CC=CC=1)C1CCCCC1 LCSNDSFWVKMJCT-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 description 1
- GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- HXJFQNUWPUICNY-UHFFFAOYSA-N disiamylborane Chemical compound CC(C)C(C)BC(C)C(C)C HXJFQNUWPUICNY-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960001446 distigmine Drugs 0.000 description 1
- GJHSNEVFXQVOHR-UHFFFAOYSA-L distigmine bromide Chemical compound [Br-].[Br-].C=1C=C[N+](C)=CC=1OC(=O)N(C)CCCCCCN(C)C(=O)OC1=CC=C[N+](C)=C1 GJHSNEVFXQVOHR-UHFFFAOYSA-L 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960004242 dronabinol Drugs 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 108700032313 elcatonin Proteins 0.000 description 1
- 229960000756 elcatonin Drugs 0.000 description 1
- 229950000269 emiglitate Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- 239000002308 endothelin receptor antagonist Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 description 1
- 229960004563 eprosartan Drugs 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 1
- 229960003199 etacrynic acid Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229950007164 ethiazide Drugs 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 1
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 description 1
- BAYWUAWGVDHBDA-UHFFFAOYSA-N ethyl 3-(4-amino-2-fluorophenyl)propanoate Chemical compound CCOC(=O)CCC1=CC=C(N)C=C1F BAYWUAWGVDHBDA-UHFFFAOYSA-N 0.000 description 1
- NWWORXYTJRPSMC-QKPAOTATSA-N ethyl 4-[2-[(2r,3r,4r,5s)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]ethoxy]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1OCCN1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C1 NWWORXYTJRPSMC-QKPAOTATSA-N 0.000 description 1
- OHLRLMWUFVDREV-UHFFFAOYSA-N ethyl 4-chloro-3-oxobutanoate Chemical compound CCOC(=O)CC(=O)CCl OHLRLMWUFVDREV-UHFFFAOYSA-N 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 229940105994 ethylhexyl acetate Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960001582 fenfluramine Drugs 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- XOEVKNFZUQEERE-UHFFFAOYSA-N flavoxate hydrochloride Chemical compound Cl.C1=CC=C2C(=O)C(C)=C(C=3C=CC=CC=3)OC2=C1C(=O)OCCN1CCCCC1 XOEVKNFZUQEERE-UHFFFAOYSA-N 0.000 description 1
- 229960003064 flavoxate hydrochloride Drugs 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- AIWAEWBZDJARBJ-PXUUZXDZSA-N fz7co35x2s Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCNC(=O)COCCOCCNC(=O)CCN1C(C=CC1=O)=O)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 AIWAEWBZDJARBJ-PXUUZXDZSA-N 0.000 description 1
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- BGLNUNCBNALFOZ-WMLDXEAASA-N galanthamine Natural products COc1ccc2CCCC[C@@]34C=CCC[C@@H]3Oc1c24 BGLNUNCBNALFOZ-WMLDXEAASA-N 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 231100000025 genetic toxicology Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 1
- 229960000346 gliclazide Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 238000007446 glucose tolerance test Methods 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229940095529 heparin calcium Drugs 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004312 hexamethylene tetramine Substances 0.000 description 1
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 1
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
- ALBYIUDWACNRRB-UHFFFAOYSA-N hexanamide Chemical compound CCCCCC(N)=O ALBYIUDWACNRRB-UHFFFAOYSA-N 0.000 description 1
- JQOAQUXIUNVRQW-UHFFFAOYSA-N hexane Chemical compound CCCCCC.CCCCCC JQOAQUXIUNVRQW-UHFFFAOYSA-N 0.000 description 1
- UQWQCMSYGMAGKF-UHFFFAOYSA-N hexane;lithium Chemical compound [Li].CCCCCC UQWQCMSYGMAGKF-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 102000050109 human Il16 Human genes 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 229960002600 icosapent ethyl Drugs 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical group 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- LWRDQHOZTAOILO-UHFFFAOYSA-N incadronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)NC1CCCCCC1 LWRDQHOZTAOILO-UHFFFAOYSA-N 0.000 description 1
- 229950006971 incadronic acid Drugs 0.000 description 1
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 description 1
- 229960004569 indapamide Drugs 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 206010022498 insulinoma Diseases 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000000752 ionisation method Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 229960002479 isosorbide Drugs 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229940062717 keppra Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 1
- 229960001848 lamotrigine Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- HPHUVLMMVZITSG-LURJTMIESA-N levetiracetam Chemical compound CC[C@@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-LURJTMIESA-N 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 230000000512 lipotoxic effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910001386 lithium phosphate Inorganic materials 0.000 description 1
- CNOXNGAZMFFQSR-UHFFFAOYSA-N lithium;propylazanide Chemical compound [Li+].CCC[NH-] CNOXNGAZMFFQSR-UHFFFAOYSA-N 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- IYVSXSLYJLAZAT-NOLJZWGESA-N lycoramine Natural products CN1CC[C@@]23CC[C@H](O)C[C@@H]2Oc4cccc(C1)c34 IYVSXSLYJLAZAT-NOLJZWGESA-N 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- ANEBWFXPVPTEET-UHFFFAOYSA-N manidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ANEBWFXPVPTEET-UHFFFAOYSA-N 0.000 description 1
- 229960003963 manidipine Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- WVJKHCGMRZGIJH-UHFFFAOYSA-N methanetriamine Chemical compound NC(N)N WVJKHCGMRZGIJH-UHFFFAOYSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
- FWMHZWMPUWAUPL-NDEPHWFRSA-N methyl (4s)-3-[3-[4-(3-acetamidophenyl)piperidin-1-yl]propylcarbamoyl]-4-(3,4-difluorophenyl)-6-(methoxymethyl)-2-oxo-1,4-dihydropyrimidine-5-carboxylate Chemical compound N1([C@H](C(=C(NC1=O)COC)C(=O)OC)C=1C=C(F)C(F)=CC=1)C(=O)NCCCN(CC1)CCC1C1=CC=CC(NC(C)=O)=C1 FWMHZWMPUWAUPL-NDEPHWFRSA-N 0.000 description 1
- IVAQJHSXBVHUQT-ZVHZXABRSA-N methyl (e)-3-(3,5-dimethoxyphenyl)-2-[4-[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]phenyl]prop-2-enoate Chemical compound C=1C=C(OC=2C=CC(CC3C(NC(=O)S3)=O)=CC=2)C=CC=1/C(C(=O)OC)=C\C1=CC(OC)=CC(OC)=C1 IVAQJHSXBVHUQT-ZVHZXABRSA-N 0.000 description 1
- MCVVUJPXSBQTRZ-ONEGZZNKSA-N methyl (e)-but-2-enoate Chemical compound COC(=O)\C=C\C MCVVUJPXSBQTRZ-ONEGZZNKSA-N 0.000 description 1
- ZXRXEUBNPCUQJB-UHFFFAOYSA-N methyl 3-bromo-4-hydroxy-5-(2-methylprop-2-enyl)benzoate Chemical compound COC(=O)C1=CC(Br)=C(O)C(CC(C)=C)=C1 ZXRXEUBNPCUQJB-UHFFFAOYSA-N 0.000 description 1
- ZREVPFANJBZHEU-UHFFFAOYSA-N methyl 3-bromo-4-methoxybenzoate Chemical compound COC(=O)C1=CC=C(OC)C(Br)=C1 ZREVPFANJBZHEU-UHFFFAOYSA-N 0.000 description 1
- HVUYIEIHXSRIFZ-UHFFFAOYSA-N methyl 3-bromo-4-propan-2-yloxybenzoate Chemical compound COC(=O)C1=CC=C(OC(C)C)C(Br)=C1 HVUYIEIHXSRIFZ-UHFFFAOYSA-N 0.000 description 1
- GKWWRXCPQAQURQ-UHFFFAOYSA-N methyl 3-propan-2-yloxybenzoate Chemical compound COC(=O)C1=CC=CC(OC(C)C)=C1 GKWWRXCPQAQURQ-UHFFFAOYSA-N 0.000 description 1
- HNNUQHJWFIPTLJ-UHFFFAOYSA-N methyl 4-(2-bromoethyl)benzoate Chemical compound COC(=O)C1=CC=C(CCBr)C=C1 HNNUQHJWFIPTLJ-UHFFFAOYSA-N 0.000 description 1
- VQGYTTFCWDDSPD-UHFFFAOYSA-N methyl 4-[(2,2-dimethylquinolin-1-yl)methyl]-3-propan-2-yloxybenzoate Chemical compound CC(C)OC1=CC(C(=O)OC)=CC=C1CN1C(C)(C)C=CC2=CC=CC=C21 VQGYTTFCWDDSPD-UHFFFAOYSA-N 0.000 description 1
- WWPIFUWLJWWVCL-UHFFFAOYSA-N methyl 4-[(3,5-diphenylpyrazol-1-yl)methyl]-3-methoxybenzoate Chemical compound COC1=CC(C(=O)OC)=CC=C1CN1C(C=2C=CC=CC=2)=CC(C=2C=CC=CC=2)=N1 WWPIFUWLJWWVCL-UHFFFAOYSA-N 0.000 description 1
- QRJXNJNKVYKYQK-UHFFFAOYSA-N methyl 4-[[2-phenylethyl-(4-phenyl-1,3-thiazol-2-yl)amino]methyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CN(C=1SC=C(N=1)C=1C=CC=CC=1)CCC1=CC=CC=C1 QRJXNJNKVYKYQK-UHFFFAOYSA-N 0.000 description 1
- QWIWAYQURSEIAV-UHFFFAOYSA-N methyl 4-[[4-(2,6-dimethylphenoxy)piperidin-1-yl]methyl]-3-propan-2-yloxybenzoate Chemical compound CC(C)OC1=CC(C(=O)OC)=CC=C1CN1CCC(OC=2C(=CC=CC=2C)C)CC1 QWIWAYQURSEIAV-UHFFFAOYSA-N 0.000 description 1
- XWUDZXSDVCPCNO-UHFFFAOYSA-N methyl 4-hydroxy-3-(2-methylpropyl)benzoate Chemical compound COC(=O)C1=CC=C(O)C(CC(C)C)=C1 XWUDZXSDVCPCNO-UHFFFAOYSA-N 0.000 description 1
- KMYMORPDUMXMEN-UHFFFAOYSA-N methyl 4-methyl-3-methylsulfonyloxybenzoate Chemical compound COC(=O)C1=CC=C(C)C(OS(C)(=O)=O)=C1 KMYMORPDUMXMEN-UHFFFAOYSA-N 0.000 description 1
- FZTVBLUGAOJMAK-UHFFFAOYSA-N methyl 4-methyl-3-propan-2-yloxybenzoate Chemical compound COC(=O)C1=CC=C(C)C(OC(C)C)=C1 FZTVBLUGAOJMAK-UHFFFAOYSA-N 0.000 description 1
- AJNPYYYAGKQFPX-UHFFFAOYSA-N methyl 5-methoxy-2-methylpyrazole-3-carboxylate Chemical compound COC(=O)C1=CC(OC)=NN1C AJNPYYYAGKQFPX-UHFFFAOYSA-N 0.000 description 1
- LNOHCHYFEKITIQ-UHFFFAOYSA-N methylsulfonyl benzenecarboperoxoate Chemical compound CS(=O)(=O)OOC(=O)C1=CC=CC=C1 LNOHCHYFEKITIQ-UHFFFAOYSA-N 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- 229960003404 mexiletine Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 101150067960 mmoD gene Proteins 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 description 1
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 229950001135 muraglitazar Drugs 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical class OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- SFMJNHNUOVADRW-UHFFFAOYSA-N n-[5-[9-[4-(methanesulfonamido)phenyl]-2-oxobenzo[h][1,6]naphthyridin-1-yl]-2-methylphenyl]prop-2-enamide Chemical compound C1=C(NC(=O)C=C)C(C)=CC=C1N1C(=O)C=CC2=C1C1=CC(C=3C=CC(NS(C)(=O)=O)=CC=3)=CC=C1N=C2 SFMJNHNUOVADRW-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- DISPOJHKKXSCLS-UHFFFAOYSA-N n-diaminophosphorylmethanamine Chemical compound CNP(N)(N)=O DISPOJHKKXSCLS-UHFFFAOYSA-N 0.000 description 1
- IXEGRINNWXKNJO-UHFFFAOYSA-N n-hexadecylaniline Chemical compound CCCCCCCCCCCCCCCCNC1=CC=CC=C1 IXEGRINNWXKNJO-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 150000002791 naphthoquinones Chemical class 0.000 description 1
- 125000001038 naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- 125000005146 naphthylsulfonyl group Chemical group C1(=CC=CC2=CC=CC=C12)S(=O)(=O)* 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 229940037525 nasal preparations Drugs 0.000 description 1
- 239000000978 natural dye Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229950001628 netoglitazone Drugs 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000002660 neuropeptide Y receptor antagonist Substances 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- ZBRJXVVKPBZPAN-UHFFFAOYSA-L nickel(2+);triphenylphosphane;dichloride Chemical compound [Cl-].[Cl-].[Ni+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 ZBRJXVVKPBZPAN-UHFFFAOYSA-L 0.000 description 1
- KFBKRCXOTTUAFS-UHFFFAOYSA-N nickel;triphenylphosphane Chemical compound [Ni].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 KFBKRCXOTTUAFS-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- KPADFPAILITQBG-UHFFFAOYSA-N non-4-ene Chemical compound CCCCC=CCCC KPADFPAILITQBG-UHFFFAOYSA-N 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- ZCYXXKJEDCHMGH-UHFFFAOYSA-N nonane Chemical compound CCCC[CH]CCCC ZCYXXKJEDCHMGH-UHFFFAOYSA-N 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- BKIMMITUMNQMOS-UHFFFAOYSA-N normal nonane Natural products CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 description 1
- 229960005117 olmesartan Drugs 0.000 description 1
- 229940125395 oral insulin Drugs 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229960005434 oxybutynin Drugs 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- ULYNIEUXPCUIEL-UHFFFAOYSA-L palladium(2+);triethylphosphane;dichloride Chemical compound [Cl-].[Cl-].[Pd+2].CCP(CC)CC.CCP(CC)CC ULYNIEUXPCUIEL-UHFFFAOYSA-L 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 1
- 229960003978 pamidronic acid Drugs 0.000 description 1
- 208000021255 pancreatic insulinoma Diseases 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- ATGAWOHQWWULNK-UHFFFAOYSA-I pentapotassium;[oxido(phosphonatooxy)phosphoryl] phosphate Chemical compound [K+].[K+].[K+].[K+].[K+].[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O ATGAWOHQWWULNK-UHFFFAOYSA-I 0.000 description 1
- YWAKXRMUMFPDSH-UHFFFAOYSA-N pentene Chemical compound CCCC=C YWAKXRMUMFPDSH-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 229960003562 phentermine Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 229960005235 piperonyl butoxide Drugs 0.000 description 1
- 229960001085 piretanide Drugs 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 150000003058 platinum compounds Chemical class 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 108010001062 polysaccharide-K Proteins 0.000 description 1
- 229960005483 polythiazide Drugs 0.000 description 1
- 229920000046 polythiazide Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 229960003611 pramlintide Drugs 0.000 description 1
- 108010029667 pramlintide Proteins 0.000 description 1
- NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- 150000003145 progesterone derivatives Chemical class 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- YKYONYBAUNKHLG-UHFFFAOYSA-N propyl acetate Chemical compound CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 108010076038 prosaptide Proteins 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 125000005495 pyridazyl group Chemical group 0.000 description 1
- 235000008151 pyridoxamine Nutrition 0.000 description 1
- 239000011699 pyridoxamine Substances 0.000 description 1
- HNWCOANXZNKMLR-UHFFFAOYSA-N pyridoxamine dihydrochloride Chemical compound Cl.Cl.CC1=NC=C(CO)C(CN)=C1O HNWCOANXZNKMLR-UHFFFAOYSA-N 0.000 description 1
- 125000005030 pyridylthio group Chemical group N1=C(C=CC=C1)S* 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003246 quinazolines Chemical class 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 150000003252 quinoxalines Chemical class 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 235000003499 redwood Nutrition 0.000 description 1
- 238000002407 reforming Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 231100000372 reproductive toxicity Toxicity 0.000 description 1
- 230000007696 reproductive toxicity Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003284 rhodium compounds Chemical class 0.000 description 1
- BDDWSAASCFBVBK-UHFFFAOYSA-N rhodium;triphenylphosphane Chemical compound [Rh].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 BDDWSAASCFBVBK-UHFFFAOYSA-N 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- XMSXOLDPMGMWTH-UHFFFAOYSA-N rivoglitazone Chemical compound CN1C2=CC(OC)=CC=C2N=C1COC(C=C1)=CC=C1CC1SC(=O)NC1=O XMSXOLDPMGMWTH-UHFFFAOYSA-N 0.000 description 1
- 229950010764 rivoglitazone Drugs 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- JWHOQZUREKYPBY-UHFFFAOYSA-N rubonic acid Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(=O)C(C)(C)C5CC(=O)C34C)C2C1)C(=O)O JWHOQZUREKYPBY-UHFFFAOYSA-N 0.000 description 1
- 229950000261 ruboxistaurin Drugs 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 108010068072 salmon calcitonin Proteins 0.000 description 1
- FFYNAVGJSYHHFO-UHFFFAOYSA-N sarpogrelate Chemical compound COC1=CC=CC(CCC=2C(=CC=CC=2)OCC(CN(C)C)OC(=O)CCC(O)=O)=C1 FFYNAVGJSYHHFO-UHFFFAOYSA-N 0.000 description 1
- 229950005789 sarpogrelate Drugs 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- 125000004469 siloxy group Chemical group [SiH3]O* 0.000 description 1
- 229960004058 simfibrate Drugs 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- SIGUVTURIMRFDD-UHFFFAOYSA-M sodium dioxidophosphanium Chemical compound [Na+].[O-][PH2]=O SIGUVTURIMRFDD-UHFFFAOYSA-M 0.000 description 1
- 229910001379 sodium hypophosphite Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- CMZUMMUJMWNLFH-UHFFFAOYSA-N sodium metavanadate Chemical compound [Na+].[O-][V](=O)=O CMZUMMUJMWNLFH-UHFFFAOYSA-N 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000004059 squalene synthase inhibitor Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 125000005156 substituted alkylene group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 230000035322 succinylation Effects 0.000 description 1
- 238000010613 succinylation reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960001685 tacrine Drugs 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
- 108010009573 talabostat Proteins 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- ADXGNEYLLLSOAR-UHFFFAOYSA-N tasosartan Chemical compound C12=NC(C)=NC(C)=C2CCC(=O)N1CC(C=C1)=CC=C1C1=CC=CC=C1C=1N=NNN=1 ADXGNEYLLLSOAR-UHFFFAOYSA-N 0.000 description 1
- 229960000651 tasosartan Drugs 0.000 description 1
- WRGVLTAWMNZWGT-VQSPYGJZSA-N taspoglutide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 WRGVLTAWMNZWGT-VQSPYGJZSA-N 0.000 description 1
- 229950007151 taspoglutide Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960005187 telmisartan Drugs 0.000 description 1
- XMLAPVZZWVHGGX-UHFFFAOYSA-N tert-butyl 3-(4-amino-2-fluorophenyl)propanoate Chemical compound CC(C)(C)OC(=O)CCC1=CC=C(N)C=C1F XMLAPVZZWVHGGX-UHFFFAOYSA-N 0.000 description 1
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
- JAELLLITIZHOGQ-UHFFFAOYSA-N tert-butyl propanoate Chemical compound CCC(=O)OC(C)(C)C JAELLLITIZHOGQ-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229950004704 tesaglitazar Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 229910052716 thallium Inorganic materials 0.000 description 1
- BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- OVRJVKCZJCNSOW-UHFFFAOYSA-N thian-4-one Chemical compound O=C1CCSCC1 OVRJVKCZJCNSOW-UHFFFAOYSA-N 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- MTKNGOHFNXIVOS-UHFFFAOYSA-N ticlopidine hydrochloride Chemical compound [H+].[Cl-].ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 MTKNGOHFNXIVOS-UHFFFAOYSA-N 0.000 description 1
- 229960002961 ticlopidine hydrochloride Drugs 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- LUBHDINQXIHVLS-UHFFFAOYSA-N tolrestat Chemical compound OC(=O)CN(C)C(=S)C1=CC=CC2=C(C(F)(F)F)C(OC)=CC=C21 LUBHDINQXIHVLS-UHFFFAOYSA-N 0.000 description 1
- 229960003069 tolrestat Drugs 0.000 description 1
- 125000005147 toluenesulfonyl group Chemical group C=1(C(=CC=CC1)S(=O)(=O)*)C 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- 108091008023 transcriptional regulators Proteins 0.000 description 1
- 229960001288 triamterene Drugs 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 1
- UBOXGVDOUJQMTN-UHFFFAOYSA-N trichloroethylene Natural products ClCC(Cl)Cl UBOXGVDOUJQMTN-UHFFFAOYSA-N 0.000 description 1
- 125000005950 trichloromethanesulfonyloxy group Chemical group 0.000 description 1
- PTMFUWGXPRYYMC-UHFFFAOYSA-N triethylazanium;formate Chemical compound OC=O.CCN(CC)CC PTMFUWGXPRYYMC-UHFFFAOYSA-N 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 229940061414 trileptal Drugs 0.000 description 1
- TWQULNDIKKJZPH-UHFFFAOYSA-K trilithium;phosphate Chemical compound [Li+].[Li+].[Li+].[O-]P([O-])([O-])=O TWQULNDIKKJZPH-UHFFFAOYSA-K 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- IIHPVYJPDKJYOU-UHFFFAOYSA-N triphenylcarbethoxymethylenephosphorane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)OCC)C1=CC=CC=C1 IIHPVYJPDKJYOU-UHFFFAOYSA-N 0.000 description 1
- AVCVDUDESCZFHJ-UHFFFAOYSA-N triphenylphosphane;hydrochloride Chemical compound [Cl-].C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 AVCVDUDESCZFHJ-UHFFFAOYSA-N 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- NHDIQVFFNDKAQU-UHFFFAOYSA-N tripropan-2-yl borate Chemical compound CC(C)OB(OC(C)C)OC(C)C NHDIQVFFNDKAQU-UHFFFAOYSA-N 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- ACWBQPMHZXGDFX-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 ACWBQPMHZXGDFX-QFIPXVFZSA-N 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- HHJUWIANJFBDHT-KOTLKJBCSA-N vindesine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(N)=O)N4C)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 HHJUWIANJFBDHT-KOTLKJBCSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- 229940100050 virazole Drugs 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- SXONDGSPUVNZLO-UHFFFAOYSA-N zenarestat Chemical compound O=C1N(CC(=O)O)C2=CC(Cl)=CC=C2C(=O)N1CC1=CC=C(Br)C=C1F SXONDGSPUVNZLO-UHFFFAOYSA-N 0.000 description 1
- 229950006343 zenarestat Drugs 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 229910000166 zirconium phosphate Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
- C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
- C07C309/66—Methanesulfonates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/51—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/18—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/11—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/12—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
- C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
- C07D231/24—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms having sulfone or sulfonic acid radicals in the molecule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Definitions
- the present invention relates to a novel compound having a GPR40 receptor function regulating activity and useful as an agent for preventing and treating diabetes.
- GPR40 G-protein coupled receptors
- GPR40 agonist promotes insulin secretion
- GPR40 antagonist inhibits insulin secretion
- these agonists and antagonists are useful as therapeutic agents for type 2 diabetes, obesity, impaired glucose tolerance, insulin resistance, and neurodegenerative diseases (Alheimer's disease) (WO 02/057783). See bread fret).
- WO 03Z0721 02 pamphlet has the formula:
- R 3, R4 H or the like; R 9, R 1 0: H, (C X -C 4) alkyl, halo, (Ci -C 4) alkoxy such as; Q: CH 2; W: (CH 2) r N (R 20) (CH 2 ) k
- WO 02/0 2 6 7 32 No. 2 has the formula:
- U.S. Patent Application Publication No. 200 2/000 2203 includes the formula:
- the compound represented by is useful for diabetes, arteriosclerosis, Alzheimer's disease, and rheumatoid arthritis.
- An object of the present invention is to provide a novel compound having a PR40 receptor function regulating action.
- the present inventors have conducted various studies and found that the compounds represented by the following formulas (1) and (1,) have unexpectedly excellent GPR40 receptor agonist activity, and It also has excellent properties as a pharmaceutical such as stability, and has been found to be a safe and useful drug as a preventive and therapeutic drug for mammalian GPR40 receptor-related conditions or diseases.
- the present invention has been completed based on the findings.
- the present invention is as follows.
- Ar represents a cyclic group which may be substituted (provided that the cyclic group is not a 4-piperiduryl group)
- Ring B is an optionally substituted ring (wherein the ring is not a thiazole or oxazole ring)
- W represents a bond or a C 6 alkylene group which may be substituted with a — 6 alkoxy group
- X and Xa are the same or different and each represents CH or N,
- Y is O or CR 6 R 7 (R 6 and R 7 are the same or different and each represent a hydrogen atom, a halogen atom, an alkyl group or an optionally substituted hydroxy group, or R 7 is R 1a To form a 4- to 8-membered ring)
- R 1 and R la are the same or different and each represents a hydrogen atom, a halogen atom, a di- 6 alkyl group or a C i- 6 alkoxy group,
- R 2 represents a hydrogen atom, a —6 alkyl group or an optionally substituted acyl group
- R 3 and R 4 are the same or different and each represents a hydrogen atom or a halogen atom, R 5 represents an amino group which may optionally be a good heat Dorokishi group or substituted or optionally substituted.
- ring B represents an optionally substituted benzene ring fused non-aromatic ring ( ⁇ , the ring is not a tetrahydroquinoline ring).
- X and R 1 have the same meanings as in the above [1]
- Y is O or CR 6 R 7 (R 6 and R 7 are the same or different and each represents a hydrogen atom, a halogen atom, a C- 6 Represents a kill group or an optionally substituted hydroxy group, or R 7 is bonded to a methine group adjacent to X to form a 4- to 8-membered ring).
- R 6 and R 7 are the same or different and each represents a hydrogen atom, a halogen atom, a C- 6 Represents a kill group or an optionally substituted hydroxy group, or R 7 is bonded to a methine group adjacent to X to form a 4- to 8-membered ring).
- Ar represents an optionally substituted cyclic group
- Ring B ′ is an optionally substituted ring
- V represents a bond or a spacer having 1 to 3 atoms in the main chain
- W is a bond or a 6 alkylene group which may be substituted with a C 6 alkoxy group
- X and Xa are the same or different and each represents CH or N,
- Y is O or CR 6 R 7 (R 6 and R 7 are the same or different and each represents a hydrogen atom, a halogen atom, a —6 alkyl group or an optionally substituted hydroxy group, or R 7 is R la To form a 4- to 8-membered ring)
- R 1 and R 1a are the same or different and each represents a hydrogen atom, a halogen atom, a C- 6 alkyl group or a Ci 6 alkoxy group,
- R 2 is a hydrogen atom, —6 alkyl group or an optionally substituted acyl group
- R 3 and R 4 are the same or different and each is a hydrogen atom or a halogen atom
- R 5 is an optionally substituted It represents a droxy group or an amino group which may be substituted.
- X and R 1 have the same meanings as in the above [11]
- Y is O or CR 6 R 7 (R 6 and R 7 are the same or different and each represents a hydrogen atom, a halogen atom, a Ci 6 alkyl R 7 represents a group or an optionally substituted hydroxy group, or R 7 is bonded to a methine group adjacent to X to form a 4- to 8-membered ring).
- the insulin secretagogue according to the above [11].
- W may be substituted with a —6 alkoxy group.
- a GPR40 receptor function modulator comprising a compound (1, 1) or a prodrug thereof.
- a pharmaceutical comprising the compound (1) or a prodrug thereof.
- a method for regulating a GPR40 receptor function in a mammal comprising administering to the mammal an effective amount of the compound (1 ′) or a prodrug thereof.
- a method for promoting insulin secretion in a mammal comprising administering to the mammal an effective amount of compound (1,) or a prodrug thereof.
- a method for preventing or treating diabetes in a mammal comprising administering an effective amount of the compound (1) or a prodrug thereof to the mammal.
- the compound of the present invention has an excellent GPR40 receptor function regulating action, and can be used as a preventive or therapeutic agent for diabetes and the like and as an insulin secretagogue.
- halogen atom in the present specification includes a fluorine atom, a chlorine atom, a bromine atom and an iodine atom unless otherwise specified.
- examples of the “optionally substituted hydrocarbon group” in the present specification include, for example, “optionally substituted C i- 6 alkyl group” and “optionally substituted C 2 - 6 alkenyl group ",” optionally substituted C 2 - 6 alkyl group “,” Ji optionally substituted 3 - 8 cycloalkyl group “,” optionally substituted C 6 _ 14 Ariru group ",” optionally substituted C 7 even if - like 16 Ararukiru group "can be mentioned.
- examples of the “rCi-e alkyl group” in the present specification include, for example, methyl, ethyl, propyl, isopropyl, butyl, isoptyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl And so on.
- C 2 _ 6 alkenyl group in the present specification, unless otherwise specified, for example Bulle, propenyl, isopropenyl El, 2-heptene one 1 one I le, 4 _ pentene one 1 one I le , 5-hexene-1-yl and the like.
- C 2 6 alkynyl group for example, 2-butyne one 1 one I le, 4 one pentyne one 1 one I le, and 5 one to the connexin one 1 Iru No. In 4872 herein - as ". C 3 8 cycloalkyl group", unless otherwise specified, examples Ebashiku port propyl, consequent opening Buchinore, consequent opening pentyl, Kishinore can be mentioned up to consequent opening.
- Ji 6 - 1 4 Ariru group in the present specification as, unless otherwise stated, for example, phenylene Honoré, 1-naphthyl, 2-Nafuchinore, 2 - Bifue - Rinore, 3 - Bifue - Rinore, 4 Bifue Nilyl, 2-anthryl and the like.
- the C 6 one 1 4 Ariru may be partially saturated, as the C 6 ⁇ 4 Ariru which are partially saturated, such as Tetorahi Doronafuchiru the like.
- C 7 _ 1 6 Ararukiru group unless otherwise specified, For example benzyl, phenethyl, Jifueerumechiru, 1 one naphthylmethyl, 2 one naphth Noremechinore, 2, 2-Jifue - Ruechiru, 3 —Phenylphenyl, 4-phenylphenol, 5-phenolinole, 2-biphenylinolemethine, 3-biphenylinolemethine, 4-biphenylinolemethine, and the like.
- dialkoxy group includes, for example, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tert-butoxy, pentyloxy, hexyloxy and the like, unless otherwise specified.
- alkoxy group includes heptyloxy, octyloxy, noeroxy, decyloxy and the like in addition to the above Ci- 6 alkoxy group.
- the “. ⁇ (; Alkoxy group ⁇ alkoxy group” ”in the present specification includes, for example, methoxymethoxy, methoxyethoxy, ethoxymethoxy, ethoxymethoxy and the like, unless otherwise specified.
- substituted oxy group in the present specification, a hydroxy group substituted by a “heterocyclic group” described below can be mentioned.
- heterocyclic oxy group examples include tetrahydranyl bilanyloxy, thiazolyloxy, pyridyloxy, virazolyloxy, oxazolyloxy, cheloxy, furyloxy, tetrahydridothiopyranyl oxy, 1,1-dioxydidotetrahydro thioryloxyl, 1-oxide tetrahydrothiopyranyloxy and the like.
- alkylsulfonyloxy group in the present specification, unless otherwise specified, for example, methylsulfonyloxy, ethylsulfonyloxy and the like can be mentioned.
- the “tree Ce alkyl-silyloxy group” includes, for example, trimethylsilyloxy and tert-butyl (dimethyl) silyloxy, unless otherwise specified.
- the “optionally substituted mercapto group” in the present specification includes, for example, “mercapto group”, “optionally substituted. Alkylthio group”, “substituted Optionally substituted heterocyclic thio group "and” optionally substituted C
- rc 6 alkylthio group J in the present specification unless otherwise specified, for example, methylthio, ethylthio, propylthio, isopropylthio, butylthio, sec-butylthio, tert-butylthio and the like can be mentioned.
- the “C. alkylthio group” in the present specification includes, in addition to the above-mentioned alkylthio group, heptylthio, octylthio, noerthio, decylthio and the like.
- heterocyclic thio group in the present specification, a mercapto group substituted by the below-mentioned “heterocyclic group” can be mentioned.
- Preferred examples of the heterocyclic thio group include tetrahydroxy Raelthio, thiazolylthio, pyridylthio, virazolylthio, oxazolylthio, chenirthio, furylthio and the like.
- the “heterocyclic group” in the present specification includes, for example, one or two selected from a nitrogen atom, a sulfur atom and an oxygen atom other than a carbon atom as a ring-constituting atom.
- a 5- or 6-membered aromatic heterocyclic group is preferable. Specifically, for example,
- pyrrolidinyl eg, 1-pyrrolidinyl, 2_pyrrolidinyl, 3-pyrrolidinyl
- oxazolidinyl eg, 2-oxazolidinyl
- imidazolinyl eg, 1-imidazolinyl, 2- ⁇ f midazolinyl, 4-imidazolin-
- Piperidyl example: 1-piperidinyl, 2-piridinyl, 3-piperidinyl, 4-piperidiel
- piperazinyl example: 1-piperazinyl, 2-piperazur
- morpholinyl Example: 2-morpholinyl, 3-morpholinyl.
- morpholinolinole Thiomonoleolinyl (Example: 2-thiomorpholinolene, 3-thiomonoleolininole, 4-thiomorpholinyl), Tetrahydrobila- (Example: 2-tetrahydroviranil, 3-tetrahydroviranyl, 4-tetrahydroviranil), oxetanil (Example: 2-oxetanil) 3-oxosetanyl), oxopyrrolidinyl (example: 2-oxopyrrolidine 1-11 ⁇ , 2-oxopyrrolidine 13_yl, 2-oxopyrrolidine-4-yl, 21-oxopyrrolidine-1 5-y , 3-oxopyrrolidine-11-yl), dioxopyrrolidinyl (eg, 2,5-dioxopyrrolidine-11-yl, 25-dioxopyrrolidine-13-yl), tetrahi Dorochovillaninore (e
- rC ⁇ ealkylsulfinyl group in the present specification, unless otherwise specified, for example, methylsulfienole, ethylsulfiel and the like can be mentioned.
- the - "1 4 ⁇ reel sulfonyl group C 6" otherwise stated no limit is, for example, Fuenirusuruho - herein le, 1 one naphthylsulfonyl, etc. 2 one Nafuchirusuru Honiru the like.
- the “carboxyl group which may be esterified” in the present specification includes, for example, a carboxyl group, a C alkoxy monocarbonyl group (eg, methoxycasolevorenole, ethoxycanoleponinole, propoxy). Kanorepoenore, tert- butoxide Kishika Poniru etc.), C 6 - 1 4 Ariruokishi Ichiriki Lupo - Le group (eg phenoxy carbo - le, etc.), C 7 - 6 Ararukiruokishi one carbonyl group (e.g. Benjiruoki aryloxycarbonyl, Phenethyloxycarbol, etc.).
- the “optionally halogenated C 16 alkyl group” in the present specification may be the same as the above-mentioned “optionally substituted with 1 to 5 halogen atoms”.
- Alkyl group ".
- methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, isobutyl, trifluoromethyl and the like can be mentioned.
- the “optionally halogenated C-6 alkoxy group” in the present specification includes the above “. ⁇ 6” which may be substituted with 1 to 5 of the above “halogen atoms”.
- Alkoxy group ".
- methoxy, ethoxy, isopropoxy, tert-butoxy, trifluoromethoxy and the like can be mentioned.
- the “mono- or di-C-6 alkyl-amino group” in the present specification includes, unless otherwise specified, an amino group mono- or di-substituted with the above “-6 alkyl group”. For example, methylamino, ethylamino, propylamino, dimethylamino, getylamino and the like can be mentioned.
- N-C - 6 alkyl one N-C 6 - 14 Ariruamino group as a means, unless otherwise specified, the rc ⁇ 6 alkyl group "and the" c 6 - 14 ⁇ aryl group " And an amino group substituted with For example, N-methyl-N-phenylamino, N-ethyl-N-phenylamino and the like can be mentioned.
- N-C 6-alkyl one N-C 7 _ 16 Ararukiru primary amino group in the present specification, the rc ⁇ 6 alkyl group "and the" C 7 - 16 Ararukiru And an amino group substituted with a “group”.
- N-methyl-N_benzylamino, N-ethyl-N-benzylamino and the like can be mentioned.
- N—C 6 alkyl_N_C 6 alkyl mono-alkyl-amino group in the present specification refers to the above “.
- Alkyl group and anoalkyl-canolepo-nore group (eg, acetyl, isobutanoinole) , Isopentanoyl).
- the “mono- or di-Ci-ealkyl mono-rubamoyl group” in the present specification includes a mono- or di-substituted mono- or di-substituted lubamoyl group as described above.
- methylcarbamoyl, ethylcarbamoyl, dimethyl / recanolebamoinole, getylcarbamoyl, ethylmethylcarbamoinole and the like can be mentioned.
- the term “mono- or di-5- to 7-membered heterocyclic monovalent rubamoyl group” refers to a mono- or di-monosubstituted mono- or di-monosubstituted rubamoyl group unless otherwise specified.
- the 5- to 7-membered heterocyclic group includes, as a ring-constituting atom, a heteroatom containing one or two or one to four heteroatoms selected from a nitrogen atom, a sulfur atom and an oxygen atom in addition to a carbon atom. And a ring group.
- Preferable examples of the “mono- or di-5- to 7-membered heterocyclic-carbamoyl group” include 2-pyridylcanolebamoyl, 3-pyridylcarbamoyl, 4-pyridylcarbamoyl, 2-chlorocarbamoyl, and 3-chlorocarbamoyl. Rucarbamoyl and the like.
- the “mono- or di-Ci- 6 alkyl-sulfamoyl group” in the present specification includes A sulfamoyl group mono- or di-substituted with an “alkyl group” is used, and examples thereof include methylsulfamoyl and ethylsulfur.
- Optionally substituted C i-e alkyl group in the present specification, "optionally substituted C 2 _ 6 alkenyl group”, “optionally substituted C 2 _ 6 alkynyl group”, “Optionally substituted Ci-io alkoxy group (including optionally substituted anoreoxy group)”, “optionally substituted d-6 alkylsulferooxy group” and “substituted An alkylthio group (including an optionally substituted Ci-6 alkylthio group) ”is, for example,
- - 8 cycloalkyl group, - 6 alkoxy groups, C 6 alkoxy one C Bok 6 an alkoxy group, C 6 alkylthio group, C 6 alkylsulfinyl group, CI- 6 alkyl sulfonyl group, esterified carboxyl group which may be, power Rubamoiru group, Chiokarubamoiru group, mono- or di-C 6 alkyl Ichiriki Rubamoiru group, mono- one or di- one c 6 - 14 Ariru Ichiriki Rubamoiru group, a sulfamoyl group, mono- or di one C i-6 alkyl Ruth Alpha
- a heterocyclic group optionally substituted with 1 to 3 substituents selected from a moyl group and a mono- or di-C 6 — i 4 arylusulfamoyl group (preferably furyl, pyridyl, chloro, pyrazolyl, Thiazolyl, oxazolyl,
- N- C 6 alkyl one N-C 6 - 14 ⁇ Li Ichiru - Amino group
- N- - 6 alkyl one N-C 7 - 16 Ararukiru primary amino group
- Ci- 6 alkylthio group optionally substituted with 6 alkoxy groups
- halogen atom arsenic Dorokishi group, an amino group, Etro group, Shiano group, halogen of which may be C alkyl group, mono- or di-one C Arukirua amino group, C 6 - 1 4 Ariru group, mono- Or di C 6 — 14 arylamino, C
- halogen atom arsenic Dorokishi group, an amino group, a nitro group, Shiano group, halogen of which may be optionally C 1-6 alkyl group, mono- or di-one C 1-6 alkyl Ichia amino group, C 6 - 14 Ariru group, mono- or di-one C 6 one 14 Ariruamino groups, C
- (32) a tree C 6 alkyl-silyloxy group; (33) Nitrogen-containing heterocyclic monocarbonyl group (eg, pyrrolidyl-carbol, piberidinocarbonyl, morpholino-carbon, thiomorpholinocarbonyl);
- Nitrogen-containing heterocyclic monocarbonyl group eg, pyrrolidyl-carbol, piberidinocarbonyl, morpholino-carbon, thiomorpholinocarbonyl
- Ci- 6 alkyl group which may be substituted
- - 8 cycloalkyl group d-6 alkoxy group, C i-6 alkoxy one C 6 an alkoxy group, - 6 alkylthio group, C 1-6 'alkylsulfinyl group, C ⁇ 6 alkyl sulfonyl groups, have been esterified Good carboxyl group, carbamoyl group, thiocarbamoyl group, mono- or di-C 6 alkyl mono-rubbamoyl group, mono- or di- 6 _ 14 arylyl mono-rubbamoyl group, sulfamoyl group, mono- or di-C 6- alkyl one sulfamoyl group and mono- or di-one C 6 _ 14 ⁇ Li one loose to 1 selected from sulfamoyl group which may be substituted with 1-3 substituents C 6 - 14 Ariru group;
- halogen reduction is C i one optionally 6 alkyl group, mono- or di-one C Iota_ 6 alkyl Ichia amino group, C 6 - 14 aryl, mono or di c 6 14 aryl, amino
- a halogen atom arsenic Dorokishi group, an amino group, a nitro group, Shiano group, optionally halogen of C - 6 alkyl group, mono- one or di- one - 6 Arukirua amino group, C 6 - 14 Ariru group , mono one or di- C 6 - 14 Ariruamino groups, C
- a halogen atom arsenic Dorokishi group, an amino group, a nitro group, Shiano group, optionally halogen of C - 6 alkyl group, mono one or di- C Bok 6 alkyl Ichia amino group, C 6 _ 14 Ariru group, mono- or di-one C 6 - 14 Ariruamino groups, C
- Ci-6 optionally substituted with a 6 alkoxy group — 6 alkylthio group
- (21) a C 6 alkylsulfyl group which may be substituted with a C i-6 alkoxy group;
- Ci-6 alkylsulfol group which may be substituted by Ci-6 alkoxy group; (23) carboxyl group which may be esterified;
- Nitrogen-containing heterocyclic monoluponyl group eg, pyrrolidylcarbonyl, piberidinocarbonyl, morpholinocarbonyl, thiomorpholinocarbonyl;
- C 6 alkyl mono-l-amino group eg, acetylamino, propionylamino
- C 7 - 16 Ararukiruokishi group "heterocyclic sulfonylamino - Ruokishi group”, “heterocyclic Chi O group”, “C 6 _ 14 Ariruchio group” and “C 7 _ 16 7 Rarukiruchio group” can be mentioned.
- Ci-alkyl group (1) an optionally substituted Ci-alkyl group
- an optionally substituted heterocyclic group preferably furyl, pyridyl, chenyl pyrazolyl, thiazolyl, oxazolyl
- an amino group which may be substituted with one or two substituents selected from the above When the “optionally substituted amino group” is an amino group substituted with two substituents, these substituents form a nitrogen-containing complex ring together with an adjacent nitrogen atom. Is also good.
- the "nitrogen-containing heterocycle” include, for example, at least one nitrogen atom other than a carbon atom as a ring-constituting atom, and one or two heteroatoms selected from an oxygen atom, a sulfur atom, and a nitrogen atom. Examples thereof include a 5- or 7-membered nitrogen-containing heterocyclic ring which may be contained.
- nitrogen-containing heterocycle examples include pyrrolidine, imidazolidine, virazolidine, piperidine, piperazine, morpholine, thiomorpholine, thiazolidine, oxazolidine and the like.
- “optionally substituted acyl group” includes, unless otherwise specified, a formula: one COR 8 , —CO—OR 8 , —SO 2 R 8 , one SOR 8 , one PO ( oR 8) (oR 9), one CO- NR 8 a R 9 a and CS- NR 8 a R 9 a [wherein, R 8 Oyo Pi R 9 are the same or different and each is a hydrogen atom, substituted shows the heterocyclic group which may optionally be a hydrocarbon group or a substituted may have, 1 83 Oyobi 1 9!
- each is a hydrogen atom, optionally substituted hydrocarbon group or or shows a replacement which may be a heterocyclic group
- tables in R 8 a and R 9 a, together with the adjacent nitrogen atom, may a nitrogen-containing heterocyclic ring which may be substituted formed. and] And the like.
- nitrogen-containing heterocycle of R 8 a and R 9 a is formed together with the adjacent nitrogen atom "substituted but it may also have nitrogen-containing heterocycle", for example, at least in addition to carbon atoms as a ring-constituting atom
- nitrogen-containing heterocycle for example, at least in addition to carbon atoms as a ring-constituting atom
- a 5- to 7-membered nitrogen-containing heterocyclic ring containing one nitrogen atom and optionally containing one or two hetero atoms selected from an oxygen atom, a sulfur atom and a nitrogen atom is exemplified.
- nitrogen-containing heterocycle examples include pyrrolidine, imidazolidine, virazolidine, piperidine, piperazine, morpholine, thiomorpholine, thiazolidine, oxazolidine and the like.
- the nitrogen-containing heterocyclic ring may have one or two substituents at substitutable positions.
- substituents a hydroxy group, optionally halogenated C one 6 alkyl group, Ji 6-1 14 Ariru group, and C 7 _ 16 7 aralkyl group.
- Preferred examples of the "optionally substituted acyl group" include:
- a C 6 alkyl-carboxy group optionally substituted by 1 to 3 halogen atoms eg, acetyl, isoptanyl, isopenpentanoyl
- a C 6 alkoxy monocarbol group which may be substituted with 1 to 3 halogen atoms (eg, methoxycanolepony ⁇ ethoxycanolepony /, propoxycanoleponinole, tert-butoxycanoleponinole); C 3 - 8 consequent opening alkyl one carbonyl group (e.g. cyclopentyl Honoré Kano levo Nino les, Kishinorekanorepo two Honoré cyclohexylene);
- C 6 _ 14 Ariruokishi one carbo - Le group (e.g. phenylalanine O propoxycarbonyl - le, naphthoquinone Chino Les oxy Kano repo sulfonyl);
- Yutoro may be substituted with a group C 6 - 14 ⁇ Li one Rusuruhoniru group (e.g. phenyl Sunorehoninore;);
- a nitrogen-containing heterocyclic monocarber group eg, pyrrolidylcarbonyl, piperidinocarbonyl, morpholinocarbol; thiomorpholinocarbophenol
- pyrrolidylcarbonyl e.g, pyrrolidylcarbonyl, piperidinocarbonyl, morpholinocarbol; thiomorpholinocarbophenol
- a C i- 6 alkylsulfuryl group which may be substituted with 1 to 3 halogen atoms;
- Dude! represent an optionally substituted cyclic group.
- the "cyclic group” for example C 3 _ 8 cycloalkyl group, C 6 - 14 Ariru groups, and heterocyclic groups.
- phenyl, naphthyl, thiazolyl, pyrazolyl, pyri Jil, indolyl, dihydroquinolinyl, tetrahydroquinolinyl, 1-piperidur and the like are preferable, and phenyl, naphthyl, thiazolyl, pyrazolyl, indolyl, dihydroquinolinyl and the like are more preferable.
- the cyclic group represented by Ar is not a 4-piperidinyl group.
- the cyclic group represented by 1: ' may have, for example, 1 to 5, preferably 1 to 3, substituents at substitutable positions.
- substituent the aforementioned
- Optionally substituted 3 - 8 cycloalkyl group those exemplified as the substituents of the may be used.
- each substituent may be the same or different.
- the substituent is preferably
- C - 6 alkyl group preferably, a halogen atom, may be halogenation - 6 alkoxy group, C 6 - 1 4 Ariru group, C 6 - 1 4 ⁇ Li Ruokishi A C 16 alkyl group which may be substituted with 1 to 3 substituents selected from groups and the like);
- Ji may be substituted with 1-3 substituents to 1 selected from such alkyl groups 6 - - (2) a halogen atom, a C may be halogenated 1 4 Ariru group;
- C i-6 alkoxy group (preferably substituted, (a) an optionally halogenated C - 6 alkoxy group; (b) C 3 - 8 cycloalkyl group; (c) carboxy (D) mono- or di-C i-6 alkyl monocyclic rubamoyl group; (e) nitrogen-containing heterocyclic monocarbonyl group (preferably morpholino phenol); (f) C 6 alkylthio group; g) C 6 alkylsulfonyl group; (h) heterocyclic group which may be substituted with 1 to 3 substituents selected from hydroxy group, Ci- 6 alkyl group, C alkoxy group and the like (preferably Is furyl, pyridyl, chenyl, pyrazolyl, thiazolyl Edinburghi Dorobiraniru, Tetorahi Dorochiobiraniru, 1, 1 - di O sulfoxide tetra arsenide Dorochiopiraeru,
- a heterocyclic oxy group which may be substituted by 1 to 3 substituents selected from C 6 alkyl group, — 6 alkoxy group and the like (preferably pyridyloxy, tetrahydrobiraniloxy, tetrahydroxy) Thioviraniloxy, 1,1-dioxide tetrahydrotillohydroraniloxy, 1-oxide tetrahydrodrothiopyraeroxy);
- Ring B and ring B represent an optionally substituted ring.
- the “ring” includes, for example, aromatic rings such as aromatic hydrocarbons and aromatic heterocycles; and non-aromatic rings such as alicyclic hydrocarbons and non-aromatic heterocycles.
- aromatic hydrocarbon examples include an aromatic hydrocarbon having 6 to 14 carbon atoms.
- aromatic hydrocarbon examples include benzene, naphthalene, anthracene, phenanthrene, and acenaphthylene.
- the aromatic heterocyclic ring examples include, for example, a 5- to 7-membered monocyclic aromatic heterocyclic ring containing 1 to 4 heteroatoms selected from an oxygen atom, a sulfur atom and a nitrogen atom in addition to a carbon atom as a ring-constituting atom. Or a fused aromatic heterocyclic ring.
- the condensed aromatic complex ring examples include a 5- to 7-membered monocyclic aromatic heterocycle, a 6-membered ring containing 1 to 2 nitrogen atoms, a benzene ring or a 5-membered ring containing one sulfur atom. And a ring in which a member ring is condensed.
- aromatic heterocycle examples include furan, thiophene, pyridine, pyrimidin, pyridazine, pyrazine, pyrrole, imidazonole, pyrazole, isoxaxonale, isothiazonole, oxazonole, thiazolone, oxazodiazolenole, and the like.
- Diazoles triazoles, tetrazoles, quinolines, quinazolines, quinoxalines, benzofurans, benzothiamines, benzoxamines, benzothiazonoles, benzui midazonoles, indonenoles, 1H-indazonoles, 1H-pyro mouths [2 , 31b] pyrazine, 1H-pyromouth pyridine, 1H-imidazopyridine, 1H-imidazopyrazine, triazine, isoquinoline, benzothiadiazole and the like.
- alicyclic hydrocarbon examples include a saturated or unsaturated alicyclic hydrocarbon having 3 to 12 carbon atoms, such as cycloalkane, cycloalkene, and cycloalkadiene. These alicyclic hydrocarbons may be condensed with a benzene ring. Examples of the benzene ring condensed alicyclic hydrocarbon include indane.
- cycloalkane examples include cycloalkane having 3 to 10 carbon atoms, for example, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, bicyclo [2.2.1] Heptane, bicyclo [2.2.2] octane, bicyclo [3.2.1] octane, bicyclo [3.2.2] nonane, bicyclo [3.3.1] nonane, bicyclo [4.2.1] ] Nonane, bicyclo [4.3.1] decane and the like.
- cycloalkene examples include a cycloalkene having 3 to 10 carbon atoms, such as cyclobutene, cyclopentene, and cyclohexene.
- cycloalkadiene examples include cycloalkadiene having 4 to 10 carbon atoms, such as 2,4-cyclopentadiene, 2,4-cyclohexadiene, and 2,5-cyclohexadiene.
- non-aromatic heterocyclic ring examples include, for example, a 5- to 7-membered monocyclic non-aromatic heterocyclic ring containing 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen atoms in addition to carbon atoms. And a ring or a fused non-aromatic heterocycle.
- condensed non-aromatic heterocyclic ring examples include these 5- to 7-membered monocyclic non-aromatic heterocyclic ring, a 6-membered ring containing 1 to 2 nitrogen atoms, a benzene ring or one sulfur atom And a ring fused with a 5-membered ring.
- non-aromatic heterocycle examples include pyrrolidine, pyrroline, virazolidine, piperidine, piperazine, monoreforin, thiomonoreforin, hexamethyleneimine, Monocyclic non-aromatic heterocycles such as oxazolidine, thiazolidine, imidazolidine, imidazoline, tetrahydrofuran, dihydrofuran, tetrahydrothiophene, dihydrothiophene, azepane, tetrahydropyridine; benzene ring such as dihydrobenzozofuran, dihydrobenzothiophene And fused non-aromatic heterocycles.
- a benzene ring, a pyrazole ring, an indane ring and the like are preferable, and a benzene ring is particularly preferable.
- ring represented by ring B is not a thiazole ring or an oxazole ring.
- Ring B is a benzene ring-fused non-aromatic ring which may be substituted when W is a bond (however, the ring is not a tetrahydroquinoline ring).
- the benzene ring condensed non-aromatic ring includes the benzene ring condensed alicyclic hydrocarbon and the benzene ring condensed non-aromatic hetero ring described above.
- the benzene fused non-aromatic ring is preferably an indane ring, a dihydrobenzofuran ring or the like. In particular, an indane ring is preferred.
- the ring represented by ring B and ring B ′ may have, for example, 1 to 5, preferably 1 to 3, substituents at substitutable positions.
- substituents those exemplified as the substituent in the "optionally substituted C 3 _ 8 cycloalkyl group" is used.
- each substituent may be the same or different.
- the substituent is preferably
- C 6 alkoxy one d-6 to 1 selected from an alkoxy group may be substituted with 1-3 location substituent C 6 - 1 4 Ariru group;
- the “main chain” here is a divalent straight chain connecting Ar and ring B, and the “number of atoms in the main chain” is counted so that the number of atoms in the main chain is minimized.
- the carbon atom and the nitrogen atom constituting the main chain may have one or more substituents at substitutable positions. When there are two or more substituents, each substituent may be the same or different.
- C 3 _ 8 cycloalkyl group As the “location substituent”, those exemplified as the substituents that put on the “optionally substituted C 3 _ 8 cycloalkyl group” is used. Among them, a good C 6 alkyl group optionally substituted (preferably, an alkyl group, C 7 - 16, etc. Ararukiru groups) and C 6 14 Ariru groups are preferable, C ⁇ e alkyl, C 7 16 Araru Kill group and C 6 ⁇ 4 Ariru group.
- C 6 alkyl group optionally substituted preferably, an alkyl group, C 7 - 16, etc. Ararukiru groups
- C 6 14 Ariru groups are preferable, C ⁇ e alkyl, C 7 16 Araru Kill group and C 6 ⁇ 4 Ariru group.
- W is a good C ⁇ 6 alkylene emissions group optionally substituted with a bond or Ci 6 alkoxy group.
- the “. ⁇ 6 alkylene group” is linear or branched, for example, Examples include methylene, ethylene, 1-methylethylene, propylene, 1-ethynoleethylene 1-methynolepropylene, 2-methynolepropylene, butylene, pentylene, hexylene and the like.
- the “ six alkylene group” may have, for example, 1 to 3, preferably 1 or 2 “0 6 alkoxy groups” at substitutable positions.
- W is preferably a C 6 alkylene group optionally substituted by a Ce alkoxy group, and more preferably methylene.
- X and Xa are the same or different and each represents CH or N, and is preferably CH.
- Y represents O or CR 6 R 7 .
- R 6 and R 7 are identical or different dates, each a hydrogen atom, a halogen atom, - 6 alkyl or substituted or showing a Moyoi hydroxy group, R 7 is combined with R la : To form an 8-membered ring. Na us, if R 7 forms a 4-8 membered ring with R 1 a, R 6 represents a hydrogen atom, a halo gen atom, Ji alkyl group or an optionally substituted hydroxy group. As the “optionally substituted hydroxy group”, a hydroxy group, a Ci 6 alkoxy group and the like are preferable.
- Examples of the “4- to 8-membered ring” formed by combining R 7 with R la include those exemplified as ring B, which are 4- to 8-membered rings.
- ring B which are 4- to 8-membered rings.
- benzene a 5- to 7-membered monocyclic aromatic heterocyclic ring (preferably furan, thiophene), a 5- to 7-membered monocyclic non-aromatic heterocyclic ring (preferably, dihydrofuran, dihydrothiophene)
- cycloalkene having 4 to 8 carbon atoms, and cycloalkadiene having 4 to 8 carbon atoms are preferred.
- a 5- to 7-membered monocyclic aromatic heterocyclic ring preferably, furan, thiophene
- a 5- to 7-membered monocyclic non-aromatic heterocyclic ring preferably, dihydrofuran, dihydrofurothiophene
- X and R 1 are as defined above, Y is O or CR 6 R 7 (R 6 and R 7 are the same or different and each may be a hydrogen atom, a halogen atom, an alkyl group or substituted Or a good hydroxy group, or R 7 is bonded to a methine group adjacent to X to form a 4- to 8-membered ring].
- R 6 and R 7 are preferably the same or different and are each a hydrogen atom or a hydroxy group, and more preferably a hydrogen atom.
- R 1 and R 1a are the same or different and each represent a hydrogen atom, a halogen atom, a C 6 alkyl group or a C 6 alkoxy group.
- a hydrogen atom, a 6- alkyl group and a halogen atom are preferable, and a hydrogen atom and a halogen atom (preferably a fluorine atom) are particularly preferable.
- R 2 represents a hydrogen atom, a C 6 alkyl group or an optionally substituted acyl group
- R 2 is preferably a hydrogen atom.
- R 3 and R 4 are the same or different and each represent a hydrogen atom or a halogen atom 20, and are preferably a hydrogen atom.
- R 5 represents a optionally substituted arsenide Dorokishi be the group or an optionally substituted amino group, preferably a human Dorokishi group or C ⁇ e alkoxy group, more favorable Mashiku is a hydroxy group.
- the compound (1) or a salt thereof is 3- [4-[[3- (tetrahydropyran-2-yloxy 25 cis) benzyl]-(2,4,6-trimethinolebenzenebenzenesulfo-nore) amino] phenyl] Contains no methyl propionate.
- Compound (1 ′) is preferably compound (1).
- Preferred examples of the compound (1) include the following compounds. [Compound A]
- CI- 6 alkyl group preferably, optionally substituted with halide which may be C Bok 6 alkoxy group, 1 to 3 substituents selected from such C 6 one 14 Ariru group Or a C ⁇ 6 alkyl group);
- One to three substituted with a substituent is C 6 one 14 optionally Ariru group selected from a halogen atom;
- Optionally substituted C - 6 alkoxy group (preferably, halogenated may CI- 6 alkoxy group, C 3 - 8 have been substituted with 1 selected from cycloalkyl group and the like to three substituents C ⁇ 6 alkoxy group);
- Alkoxy one C - 1 no selected from such 6 alkoxy to three optionally substituted with a substituent Ji may 6 _ 14 Ariru group;
- a benzene ring or a pyrazole ring each of which may have 1 to 3 substituents selected from:
- V is a bond; -CH 2 -; - CH 2 0-; ⁇ 1 -6 Arukiru group Oyopi.
- One NH—CH 2 — or one CH 2 —NH—; or one CH N— which may have a substituent selected from 7 to 16 aralkyl groups;
- W is — 6 alkylene group (preferably methylene);
- X is CH or N
- X a is CH
- Y is O or CR 6 R 7 , and R 6 and R 7 are the same or different and are each a hydrogen atom or a hydroxy group;
- R 1 is a hydrogen atom or a halogen atom
- R 1 a is a hydrogen atom
- R 2 is a hydrogen atom; an alkyl group; a C 6 alkyl monopropyl group; or a Ce—i 4 arylsulfoyl group optionally substituted with a dinitro group;
- R 3 and R 4 are the same or different and are each a hydrogen atom or a halogen atom
- R 5 is a hydroxy group or a C-6 alkoxy group (preferably a hydroxy group);
- optionally substituted - 6 alkyl group preferably, an optionally halogenated C - 6 alkoxy group, C 6 _ 14 Ariru group, to 1 selected from etc.
- C 6 _ 14 Ariruokishi group A C i-e alkyl group which may be substituted with three substituents;
- halogen atom an optionally substituted to 1 selected from such Nono halogenated which may be optionally CI- 6 alkyl group with 1-3 substituents C 6 - 14 Ariru group;
- optionally substituted - 6 alkoxy group (preferably, (a) halogenated which may be C i-6 alkoxy group; (b) C 3 - 8 cycloalkyl group; (c) carboxyl (D) mono- or di-Ci-6 alkyl mono-rubamoyl group; (e) nitrogen-containing heterocyclic monocarbonyl group (preferably morpholinocarbonyl); (f) C 6 alkylthio group; (g) C 6 alkyl sulfonyl group (H) a heterocyclic group (preferably furyl, pyridyl, cherry, or the like) which may be substituted with 1 to 3 substituents selected from a hydroxy group, a C 6 alkyl group, a C 6 alkoxy group and the like; Pyrazolyl, thiazolyl, oxazolyl, isoxazolyl, isothiazolyl, oxetanyl, morpholinyl, thiomorpholinyl,
- Tree C ealkyl-silyloxy group
- a heterocyclic oxy group which may be substituted with 1 to 3 substituents selected from a C alkyl group, a de-e alkoxy group and the like (preferably pyridyloxy, tetrahydrobilanyloxy, tetrahydroxy) Thioviraniloxy, 1,1-dioxide tetrahydrothioviraniloxy); and
- C i-6 optionally substituted with a 6-alkoxy group — 6- alkylsulfonyl group; each having 13 substituents selected from phenyl, naphthyl, thiazolyl, pyrazolyl, indolyl Or dihydroquinolinyl;
- C i-6 alkoxy _C 6 to 1 selected from an alkoxy group may be substituted with 1-3 of location substituent. 6 _ 14 reel group;
- Y is O or CR 6
- R 7 and R 6 and R 7 are the same or different and each represent a hydrogen atom or a hydroxy group, or R 7 is bonded to R la to form a 48-membered ring (preferably Preferably a 5- to 7-membered monocyclic aromatic heterocycle (preferably furan, thiophene) ) And a 5- to 7-membered monocyclic non-aromatic heterocycle (preferably dihydrofuran, dihydrothiophene));
- R 1 is a hydrogen atom, a C 6 alkyl group or a halogen atom
- R la is a hydrogen atom
- Ci- 6 alkoxy one C 1 to 3 C 6 _ 14 may be substituted with location substituent of Ariru group selected from an alkoxy group;
- An indane ring optionally having 1 to 3 substituents selected from;
- W is a bond
- C - 6 alkyl group preferably, a halogen atom, may be halogenation - 6 alkoxy group, C 6 - 14 Ariru group, C 6 -, etc. 14 ⁇ Li Ruokishi group A C- 6 alkyl group which may be substituted with 1 to 3 substituents selected from
- a halogen atom, halogenated 1 to 3 substituents may be substituted with a group C 6 selected from such may also be ⁇ Arukiru group optionally - 14 7 aryl group;
- C 7 one 16 Ararukiruokishi group (4) optionally substituted - 6 alkoxy group (preferably, (a) halogenated which may be C - 6 alkoxy group; (b) C 3 _ 8 cycloalkyl group; (c) carboxyl group (D) mono- or di- ⁇ -alkyl monorubumoyl group; (e) nitrogen-containing heterocyclic monocarbonyl group (preferably morpholinocarbonyl); (f) C- 6 alkylthio group; (g) C- 6 alkyl sulfonyl group; (H) 1 to 3 heterocyclic groups which may be substituted with 1 to 3 substituents selected from a hydroxy group, a C- 6 alkyl group, a C-6 alkoxy group and the like (preferably furyl, pyridyl, cheel, Pyrazolyl, thiazolyl oxazolyl, isoxazolyl, isothiazolyl, oxetany
- a heterocyclic oxy group which may be substituted by 1 to 3 substituents selected from C 16 alkyl groups, C 16 alkoxy groups and the like (preferably pyridyloxy, tetrahydrovinyliloxy, .tetrahydrothio) Vilanyloxy, 1,1-dioxide tetrahydrodrothioviranyloxy, 1-oxide tetrahydrodrothiovillaroxy);
- C i-6 alkoxy one C ⁇ 6 to 1 selected from an alkoxy group may be substituted with 1-3 location substituent C 6 - 14 Ariru group;
- C 3 - 8 may be substituted with a cycloalkyl group CI- 6 alkoxy group
- a benzene ring or a pyrazole ring each of which may have 1 to 3 substituents selected from:
- X and Xa are the same or different and each is CH or N;
- R 1 a is a hydrogen atom or a halogen atom
- C 6 alkoxy one C Bok 6 1 to 3 C 6 _ 14 may be substituted with location substituent of Ariru group selected from an alkoxy group;
- C 3 _ 8 may be substituted with a cycloalkyl group CI- 6 alkoxy group
- An indane ring optionally having 1 to 3 substituents selected from;
- W is a bond
- Salts of compound (1) and compound (1 ′) of the present invention include, for example, metal salts, ammomium salts, and organic bases. Salts, salts with inorganic acids, salts with organic acids, salts with basic or acidic amino acids, and the like.
- the metal salt include an alkali metal salt such as a sodium salt and a potassium salt; and an alkaline earth metal salt such as a calcium salt, a magnesium salt and a barium salt.
- Preferred examples of the salt with an organic base include trimethylamine, triethynoleamine, pyridine, picoline, 2,6-noretidine, ethanolanolamine, jetanolamine, triethanolamine, cyclohexylamine, dicyclohexylamine, N , N'-dibenzylethylenediamine and the like.
- salts with an inorganic acid include salts with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid and the like.
- salts with organic acids include formic acid, acetic acid, trifluoroacetic acid, phthalic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, Examples thereof include salts with p-toluenesulfonic acid.
- Preferable examples of the salt with a basic amino acid include salts with argien, lysine, orditin and the like.
- Preferred examples of the salt with an acidic amino acid include salts with aspartic acid, glutamic acid and the like. Salts.
- salts pharmaceutically acceptable salts are preferred.
- a metal such as an alkali metal salt or an alkaline earth metal salt is used.
- a basic functional group for example, a salt; an ammonium salt or the like; a salt with an inorganic acid or a salt with an organic acid is preferable.
- Compound (I) and a prodrug thereof are compounds that are converted into compound (I) by a reaction with an enzyme, stomach acid, or the like under physiological conditions in a living body, that is, compounds (I) that are oxidized, reduced, hydrolyzed, etc. ), Or a compound that is hydrolyzed by stomach acid or the like to change to compound (I).
- Examples of the prodrug of compound (I) include compounds in which the amino group of compound (I) is acylated, alkylated, or phosphorylated (for example, the amino group of compound (I) is icosanoylated, Pentylaminocarbonylation, (5-methyl-2-oxo1-1,3-dioxolen-1-yl) methoxycarponylation, 'tetrahydrofuration, pyrrolidylmethylation, bivaloyloxymethylation, tert-butyl
- a compound in which the hydroxyl group of compound (I) is acylated, alkylated, phosphorylated or borated for example, the hydroxyl group of compound (I) is acetylated, palmitoylated, propanoylated, vivaloyl) , Succinylation, fumarylation, alanylation, dimethylaminomethylcarbonated compounds, etc.); compounds in which the amino group of compound (
- the carboxy group of compound (I) is a Ci- 6 alkyl such as methyl, ethyl and tert-butyl.
- Compounds esterified with a group are preferred. These compounds can be produced from compound (I) by a method known per se.
- the prodrug of compound (I) can be prepared under physiological conditions as described in Hirokawa Shoten, 1990, “Development of Pharmaceuticals,” Vol. 7, Molecular Design, pp. 163-198. (I) may be changed.
- the compound obtained in each step can be used as a crude product in the next reaction as a reaction solution, but it can also be isolated from the reaction mixture according to a conventional method, and further recrystallized, distilled, and chromatographed. It can be easily purified by such separation means.
- Compounds (I) for example, compounds represented by the following formulas (la), (la '), (lb') and (Ic ') (compounds (la), compounds (la'), compounds (lb '), Compound (abbreviated as Ic '))
- the compound (la ') is produced by reacting a compound represented by the formula (II) with a compound represented by the formula (II) (abbreviated as compound (II) and compound (III), respectively). Can be.
- R 5 ′ may be substituted — 6 alkoxy group
- W 1 is a bond or a 5- alkylene group
- R is a hydrogen atom or a C 5 alkyl group
- other symbols are as described above. Indicates synonymous.
- Ci 5 alkylene group represented by W 1 of C 6 alkylene group exemplified as W, include those having a carbon number of 1-5.
- the C Bok 5 alkyl group represented by R for example methyl, Echiru, propyl, isopropyl Honoré, Puchinore, Isobuchinore, sec- Buchinore, tert- Puchinore, Penchinore, I Sopenchiru, neopentyl and the like.
- the dehydration reaction is promoted by adding a dehydrating agent such as molecular sheep or a catalyst such as zinc chloride, phosphoryl chloride, boron trifluoride or titanium tetrachloride to the system.
- a dehydrating agent such as molecular sheep or a catalyst such as zinc chloride, phosphoryl chloride, boron trifluoride or titanium tetrachloride to the system.
- the reduction reaction is usually performed using a reducing agent according to a conventional method.
- the reducing agent include metal hydrides such as aluminum hydride, diisobutylaluminum hydride, triptyltin hydride; sodium cyanoborohydride, sodium triacetoxyborohydride, sodium borohydride, lithium hydride
- Metal hydrogen complex compounds such as aluminum; borane complexes such as porane tetrahydrofuran complex and borane dimethyl sulfide complex; alkylporans such as texyl porane and disiamyl borane; diborane; metals such as zinc, aluminum, tin and iron; sodium and lithium Alkali metal / liquid ammonia (perch reduction).
- the amount of the reducing agent used is appropriately determined depending on the type of the reducing agent. For example, use of metal hydrides, metal hydride complexes, borane complexes, alkylboranes or diborane
- the dose is about 0.25 to about 10 moles, preferably about 0.5 to about 5 moles, per 1 mole of the compound (II), and the metal (alkali metal used in the perch reduction) is used. Is used in an amount of about 1 to about 20 mol, preferably about 1 to about 5 mol, per 1 mol of compound (II).
- the reduction reaction can be performed by a hydrogenation reaction.
- a catalyst such as palladium carbon, palladium black, platinum dioxide, Raney-Eckel, or Raneycoparte is used.
- the amount of the catalyst to be used is about 5 to about 1000% by weight, preferably about 10 to about 30.0% by weight, per 1 mol of compound (II).
- the hydrogenation reaction can also be performed by using various hydrogen sources instead of gaseous hydrogen. Examples of such a hydrogen source include formic acid, ammonium formate, triethylammonium formate, sodium phosphinate, hydrazine and the like.
- the amount of the hydrogen source to be used is about 1 to about 10 mol, preferably about 1 to about 5 mol, per 1 mol of compound (II).
- This reaction is advantageously performed using a solvent inert to the reaction.
- a solvent is not particularly limited as long as the reaction proceeds, and examples thereof include methanol, ethanol, 1-propanol, 2-propanol, tert-butyl / leano-reconole, and the like; Ethers such as isopropylinoleatene, dipheninoleatel, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxetane; aromatic hydrocarbons such as benzene and toluene '; cyclohexane and hexane Saturated hydrocarbons; Amides such as N, N-dimethylformamide, N, N-dimethylacetamide, hexamethylphosphoramide; Organics such as formic acid, acetic acid, propanoic acid, trifluoroacetic acid, and methanesulfonic acid A solvent such as an acid or a mixed solvent
- the reaction time varies depending on the reagents and solvents used, but is usually from 10 minutes to 100 hours, preferably from 30 minutes to 50 hours.
- the reaction temperature is usually from 120 to 100 ° C, preferably from 0 to 80 ° C.
- the amount of compound (III) to be used is about 0.5 to about 5 mol, preferably about 1 to about 2 mol, per 1 mol of compound (III).
- the reaction between compound ( ⁇ ) and compound ( ⁇ ⁇ ') is compound (II)
- the compound represented by the formula (IV) reacts the compound (II) with the compound represented by the formula: R 2 ′ -L (abbreviated as compound R 2 ′ _L) It can be manufactured by the following.
- R 2 ′ represents an acyl group
- L represents a leaving group
- other symbols have the same meanings as described above.
- Examples of the acyl group represented by R 2 ′ include 2-nitrobenzene benzene sulfoel, 4-nitrobenzene snorehononi / le, 2,4-dinitrobenzene snorehonore, methane snorehoninore, ethane snorehoninore, and benzene snorehonole.
- Substituted sulfuryl groups such as ninore and ⁇ -tonoreensnorehoninole; substituted carbonyl groups such as trichloroacetyl and trifluoroacetyl.
- Examples of the leaving group represented by L include a halogen atom (eg, fluorine, chlorine, bromine, and iodine), an optionally substituted C-6 alkylsulfonyloxy group
- Arylsulfo-oxyl group for example, 6 alkyl groups (eg, methyl, ethyl), Ci-6 alkoxy group (for example, methoxy, ethoxy), and 1 to 3 substituents selected from ethoxy) good C 6 - 1 0 ⁇ Li one Rusuruho - Le Okishi group (e.g.
- Compound (IV) can be produced by a method known per se, for example, by reacting compound (II) with compound R 2 ′ — in the presence of a base.
- Examples of the base include alkali metal hydroxides such as lithium hydroxide, sodium hydroxide and potassium hydroxide; alkaline earth metal hydroxides such as magnesium hydroxide and calcium hydroxide; sodium carbonate, carbonated carbonate, cesium carbonate and the like.
- Carbonated Lucali metal trimethylamine, triethylamine, diisopropylethylamine, pyridine, picoline, lutidine, 4-dimethylaminopyridine, N-methylpyrrolidine, N-methylmorpholine, 1,5-diazabicyclo [4.3.0] ] — Organic bases such as 5-nonene, 1,4-diazabicyclo [2.2.2] octane, 1,8-diazabicyclo [5.4.0] — 7-undecene.
- This reaction is advantageously performed using a solvent inert to the reaction. Such a solvent is not particularly limited as long as the reaction proceeds.
- Examples thereof include getyl ether, disopropinoleate / re, diphenoleatenore, tetrahydrofuran, 1,4-dioxane, 1,2 —Ethenoles such as dimethoxetane; aromatic hydrocarbons such as benzene and toluene; saturated hydrocarbons such as cyclohexane and 7-hexane; N, N-dimethylformamide, N, N-dimethylacetoamide, hexa Amides such as methylphosphoramide; halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, and 1,2-dichloroethane; utrils such as acetonitrile and propionitrile; acetone and ethyl methyl ketone Ketones; solvents such as sulphoxides such as dimethylsulphoxide Etc. are preferred solvents mixed.
- the reaction time varies depending on the reagents and solvents used, but is usually from 10 minutes to 100 hours, preferably from 30 minutes to 50 hours.
- the reaction temperature is usually 30 to L; L is 00 ° C, preferably 0 to 80 ° C.
- the amount of compound R 2 ′ -L to be used is about 0.5 to about 5 mol, preferably about 1 to about 3 mol, per 1 mol of compound (II).
- the amount of the base to be used is about 1 to about 10 mol, preferably about 1 to about 3 mol, per 1 mol of compound (II).
- Compound (lb ') can be produced by reacting compound (IV) with a compound represented by formula (V) (abbreviated as compound (V)). .
- L represents a leaving group or a hydroxy group, and the other symbols have the same meanings as described above.
- the leaving group represented by L ′ those exemplified as the aforementioned L can be used.
- compound (lb ') reacts compound (IV) with compound (V) by a Mitsunobu reaction (eg, Synthesis, pp. 1-27, 1981-1).
- a Mitsunobu reaction eg, Synthesis, pp. 1-27, 1981-1).
- Tetrahedron Lett., 38, Vol. 583 See pages 1-5 834, 1997)).
- the compound (IV) and the compound (V) are reacted with azodicarboxylates such as jetinole azodicarbonate, diisopropinole azodicarboxylic acid, 1,1,1- (azodiforce / repoyl) dipiperidine and the like.
- azodicarboxylates such as jetinole azodicarbonate, diisopropinole azodicarboxylic acid, 1,1,1- (azodiforce / repoyl) dipiperidine and the like.
- phosphines such as triphenylphosphine and triptylphosphine.
- This reaction is advantageously performed using a solvent inert to the reaction.
- the solvent the solvent exemplified in Step 2 is used.
- the reaction time is generally 5 minutes to 100 hours, preferably 30 minutes to 72 hours.
- the reaction temperature is usually from 20 to 200 ° C, preferably from 0 to 100 ° C.
- the amount of compound (V) to be used is about 1 to about 5 mol, preferably about 1 to about 2 mol, per 1 mol of compound (IV).
- the azodicarboxylates and phosphines are used in an amount of about 1 to about 5 mol, preferably about 1 to about 2 mol, per 1 mol of compound (IV).
- L ' is a leaving group
- compound (lb') can be produced by reacting compound (IV) with compound (V) in the presence of a base.
- Such bases include, for example, lithium hydroxide, sodium hydroxide, and alkali metal hydroxides such as hydroxide hydroxide; alkaline metal hydroxides such as barium hydroxide; sodium carbonate, carbonate carbonate, and the like.
- Alkali metal carbonates such as cesium carbonate; alkali metal bicarbonates such as sodium hydrogen carbonate; acetates such as sodium acetate and ammonium acetate; aromatic amines such as pyridine and lutidine; triethylamine, tripropylamine, triptylamine, N-ethyldiisopropyl Tertiary amines such as hexamine, cyclohexyl dimethylamine, 4-dimethylaminopyridine, N, N-dimethylfurin, N-methyl / reviperidine, 'N-methinolepyrrolidine, and N-methinolemonorefolin.
- alkali metal water such as sodium hydride and potassium hydride
- Iodide Iodide
- Metal amides such as tildisilazide
- C1-C6 alkali metal alkoxides such as sodium methoxide, sodium ethoxide, sodium tert-butoxide, and potassium tert-butoxide.
- This reaction is advantageously performed using a solvent inert to the reaction.
- a solvent inert those exemplified in Step 2 are used.
- the amount of compound (V) to be used is about 0.8 to about 10 mol, preferably about 0.9 to about 2 mol, per 1 mol of compound (IV).
- the amount of the base to be used is about 1-about 10 mol, preferably about 1-about 3 mol, per 1 mol of compound (IV).
- the reaction time is generally 10 minutes to 12 hours, preferably 20 minutes to 6 hours.
- the reaction temperature is usually from 170 to 150 ° C, preferably from -20 to: L00 ° C.
- Compound (la ′) can be produced by removing R 2 ′ of compound (lb ′).
- Compound (Ia,) is, for example, Tetrahedron Lett., Vol. 36, pp. 637-63 374, 1995, Tetrahedron Letters
- R 2 ′ is, for example, a 2-nitrobenzenesulfonyl group, a 4-nitrobenzenesulfonyl group or a 2,4-jetrobenzenesulfonyl group
- the compound (Ib,) is converted to thiophenol, benzylmercaptan
- thiols such as mercaptoacetic acid and 2-mercaptoethanol ⁇ React with a large excess of amines such as methylamine, ethylamine, propylamine and butylamine.
- This reaction is advantageously performed using a solvent inert to the reaction.
- a solvent inert those exemplified in Step 2 are used.
- the solvent in this step include N, N
- the amount of the thiols to be used is about 1 to about 10 mol, preferably 5 to about 3 mol, per 1 mol of the compound (lb ').
- the amount of the base to be used is about 1 to about 10 mol, preferably about 2 to about 6 mol, per 1 mol of compound (lb ').
- the amount of the amine to be used is about 5 to about 100 mol, preferably about 10 to about 30 mol, per 1 mol of compound (Ib,).
- the reaction time is generally 1 minute to 24 hours, preferably 5 minutes to 6 hours.
- the reaction temperature is usually from 10 to 150 ° C, preferably from 110 to: L00 ° C.
- the compound (Ic ') is a compound (la') and a compound represented by the formula: R 2 '' 1 L (abbreviated as compound R 2 ''-L) or a compound represented by (VI) (compound ( VI)).
- R 2 ′′ is a C i-e alkyl group or an optionally substituted acyl group
- R 2 ′ ′′ is a C alkyl group
- R ′ is a hydrogen atom or C — 4 Alkyl groups, and other symbols have the same meanings as described above.
- Ci-s alkyl group represented by R 2 ′ ′′ those exemplified as the aforementioned R can be used.
- the compound (Ic ′) in which R 2 ′′ is a C alkyl group is a compound exemplified in Step 3.
- ⁇ ⁇ R 2 '' is an acyl group (Ic ')
- Compound (la) in which R 2 is a hydrogen atom can be produced by subjecting compound (la ′) to a hydrolysis reaction.
- the hydrolysis reaction is carried out according to a conventional method using an acid or a base.
- the acid examples include mineral acids such as hydrochloric acid and sulfuric acid; Lewis acids such as boron trichloride and boron tribromide; and organic acids such as trifluoroacetic acid and p-toluenesulfonic acid.
- the Lewis acid can be used in combination with a thiol or a sulfide.
- the base examples include alkali metal hydroxides such as lithium hydroxide, sodium hydroxide, and potassium hydroxide; alkali earth metal hydroxides such as barium hydroxide; alkali metal carbonates such as sodium carbonate and carbonic acid lime; C1 to C6 alkali metal alkoxides such as toxide, sodium ethoxide and potassium tert-butoxide; and organic bases (including hydrates) such as triethylamine, imidazole and formamidine.
- the amount of the acid or base to be used is about 0.5 to about 10 moles, preferably about 0.5 to about 6 moles, per 1 mole of compound (la ').
- the hydrolysis reaction is performed without a solvent or using a solvent inert to the reaction.
- a solvent is not particularly limited as long as the reaction proceeds. Examples thereof include alcohols such as methanol, ethanol, and propanol; aromatic hydrocarbons such as benzene and tonolene; and saturated hydrocarbons such as cyclohexane and hexane.
- Hydrocarbons organic acids such as formic acid and acetic acid; ethers such as tetrahydrofuran, 1,4-dioxane and 1,2-dimethyloxetane; N, N-dimethylformamide, N, N-dimethylacetamide Halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride and 1,2-dichloroethane; nitriles such as acetonitrile and propionitrile; ketones such as acetone and methylethyl ketone; Sulfoxides such as dimethyl sulfoxide; solvents such as water or mixtures thereof Such as a medium is preferable.
- the reaction time is generally 10 minutes to 100 hours, preferably 10 minutes to 24 hours.
- the reaction temperature is usually from 110 to 200 ° C, preferably from 0 to 120 ° C.
- the hydrolysis reaction can be carried out in the same manner as in Step 6A or according to a method analogous thereto.
- the compound ( ⁇ ) in which Y is CHR 6 and R 4 is a hydrogen atom can be produced, for example, according to the method represented by the reaction formula 2A or a method analogous thereto. .
- the compound represented by the formula (VIII.) (Abbreviated as compound (VIII)) is produced by subjecting the compound represented by the formula (VII) (abbreviated as compound (VII)) to a Heck reaction. can do.
- L ′ ′ As the leaving group represented by L ′ ′, those exemplified above as L are used.
- the leaving group in this step is preferably a halogen atom or a trifluoromethanesulfonyloxy group.
- Compound (VIII) can be prepared using compound (VII) by a method known per se, for example, the method described in Organic. Reactions, Vol. 27, pp. 345-390, 1982, or It can be manufactured according to a method according to.
- Compound (VI II) can be produced, for example, by reacting compound (VII) with [,] 3-unsaturated ester in the presence of a palladium catalyst and a base. Examples of the ⁇ ,
- palladium catalyst examples include palladium acetate (II), palladium chloride (II), dichlorobis (tri-norephosphine) palladium (II), dibromobis
- Triphenylphosphine palladium (II)
- Jodobis triphenylphosphine) palladium (II)
- dichlorobis tri. Tolylphosphine
- chlorobisphenyl triphenylphosphine
- the amount of the palladium catalyst to be used is about 0.00001 to about 5 mol, preferably about 0.001 to about 1 mol, per 1 mol of compound (VII).
- the reaction may be advantageously promoted by allowing about 1 to 50 mol, preferably about 2 to 20 mol, of the phosphine ligand to coexist with the palladium catalyst.
- the phosphine ligand include triarylphosphines such as triphenylphosphine and tris (2-methylphenyl) phosphine; 1,2-bis (diphenylphosphine) ethane, and 1,3-bis (diphenyl) phosphine; Bis (diarylphosphino) alkyls such as 2,4-bis (diphenyl-norethosphino) butane and the like are used.
- Examples of the base include secondary amines such as getylamine and dicyclohexylamine; tertiary amines such as triethylamine, triptylamine and tetramethylethylenediamine; and carbonates such as sodium carbonate, sodium carbonate and sodium hydrogen carbonate. Is used.
- secondary amines such as getylamine and dicyclohexylamine
- tertiary amines such as triethylamine, triptylamine and tetramethylethylenediamine
- carbonates such as sodium carbonate, sodium carbonate and sodium hydrogen carbonate. Is used.
- This reaction is advantageously performed using a solvent inert to the reaction.
- the solvent the solvents exemplified in step 2 are used, and as the solvent in this step, amides such as ⁇ , ⁇ -dimethylformamide, ⁇ -methylpyrrolidinone, and hexamethylphosphoramide; Nitriles such as acetonitrile and propio-tolyl are preferred.
- This reaction is preferably performed in an inert gas such as argon.
- the amount of the acrylate ester and the base to be used is generally about 1 to about 10 mol, preferably about 1 to about 3 mol, per 1 mol of compound (VII).
- the reaction time varies depending on the amounts and types of reagents, catalysts, bases and reaction solvents used, and the reaction temperature, but is usually 1 to 100 hours, preferably 5 to 80 hours.
- the reaction temperature is usually from 10 to 200 ° C, preferably from 20 to 150 ° C.
- Compound (II) can be produced by subjecting compound (VIII) to a hydrogenation reaction.
- the hydrogenation reaction can be performed in the same manner as the hydrogenation reaction exemplified in Step 1.
- reaction formula 2B the compound ( ⁇ ′ ⁇ ) wherein Y is CHR 7 can be produced, for example, according to the method represented by the reaction formula 2B or a method analogous thereto.
- Step 9>-The compound represented by the formula 00 (abbreviated as compound (X)) is composed of the compound represented by the formula (IX) (abbreviated as food (IX)) and (i) alkyl Base treatment of phosphonic acid diester By reacting the phosphonate carporione produced by the above process or (ii) triphenylphosphinylide to produce E- or Z-configuration isomers alone or a mixture of E- and Z-configuration isomers. You.
- This step is carried out by a method known per se, for example, a journal of the chemical society.
- Perkin Trans. 1 J. Chera. Soc. Perkin Trans. 1
- pp. 2895—290, pp. 1990, etc. or a method analogous thereto. .
- alkylphosphonic acid diester or triphenylsubuinylide examples include acetyl ethyl ethylphosphonoacetate, tert-butyl ethyl ethyl phosphonoacetate, ethyl phosphono 2-ethyl fluoroacetate, (carbethoxymethylene) triphenylphosphorane, and (tert-butoxycarbomethylene). Triphenyl phosphorane and the like are used.
- the amount of the alkylphosphonic acid diester or triphenylphosphinyl to be used is about 1 to about 3 mol, preferably about 1 to about 2 mol, per 1 mol of compound (IX).
- Examples of the base include alkali metal hydrides such as sodium hydride and potassium hydride; alkali metal hydroxides such as lithium hydroxide, sodium hydroxide and potassium hydroxide; water such as magnesium hydroxide and calcium hydroxide.
- Alkaline earth metal oxides alkali metal carbonates such as sodium carbonate and carbon dioxide; alkali metal bicarbonates such as sodium hydrogen carbonate and hydrogen carbonate; sodium methoxide, sodium methoxide, sodium tert-butoxide
- An alkali metal alkoxide having 1 to 6 carbon atoms such as, for example, trimethylamine, triethylamine, diisopropylethylamine, pyridine, picoline, N-methylpyrrolidine, N-methylmorpholine, 1,5-diazavicic mouth [4.3 .
- Step 2 This reaction is advantageously performed using a solvent inert to the reaction.
- the solvent the solvent exemplified in Step 2 is used.
- the reaction time is generally 1 hour to 50 hours, preferably 1 hour to 10 hours.
- the reaction temperature is usually from 180 to 200 ° C, preferably from 0 to 150 ° C.
- Compound (11,,) wherein R 4 is a hydrogen atom can be produced by subjecting compound (X) to a hydrogenation reaction.
- the hydrogenation reaction can be performed in the same manner as the hydrogenation reaction exemplified in Step 1. '.'
- the compound represented by the formula (XI) (abbreviated as the compound (XI)) is obtained by reforming the compound (IX) and the compound represented by the formula (a) (abbreviated as the compound (a))
- Ha 1 represents a halogen atom (eg, chlorine, bromine).
- Step 1 1. ⁇ .
- the compound represented by the formula (XII) (abbreviated as compound (XII)) can be produced by converting a hydroxyl group of compound (XI) into a leaving group L ′ ′′ ′′.
- Examples of the leaving group represented by L ′ ′′ ′ include those exemplified above for L.
- Examples of the leaving group in this step include arylsulfoyl such as benzenesulfonyloxy and p-toluenesulfonyloxy. An oxy group is preferred. .
- This process is performed by a method known per se, for example, the method described in Journal of Organic Chemistry (J. Org. Chera.), Vol. 3.9, pp. 878-881, 1974.
- This step is carried out according to a method known per se, for example, the method described in J. Org. Chem., Vol. 39, pp. 878-881, 1974, or a method analogous thereto. It can be carried out.
- compounds wherein Y is O can be obtained by a method known per se, for example, Journal of Medicinal Chemistry (J. Med. Chem.), 43, 3052-3066, 2000, etc. It can be performed according to the method described or a method analogous thereto.
- V is V 1 (V 1 is a bond, an optionally substituted alkylene group, one W 3 — N (R A ) —W 2 _, one W 3 — O—W 2 — Or one W 3 — S
- (O) k23 —W 2 —) can be produced, for example, according to the method shown in Reaction Scheme 3 or a method analogous thereto.
- Examples of the ⁇ optionally substituted C ⁇ 3 alkylene group '' represented by V 1 include, for example, methylene, ethylene or propylene, each of which may have one or two substituents exemplified in the above V Can be Reaction formula 3
- W 2 and W 3 are the same or different, and each is a bond or an optionally substituted C i—2 alkylene group, and Q is one N (R A ) one, one O— or one S
- R A is an optionally substituted C — 6 alkyl group or substituted K 23 represents the same as defined above
- IV represents a hydrogen atom or a metal (for example, potassium, sodium, lithium, magnesium, copper, mercury, zinc, thallium boron, tin, etc. And other symbols have the same meaning as above.]
- Examples of the ⁇ optionally substituted C- 2 alkylene group '' represented by W 2 and W 3 include, for example, methylene or ethylene, each having one or two substituents exemplified in the above V. No.
- Compound ( ⁇ ) can be prepared by reacting (i) compound (XIII-1) with compound (XVI-1) or (compound (5)
- the reaction between compound (XIII) and compound (XVI) is usually performed in the presence of a base.
- a base examples include alkali metal hydrides such as sodium hydride and hydrogenation hydride; alkali metal hydroxides such as lithium hydroxide, sodium hydroxide and potassium hydroxide; magnesium hydroxide, calcium hydroxide and the like.
- Alkaline metal hydroxides alkali metal carbonates such as sodium carbonate and carbonated carbonate; alkali metal bicarbonates such as sodium hydrogen carbonate and potassium carbonate; sodium methoxide, sodium ethoxy, sodium terf —Alkyl metal alkoxides having 1 or 6 carbon atoms such as butoxide; for example, trimethylamine, triethylamine, diisopropinoleetinoleamine, pyridine, picoline, N-methinolepyrrolidine.
- the reaction between compound (XI II) and compound (XVI) is advantageously performed using a solvent inert to the reaction. Such a solvent is not particularly limited as long as the reaction proceeds.
- alcohols such as methanol, ethanol, propanol, isopropanol, butanol and tert-butanol; 1,4-dioxane, tetrahydrofuran, getyl ether, ethers such as tert-butynolemethinolate ether, diisopropyl ether and 1,2-dimethyloxetane; esters such as ethyl formate, ethyl acetate and n-butyl acetate; dichloromethane, chloroform, carbon tetrachloride, Halogenated hydrocarbons such as trichloroethylene; hydrocarbons such as n-hexane and benzene toluene; amides such as N, N-dimethylformamide and N, N-dimethylacetamide; acetonitrile and propionitrile Nitriles, etc .; dimethyl sulfoxide, etc. Sulfoxides;
- the reaction between compound (XIII) and compound (XVI) can generally be promoted using a metal catalyst.
- metal catalyst metal complexes having various ligands are used.
- palladium compounds eg, palladium (II) acetate, tetrax (triphenylphosphine) palladium (0), bis (triphenylphosphine chloride) Indine) palladium (11), dichlorobis (triethylphosphine) palladium (II) tris (dibenzylideneacetone) dipalladium 1,2,1, bis (diphenylphosphine) -1,1'-binaphthyl, palladium acetate ( ⁇ ) and 1,1,1-bis (diphenylphosphino) phenecene complex etc.]; Nickel compound [Example: Tetrakis (triphenylphosphine) nickel (0), bis (triethylphosphine) nickel chloride ( II),
- the amount is about 0.001 to about 5 mol, preferably about 0.001 to about 1 mol, per 1 mol.
- the reaction is preferably performed in an inert gas (eg, argon gas or nitrogen gas) stream.
- the amount of compound (XVI) to be used is about 0.1 to about 10 mol, preferably about 0.5 to about 2 mol, per 1 mol of compound (XIII).
- the amount of the base to be used is about 1-about 20 mol, preferably about 1-about 5 mol, per 1 mol of compound 5 (XIII).
- the reaction temperature is from 110 to 250 ° C, preferably from 0 to 150 ° C.
- the reaction time varies depending on the compound (XIII), the compound (XVI), the metal catalyst, the type of the base or the solvent, the reaction temperature, etc., but is usually 1 minute to 200 hours, preferably 5 minutes to 100 hours. is there.
- Compound ( ⁇ ′) can be produced from compound ⁇ (III ′).
- the compound (V ') in which L' is a hydroxy group can be produced by subjecting the compound (II) to a reduction reaction.
- the reduction reaction can be performed according to a conventional method using the reducing agent exemplified in Step 1.
- V (hereinafter sometimes abbreviated as compound (V ′ ′)) can be produced by reacting with a halogenating agent or a sulfolating agent.
- halogenating agent for example, thiol chloride, phosphorus tribromide or the like is used.
- L ′ is represented by a halogen atom (eg, chlorine, bromine, etc.)
- the reaction of the compound ( ⁇ ') with the halogenated compound ⁇ is usually performed in a solvent that does not adversely influence the reaction.
- Solvents that do not adversely affect the reaction include, for example, halogenated hydrocarbons such as dichloromethane, chloroform, and carbon tetrachloride; aromatic hydrocarbons such as benzene, toluene, and xylene; getyl ether, diisopropyl ether
- Ethers such as 25, tert-butyl methyl ether, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxetane; esters such as methyl acetate, ethyl acetate, n-butyl acetate, and tert-butyl acetate; Can be Also,
- the amount of the halogenating agent to be used is generally about 1-about 10 mol per 1 mol of compound ( ⁇ ′ ′′).
- the reaction temperature is usually from 120 to 100 ° C.
- the reaction time is generally 0.5 to 24 hours.
- sulfolating agent examples include methanesulfonyl chloride, benzenesulfonyl chloride, and chloride! 1) Toluenesulfonyl and the like are used.
- L' is, for example, methansnoreffoninolexy, benzenesnorefoninolexy, p-tonolenesnorefoninoleoxy, etc.
- the reaction with the compound (V ′ ′) sulfonylating agent is generally performed in a solvent that does not adversely influence the reaction, in the presence of a base.
- Solvents that do not adversely affect the reaction include, for example, halogenated hydrocarbons such as dichloromethane, chloroform, and carbon tetrachloride; aromatic hydrocarbons such as benzene, toluene, and xylene; getyl ether, diisopropyl ether, athenoles such as tert-butyl methyl ether, tetrahydrofuran, 1,4-dioxane and 1,2-dimethyloxetane; and esters such as methyl acetate, ethyl acetate, n-butyl acetate and tert-butyl acetate.
- the amount of the sulfolating agent to be used is generally about 1 to about 10 mol per 1 mol of compound (v, ').
- Examples of the base include amines such as triethylamine and N-methylmorpholine; and alkali metal salts such as sodium hydrogen carbonate, potassium hydrogen carbonate, and potassium carbonate.
- the amount of the base to be used is generally about 1 to about 10 mol per 1 mol of compound (V ',').
- the reaction temperature is usually from 120 to 100 ° C.
- the reaction time is usually 5 to 24 hours.
- a known hydrolysis reaction, deprotection reaction, acylation reaction, alkylation reaction, hydrogenation reaction, oxidation reaction, reduction reaction, carbon chain extension reaction, and substituent exchange reaction may be further performed, if desired.
- Compound (I) can also be produced by performing each alone or in combination of two or more thereof. These reactions are For example, the method may be performed according to the method described in Experimental Chemistry, Vol. 14, Vol. 15 (edited by The Chemical Society of Japan).
- the raw material compound when the raw material compound has an amino group, a hydroxyl group, a hydroxy group, or a mercapto group as a substituent, such a group is protected as generally used in peptide chemistry and the like.
- the target compound can be obtained by removing a protecting group as necessary after the reaction, if necessary.
- the protecting group for an amino group include a formyl group; a C- 6 alkyl-carboyl group which may have a substituent (for example, acetyl, ethylcarbyl, etc.), a phenylcarbonyl group, and a Ci- group.
- alkoxy monocarbonyl groups for example, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl (Boc), etc.
- aryloxycarbonyl (A11oc) group phenyloxycarbonyl group, full O Les methylpropenylmethyl O carboxymethyl carbonylation Honoré (F moc) group, C 7 10 Aranore kill one carbonyl group (e.g., benzyl carbo - Le etc.), C 7.
- Arazorekinore Okishi Ichiriki Ruponiru group e.g., benzyl O propoxycarbonyl El (Z), etc..
- C 7 - 1 0 Ararukiru group e.g., benzyl, etc.
- trityl group phthaloyl group, dithiasuccinoyl Asukushinoiru group or N, N-dimethyl An aminomethylene group and the like.
- examples of the substituent include a fuel group, a halogen atom, an alkylcarbyl group (eg, acetyl, ethylcarbonyl, butylcarboell, etc.), and a C—i-e alkoxy group (eg, , Methoxy, ethoxy, trifluoromethyl, etc.), nitro group, etc., and the number of substituents is 1 to 3.
- an alkylcarbyl group eg, acetyl, ethylcarbonyl, butylcarboell, etc.
- a C—i-e alkoxy group eg, Methoxy, ethoxy, trifluoromethyl, etc.
- nitro group etc.
- Examples of the protecting group for the carboxyl group include a —6 alkyl group, an aryl group, a benzyl group, a phenyl group, a trityl group, and a trialkylsilyl group, each of which may have a substituent.
- examples of the substituent include a halogen atom, a formyl group, a C i-6 alkyl-carbonyl group (for example, acetyl, ethylcarbyl, butylcarbonyl, etc.), and a C atom which may be substituted with a halogen atom.
- — 6 alkoxy groups for example, 'methoxy, ethoxy, trifluoromethoxy, etc.
- Ethoxy groups, etc. are used, and the number of substituents is 1 to 3.
- Examples of the hydroxy-protecting group include, for example, ', each of which may have a substituent,
- C i-6 alkyl groups C 7 - 2 0 Ararukiru group (e.g., benzyl, trityl, etc.), formyl groups, C alkyl one carbonyl group (e.g., Asechiru, Echirukarubo
- -Le benzoyl group
- benzoyl group and so on. 7— Examples thereof include an aralkyl-carboxy group (eg, benzylcarbyl), a 2-tetrahydropyrael group, a tetrahydrofurael group, and a trialkylsilyl group (eg, trimethylsilyl, tert-butyldimethylsilyl, diisopropylethylsilyl, etc.).
- aralkyl-carboxy group eg, benzylcarbyl
- 2-tetrahydropyrael group etrahydrofurael group
- a trialkylsilyl group eg, trimethylsilyl, tert-butyldimethylsilyl, diisopropylethylsilyl, etc.
- halogen atom for example, halogen atom, C ⁇ 6 alkyl group> Fueyuru group, C 7 - 1 0 ⁇ aralkyl group (e.g., benzyl, etc.), - 6 alkoxy groups, nitro group and the like use Irare, substituted
- the number of groups is one to four.
- each may have a substituent
- Aralkyl groups eg, benzyl, trityl, etc.
- substituents for example, a halogen atom, Ji al kill group, phenyl group, C 7 _ 1 0 Ararukiru group (e.g., benzyl etc.), C ⁇ e alkoxy group, C 6 Arukinore force Ruponiru group (e.g., Asechiru , Ethylcarbonyl, etc.), a nitro group, etc. are used, and the number of substituents is 1 to 4.
- the method for removing the protecting group a method known per se or a method analogous thereto can be used. Examples thereof include an acid, a base, a reduction, ultraviolet light, hydrazine, phenol-hydrazine, sodium N-methyldithiolrubinate, A method of treating with tetrabutylammonium fluoride, palladium acetate or the like is used.
- the compound (I), other reaction intermediates and the starting compounds thus obtained can be obtained from the reaction mixture by a method known per se, for example, extraction, concentration, neutralization, filtration, distillation, recrystallization, column chromatography. , Thin-layer chromatography, preparative high-performance liquid chromatography (preparative HPLC), medium-pressure preparative liquid chromatography (medium-pressure preparative LC), etc. .
- the salt of the compound (I) can be produced by a known method, for example, by adding an inorganic or organic acid when the compound (I) is a basic compound, or by adding the compound (I) to an acidic compound. In some cases, it can be produced by adding an organic base or an inorganic base.
- compound (I) may have optical isomers, each of these individual optical isomers and a mixture thereof is naturally included in the scope of the present invention. It can be optically divided according to the means or can be manufactured individually.
- each can be isolated by the above separation and purification means, if desired.
- the compound (I) is in a racemic form, it can be separated into an S-form and an R-form by ordinary optical resolution means.
- the present invention includes a case where the isomer is a single compound and a case where the compound is a mixture thereof.
- Compound (I) may be a hydrate or a non-hydrate.
- Compound (I) may be labeled with an isotope (eg, 3 H, 14 C, 35 S) or the like.
- an isotope eg, 3 H, 14 C, 35 S
- Compound (I) and its prodrug have GPR40 receptor function-modulating activity (GPR40 receptor agonist activity and GPR40 receptor antagonist activity), particularly It has GPR40 receptor agonist activity, low toxicity and low side effects (eg, acute toxicity, chronic toxicity, genotoxicity, reproductive toxicity, cardiotoxicity, drug interaction, carcinogenicity) Safe GPR.40 receptor function modulator: preferably useful as a GPR4 agonist.
- the medicament containing the compound of the present invention has excellent GPR against mammals (for example, mice, rats, hamsters, rabbits, cats, dogs, rabbits, higgins, monkeys, humans, etc.). Since it has a 40 receptor function regulating action, it is useful as a regulator of physiological functions involving the GPR40 receptor or a prophylactic / therapeutic agent for pathological conditions or diseases involving the GPR40 receptor.
- a medicament containing the compound of the present invention is useful as an insulin secretion regulator (preferably an insulin secretagogue), a hypoglycemic agent, and a ⁇ -cell protective agent.
- a medicament containing the compound of the present invention includes, for example, diabetes, impaired glucose tolerance, ketosis, acidosis, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, macular edema, hyperlipidemia, Sexual dysfunction, skin disease, arthropathy, osteopenia, arteriosclerosis, thrombotic disease, indigestion, memory learning disorder, depression, manic depression, schizophrenia, attention deficit hyperactivity disorder, visual impairment, appetite regulation Disorders (eg, binge eating), obesity, hypoglycemia, hypertension, edema, insulin resistance, unstable diabetes, lipoatrophy, insulin allergy, insulinoma, lipotoxicity, knee fatigue, hyperinsulinemia, cancer (eg, , Breast cancer), metabolic syndrome, immune system diseases (eg, immunodeficiency), inflammatory diseases (
- diabetes impaired glucose tolerance, ketosis, acidosis, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, macular edema, hyperlipidemia, sexual dysfunction, skin disease, arthrosis, bone loss It is useful as a prophylactic / therapeutic agent for diseases such as diseases, arteriosclerosis, thrombotic diseases, indigestion, and memory and learning disorders.
- diabetes includes type 1 diabetes, type 2 diabetes and gestational diabetes.
- Hyperlipidemia also includes hypertriglyceridemia, hypercholesterolemia, hypo-HDLemia, and postprandial hyperlipidemia.
- diabetes is defined as a fasting blood glucose level (glucose concentration in venous plasma) of 126 mgd 1 or more, 75 g transglucose tolerance test (75 g OGTT), and a 2-hour value (glucose concentration in venous plasma). Is 20 Omg / d 1 or more, and the blood glucose level (glucose concentration in venous plasma) is 20 Omg / d 1 or more.
- diabetes was defined as a fasting blood level (dulcose concentration in venous plasma) of 126 mg / d1 or more, and a 75 g Glucose concentration in venous plasma) is 200 mg / d1 or more.
- impaired glucose tolerance refers to a fasting blood glucose level (glucose concentration in venous plasma) of less than 126 mg Zd1 (Glucose concentration in plasma) is not less than 140 mgZdl and less than 20 Omg / d1. Furthermore, according to the report of the ADA, a state in which the fasting blood glucose level (glucose concentration in venous plasma) is not less than 11 OmgZdl and less than 126 mgZdl is called IFG (Impaired Fasting Glucose).
- the 2-hour value (glucose concentration in venous plasma) of 75 g oral glucose tolerance test is less than 140 mgZd1
- the condition is called IFG (Impaired Fasting Glycemia).
- the compound of the present invention is also used as a preventive / therapeutic agent for diabetes, borderline type, impaired glucose tolerance, IFG (Impaired Fasting Glucose) and IFG (Impaired Fasting Glycemia) determined by the above-mentioned new criteria.
- the compound of the present invention can also prevent the progression from boundary type, impaired glucose tolerance, IFG (Impaired Fasting Glucose) or IFG (Impaired Fasting Glycemia) to diabetes.
- the compound of the present invention Since the compound of the present invention has an excellent insulin secretion promoting action, it is suitably used as a therapeutic agent for insulin secretory deficiency diabetes in patients with insulin secretory deficiency diabetes.
- the compound of the present invention is also useful as a therapeutic agent for sulfonylurea secondary ineffective diabetes, and a sulfonylurea compound or a fast-acting insulin secretagogue does not provide an insulin secretion effect, and thus a sufficient blood glucose lowering effect is obtained. It has excellent insulin secretion and hypoglycemic effects even in diabetic patients who cannot be treated.
- the sulfonylurea compound and ⁇ ′ are a compound having a sulfo-lurea skeleton or a derivative thereof, for example, tolptamide, glipenec.lamid, daliclazide, Clozoreprono II. Med, torazamide, acetohexamide, glicloviramide, glimepiride, dalipizide, dalibzole and the like.
- sulfolurerea compounds such as repaglinide, senaglinide, nateglinide, Glinide compounds such as mitiglinide or its calcium salt hydrate are exemplified.
- the medicament containing the compound of the present invention has low toxicity and can be used as it is or in a pharmacologically acceptable manner according to a method known per se which is generally used as a method for producing a pharmaceutical preparation. It can be safely orally or parenterally administered (eg, topically, rectally, intravenously, etc.) after being mixed with a carrier to give a pharmaceutical formulation.
- Examples of the dosage form of the pharmaceutical preparation include tablets (including sublingual tablets and orally disintegrating tablets), capsules (including soft capsules and microcapsules), granules, powders, troches, syrups, Oral preparations such as emulsions and suspensions; and injections (eg, subcutaneous injections, intravenous injections, intramuscular injections, intraperitoneal injections, infusions), external preparations (eg, transdermal preparations, ointments) ), Suppositories (eg, rectal suppositories, vaginal suppositories), pellets, nasal preparations, pulmonary preparations (inhalants), and parenteral preparations such as eye drops.
- tablets including sublingual tablets and orally disintegrating tablets
- capsules including soft capsules and microcapsules
- granules powders, troches, syrups, Oral preparations such as emulsions and suspensions
- injections eg, subcutaneous injections, intravenous injections, intramus
- preparations may be controlled-release preparations such as immediate-release preparations or sustained-release preparations (eg, sustained-release microcapsules).
- the content of the compound of the present invention in a pharmaceutical preparation is from about 0.01 to about 100% by weight of the whole preparation.
- the dose of the compound of the present invention varies depending on the administration subject, administration route, disease, symptom and the like. For example, when orally administered to an adult diabetic patient (body weight of about 6 O kg), the dose is about 0.0 per day. 1 to about 30 mg / kg body weight, preferably about 0.1 to about 2 mg / kg body weight, more preferably about 1 to about 2 mg / kg body weight. This amount may be administered in 11 or several divided doses.
- the above-mentioned pharmacologically acceptable carriers include various organic or inorganic carrier materials commonly used as pharmaceutical materials, such as excipients, lubricants, binders and disintegrants in solid formulations, or liquid Examples include solvents, solubilizing agents, suspending agents, isotonic agents, buffers, soothing agents and the like in the preparation. Further, if necessary, additives such as preservatives, antioxidants, coloring agents, sweeteners, adsorbents, wetting agents and the like can be used.
- the excipient include lactose, sucrose, D-mantol, starch, corn starch, crystalline cellulose, light caffeic anhydride and the like.
- Lubricants include, for example, magnesium stearate, canoresium stearate, talc, colloidal silica and the like.
- binder examples include crystalline cellulose, sucrose, D-mannitol, dextrin, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylenopyrrolidone, starch, sucrose, gelatin, methinolecellulose, and carbohydrate.
- Xymethylcellulose sodium and the like examples include crystalline cellulose, sucrose, D-mannitol, dextrin, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylenopyrrolidone, starch, sucrose, gelatin, methinolecellulose, and carbohydrate.
- Disintegrants include, for example, starch, carboxymethylcellulose, calcium carboxymethylcellulose, sodium carboxymethylstarch, L-hydroxypropylcellulose and the like.
- solvent examples include water for injection, alcohol, propylene glycol, macrogol, sesame oil, corn oil, and olive oil.
- solubilizers include polyethylene glycol, propylene glycol, D-mantol, benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, sodium citrate and the like.
- suspending agent examples include surfactants such as stearyltriethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride, benzedonyl chloride, and dariserin monostearate; for example, polyvinyl alcohol. , Poli Wierch.
- surfactants such as stearyltriethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride, benzedonyl chloride, and dariserin monostearate
- polyvinyl alcohol Poli Wierch.
- hydrophilic polymers such as mouth lidone, carboxymethylcellulose sodium, methinoresenolerose, hydroxymethinoresenolerose, hydroxyxetinoresenolerose, and hydroxypropylcellulose.
- Examples of the tonicity agent include glucose, D-sorbitol, sodium chloride, glycerin, D-mannitol and the like.
- 'Examples of the buffer include buffers such as phosphate, acetate, carbonate, and citrate.
- -Examples of the soothing agent include benzyl alcohol.
- preservatives include parahydroxybenzoic acid esters, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid and the like.
- antioxidant examples include sulfite, ascorbic acid, o; -tocopherol and the like.
- coloring agent examples include water-soluble edible tar dyes (eg, edible dyes such as edible red No. 2 and 3, edible yellow No. 4 and 5, edible blue No. 1 and 2), water-insoluble lake dyes (eg, Aluminum salt of the water-soluble edible tar dye), natural dyes (eg,] -carotene, chlorophyll, redwood) and the like.
- water-soluble edible tar dyes eg, edible dyes such as edible red No. 2 and 3, edible yellow No. 4 and 5, edible blue No. 1 and 2
- water-insoluble lake dyes eg, Aluminum salt of the water-soluble edible tar dye
- natural dyes eg,] -carotene, chlorophyll, redwood
- sweetener examples include saccharin sodium, dipotassium glycyrrhizinate, aspartame, stevia and the like.
- the compound of the present invention is a therapeutic agent for diabetes, a therapeutic agent for diabetic complications, a therapeutic agent for hyperlipidemia, an antihypertensive agent, an antiobesity agent, a diuretic agent, a chemotherapeutic agent, an immunotherapy agent, an anti-inflammatory agent, an antithrombotic agent, It can be used in combination with drugs such as osteoporosis drugs, vitamin drugs, anti-dementia drugs, pollakiuria / urinary incontinence drugs, and dysuria treatment drugs (hereinafter sometimes abbreviated as drug X).
- drugs such as osteoporosis drugs, vitamin drugs, anti-dementia drugs, pollakiuria / urinary incontinence drugs, and dysuria treatment drugs (hereinafter sometimes abbreviated as drug X).
- insulin preparations eg, animal insulin preparations extracted from the lungs of pigs and pigs; human insulin preparations genetically engineered using Escherichia coli and yeast; zinc insulin; protamine insulin).
- insulin preparations eg, animal insulin preparations extracted from the lungs of pigs and pigs; human insulin preparations genetically engineered using Escherichia coli and yeast; zinc insulin; protamine insulin).
- Zinc eg, INS-1, etc.
- oral insulin preparation etc.
- insulin sensitivity enhancer eg, pioglitazone or
- Therapeutic agents for diabetic complications include aldose reductase inhibitors (for example, tolrestat, eno ⁇ . Norestat, zenarestat, zoponorerestat, ftita, restat 5 (SNK-860), AS — 3201, Minarestat (AR I.—509)-CT-111, etc., neurotrophic factor and its increasing drugs (eg NGF, NT—3, BDNF, W001 / 14372) Neuro-fin-producing ⁇ secretion enhancer described in (for example, 4-
- aldose reductase inhibitors for example, tolrestat, eno ⁇ . Norestat, zenarestat, zoponorerestat, ftita, restat 5 (SNK-860), AS — 3201, Minarestat (AR I.—509)-CT-111, etc.
- neurotrophic factor and its increasing drugs eg NGF, NT—3, BDNF, W001 / 14372
- P KC Protein kinase C
- Drugs eg, ruboxistaurin mesylate; LY_3333531
- AGE inhibitors eg, ALT-945, pimagedin, viratoxatin, N-phenacylthiazoli
- Pembromide ALT-766
- EXO-226, ALT-71 Pyridrin Pyri dorin
- Pyridoxamine etc.
- Reactive oxygen scavengers eg, acid
- cerebral vasodilators Eg, chiapride
- somatostatin receptor agonist apoptosis signal regulatory kinase-1 (ASK-1) inhibitor and the like.
- HM G Co A reductase inhibitors (eg, pravastatin, simvastatin, lovastatin, atorvastatin, funovastatin, pita pastatin, rospastatin or a salt thereof (eg, sodium salt, calcium) Salt, etc.), squalene synthase inhibitor (eg, the compound described in W09V 10224, for example, N — [[(3R, 5S) -1_ (3-acetoxy-2,2-dimethylpropyl) _7-chloro- 5- (2,3-dimethoxyphenyl) -2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine- 3- yl [acetyl] piperidine-4-acetic acid, etc.), Fibrate compounds (eg, bezafibrate, clofibrate, simfibrate, clinofibrate, etc.), antioxidant
- Antihypertensive agents include angiotensin converting enzyme inhibitors (eg, captopril, enalapril, delapril, etc.), and angiotensin II receptor antagonists (eg, oral sultans, dexdesartan cilexetinol, eprosartan, valsartan, telmisartan) Ilbesartan, olmesartan medoxominole, tasosartan, 1-[[2 '-(2,5-dihydro-5-oxo-4H-1,2,4-oxoxadiazole-3-yl) biphenyl-4-y [Methyl] -2-ethoxy-1H-benzimidazole-7-potassium rubonic acid, etc., lucidum antagonists (eg: manidipine, difludipine, amlodipine, efo-dipine dicardipine, etc.), clonidine etc. Is mentioned.
- anti-obesity agents examples include central anti-obesity agents (eg, dexfenfluamine, fenfluramine, phentermine, cyptramine, ampuepramone, dexane fuetamine, mazindore, feninoleprono nonoleamine, clobenzolex; MCH receptor antagonist ( Examples: SB-568849; SNAP-7941; W001 / 82925 and
- diuretics examples include xanthine derivatives (eg, sodium theobium salicylate, calcium theobromine salicylate), thiazide-based preparations (eg, ethiazide, cyclopentiazide, trichloromethiazide, trichloromethiazide, hydrocyclothiazide, thiazide) Drophnoremethiazide, benzinolehydrocloth thiazide, penphnoretizide, polythiazide, methiclothiazide, etc., anti-aldosterone preparations (eg, spironolatone, triamterene, etc.), carbonic anhydrase inhibitors (eg, acetazolamide, etc.) Sulfonamide-based preparations (eg, chlorthalidone, mefluside, indapamide, etc.), azosemide, isosorbide, ethacrynic acid,
- Chemotherapeutic agents include, for example, alkylating agents (eg, cyclophosphamide, diphosphamide, etc.), antimetabolites (eg, methotrexate, 5_fluorouracil and derivatives thereof), ⁇ cancer antibiotics (eg, : Mitomycin, adriamycin, etc.), plant-derived anticancer agents (eg, vincristine, vindesine, taxol, etc.), cisplatin, carpoplatin, etoposide and the like.
- alkylating agents eg, cyclophosphamide, diphosphamide, etc.
- antimetabolites eg, methotrexate, 5_fluorouracil and derivatives thereof
- ⁇ cancer antibiotics eg, : Mitomycin, adriamycin, etc.
- plant-derived anticancer agents eg, vincristine, vindesine, taxol, etc.
- cisplatin carpoplatin
- immunotherapeutic agents include microbial or bacterial components (eg, muramyl dipeptide derivatives, picibayule, etc.), polysaccharides having immunopotentiating activity (eg, lentinan, schizophyllan, krestin, etc.), and genetic engineering techniques. (Eg, interferon, interleukin (IL), etc.) and colony stimulating factors (eg, granulocyte colony stimulating factor, erythropoietin, etc.), among which IL-1, IL-12, Inter "leukins such as IL-12 are preferred.
- the anti-inflammatory drug include non-steroidal anti-inflammatory drugs such as aspirin, acetoaminophen, indomethacin and the like.
- antithrombotic agents examples include heparin (eg, heparin sodium, heparin calcium, dalteparin sodium, etc.), perfurin (eg, perfarin potassium, etc.), antithrombin drugs (eg, argatroban ( aragatroban)), thrombolytic drugs (eg: perokine (urokinase), tisokinase (tisokinase),reteplase (alteplase), nateplase (nateplase), monteplase (monteplase;), pamiteplase (pamiteplase), etc.), Platelet aggregation inhibitor (eg, ticlopidine hydrochloride), cilostazol, ethyl icosapentate, beraprost sodium
- antithrombin drugs eg, argatroban ( aragatroban)
- thrombolytic drugs eg: perokine (urokinase),
- therapeutic agents for osteoporosis include, for example, alfacalcidol (alfacalcidol), canolecitrionole (calcitriol), enolecatonin (elcatonin), salmon canolecitonin (calcitonin salmon), estriol, estriol, ipriflavone, and ipriflavone.
- alfacalcidol alfacalcidol
- canolecitrionole calcitriol
- enolecatonin elcatonin
- salmon canolecitonin calcitonin salmon
- estriol estriol
- estriol estriol
- ipriflavone ipriflavone
- ipriflavone ipriflavone
- Vitamins agents eg vitamins, vitamin B 12 or the like.
- anti-dementia drugs examples include tacrine, donepezil, rivastigmine, galanthamine and the like.
- Frequent urinary treatments for urinary incontinence include, for example, flavoxate hydrochloride, oxybutynin hydrochloride ⁇ propivedin hydrochloride, and the like.
- therapeutic agents for dysuria include acetylcholinesterase inhibitors (eg, distigmine) and the like.
- drugs that are effective in improving cachexia in animal models and clinical settings such as cyclooxygenase inhibitors (eg, indomethacin) and progesterone derivatives
- saccharification inhibitors eg, ALT-711
- nerve regeneration promoters eg, Y-128, VX853, prosaptide, etc.
- antidepressants eg, desibramin, amitriptyline, imipramine
- antiepileptic drugs Examples: Lamotrigine, Trileptal, Keplera
- the above drug X may be used in combination of two or more kinds at an appropriate ratio.
- the dose of the compound of the present invention and / or the drug X can be reduced as compared to the case where the compound or the drug X of the present invention is administered alone.
- the treatment period can be set longer
- the timing of administration of the compound of the present invention and Drug X is not limited, and the compound of the present invention and Drug X may be administered simultaneously to a subject to be administered. It may be administered at a time interval.
- the dose of the drug X may be in accordance with the dose clinically used, and can be appropriately selected depending on the administration subject, administration route, disease, combination and the like.
- the administration form of the compound of the present invention and the drug X is not particularly limited, as long as the compound of the present invention and the drug X are combined at the time of administration.
- Such administration forms include, for example, (1) administration of a single preparation obtained by simultaneously preparing the compound of the present invention and drug X, and (2) separate administration of the compound of the present invention and drug X. (3) Simultaneous administration by the same administration route of the two preparations obtained by formulating the compound of the present invention, (3) The time difference of the two preparations obtained by separately formulating the compound of the present invention and the drug X by the same administration route.
- Root temperature in the following Reference Examples and Examples usually indicates about 10 ° C. to about 35 ° C. % Is mol / raol% for yield, solvent for chromatography is% by volume, others are weight. /. Indicates. For proton NMR spectra, those that cannot be confirmed by broad lines, such as 0H and NH protons, are not described in the data.
- MS mass spectrum
- NMR nuclear magnetic resonance spectrum
- MS measurement equipment Waters ZMD, Waters ZQ2000 or Micromass platform
- ⁇ Ionization method Electron impact ionization method (Electron Spray Ionization: ESI), or Atmospheric Pressure Chemical Ionizat method ion: APCI). Unless otherwise specified, ESI was used.
- NMR spectroscopy IJ equipment Nozian Sat Varian Gemini 200 (200 MHz) s Varian Gemini 300 (300 MHz), Pullker's Biospin AVANCE 300.
- Solvent Solution A; 0.1% water containing 1% trifluoroacetic acid.
- Solution B acetonitrile containing 0.1% trifluoroacetic acid.
- the melting point means a melting point measured using, for example, a trace melting point analyzer (Biichi, B-545 type) or the like.
- the melting point may fluctuate depending on the measurement equipment, measurement conditions, and the like.
- the crystal in this specification may be a crystal exhibiting a value different from the melting point described in this specification as long as it is within a normal error range.
- 3_Bromobenzaldehyde (18.5 g, 100 mmol) and 2,6-dimethylphenylpropionic acid (21.0 g, 140 mmol) were added to 1 M aqueous sodium carbonate (200 mL), ethanol (100 mL). After dissolving in a mixed solution of toluene (200 mL) and toluene (200 mL) and purging with argon, tetrakis (tripheninolephosphine) palladium (0) (5.78 g, 5.00 mmol) was added. The reaction solution was stirred at 80 ° C for 20 hours under an argon atmosphere.
- the reaction mixture was concentrated under reduced pressure, the residue was purified by silica gel column chromatography (20% to 60% ethyl acetate / hexane), hexane-ethyl acetate was added to the obtained residue, and the resulting insolubles were filtered. Separately, the filtrate was concentrated to give the title compound (3.65 g, yield 95%) as a red oil.
- the ethyl acetate layer was dried using a Presep Dehydration tube (manufactured by Wako Pure Chemical Industries, Ltd.) and concentrated. The residue was purified by silica gel column chromatography ⁇ - it was purified by (hexane 10% to 80% acetic acid Echiru Z), to give the title compound (220 ra g, 50% yield) as a yellow oil.
- reaction solution was diluted with ethyl acetate, washed sequentially with water and brine, dried over magnesium sulfate, and concentrated under reduced pressure.
- Lithium hydride was added to a solution of 5-ethylisopropyl-1- (2-methylphenyl) -1H-pyrazole-3-carboxylate (1.07 g, 3.54 mmol) in anhydrous tetrahydrofuran (10 mL) at 0 ° C with stirring.
- Aluminum (0.13 g, 3.54 mmol) was added, and the mixture was stirred at the same temperature for 2 hours.
- sodium sulfate decahydrate (2.28 g, 7.08 mmol) was added to the system, and the mixture was stirred at room temperature for 2 hours.
- the precipitated insoluble material was filtered, and the filtrate was concentrated under reduced pressure.
- Reference Example 50 4-isoptoxy-3- ⁇ : [(2-Lae-letyl) (4-phenyl-1,3-thiazo-l-2-yl) amino] methyl ⁇ benzaldehyde.
- reaction solution was diluted with ethyl acetate, washed with water and saturated saline, dried, and concentrated under reduced pressure.
- the reaction solution was concentrated under reduced pressure, water was added to the residue, and the mixture was extracted with ethyl acetate. The extract was washed with saturated saline, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane to 20% ethyl acetate Z hexane) to give the title compound (3.60 g , yield 87%) as a yellow oil.
- reaction mixture was poured into 2 M hydrochloric acid and extracted with ethyl acetate.
- the extract was dried over anhydrous magnesium sulfate and concentrated under reduced pressure to give the title compound (1.40 g, yield 92%) as a yellow oil.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Epoxy Compounds (AREA)
- Indole Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Furan Compounds (AREA)
- Pyrrole Compounds (AREA)
- Quinoline Compounds (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006511072A JP4875978B2 (ja) | 2004-03-15 | 2005-03-14 | アミノフェニルプロパン酸誘導体 |
CA002560111A CA2560111A1 (en) | 2004-03-15 | 2005-03-14 | Aminophenylpropanoic acid derivative |
US10/592,789 US7786165B2 (en) | 2004-03-15 | 2005-03-14 | Aminophenylpropanoic acid derivative |
EP05721059A EP1726580A4 (en) | 2004-03-15 | 2005-03-14 | AMINOPHNYLPROPANO ACID DERIVATIVE |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-073576 | 2004-03-15 | ||
JP2004073576 | 2004-03-15 | ||
JP2004-247339 | 2004-08-26 | ||
JP2004247339 | 2004-08-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005087710A1 true WO2005087710A1 (ja) | 2005-09-22 |
Family
ID=34975502
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/004872 WO2005087710A1 (ja) | 2004-03-15 | 2005-03-14 | アミノフェニルプロパン酸誘導体 |
Country Status (5)
Country | Link |
---|---|
US (1) | US7786165B2 (ja) |
EP (1) | EP1726580A4 (ja) |
JP (1) | JP4875978B2 (ja) |
CA (1) | CA2560111A1 (ja) |
WO (1) | WO2005087710A1 (ja) |
Cited By (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007525516A (ja) * | 2004-02-27 | 2007-09-06 | アムジエン・インコーポレーテツド | 代謝疾患の治療に使用するための、化合物、薬学的組成物及び方法 |
WO2008066097A1 (en) | 2006-12-01 | 2008-06-05 | Astellas Pharma Inc. | Carboxylic acid derivative |
WO2008139987A1 (ja) * | 2007-04-26 | 2008-11-20 | Japan Science And Technology Agency | Gタンパク質共役型レセプタ-作動剤 |
US7465804B2 (en) | 2005-05-20 | 2008-12-16 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders |
WO2009054390A1 (ja) * | 2007-10-23 | 2009-04-30 | Astellas Pharma Inc. | チアゾリジンジオン化合物 |
WO2009054423A1 (ja) | 2007-10-24 | 2009-04-30 | Astellas Pharma Inc. | オキサジアゾリジンジオン化合物 |
US7572934B2 (en) | 2007-04-16 | 2009-08-11 | Amgen Inc. | Substituted biphenyl GPR40 modulators |
US7582803B2 (en) | 2005-09-14 | 2009-09-01 | Amgen Inc. | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders |
WO2008001931A3 (en) * | 2006-06-27 | 2009-09-11 | Takeda Pharmaceutical Company Limited | Fused cyclic compounds |
US7687526B2 (en) | 2006-09-07 | 2010-03-30 | Amgen Inc. | Benzo-fused compounds for use in treating metabolic disorders |
WO2010035806A1 (ja) | 2008-09-25 | 2010-04-01 | 武田薬品工業株式会社 | 固形医薬組成物 |
WO2010050445A1 (ja) | 2008-10-27 | 2010-05-06 | 武田薬品工業株式会社 | 二環性化合物 |
US7714008B2 (en) | 2006-09-07 | 2010-05-11 | Amgen Inc. | Heterocyclic GPR40 modulators |
WO2010076884A1 (ja) | 2008-12-29 | 2010-07-08 | 武田薬品工業株式会社 | 新規縮合環化合物およびその用途 |
JP2010527974A (ja) * | 2007-05-25 | 2010-08-19 | アボット ゲーエムベーハー ウント カンパニー カーゲー | 代謝型グルタミン酸受容体2(mglu2受容体)の陽性調節剤としての複素環化合物 |
US7820837B2 (en) | 2003-05-30 | 2010-10-26 | Takeda Pharmaceutical Company Limited | Condensed ring compound |
WO2010123016A1 (ja) | 2009-04-22 | 2010-10-28 | アステラス製薬株式会社 | カルボン酸化合物 |
WO2010143733A1 (en) | 2009-06-09 | 2010-12-16 | Takeda Pharmaceutical Company Limited | Novel fused cyclic compound and use thereof |
JP2010540482A (ja) * | 2007-09-27 | 2010-12-24 | エフ.ホフマン−ラ ロシュ アーゲー | ビアリールスルホンアミド誘導体 |
WO2011013639A1 (ja) | 2009-07-28 | 2011-02-03 | 武田薬品工業株式会社 | 錠剤 |
US7932289B2 (en) | 2004-07-27 | 2011-04-26 | Takeda Pharmaceutical Company Limited | Remedy for diabetes |
US8030354B2 (en) | 2007-10-10 | 2011-10-04 | Amgen Inc. | Substituted biphenyl GPR40 modulators |
WO2011136385A1 (en) | 2010-04-27 | 2011-11-03 | Takeda Pharmaceutical Company Limited | Bicyclic compound derivatives and their use as acc inhibitors. |
WO2011158880A1 (ja) | 2010-06-16 | 2011-12-22 | 武田薬品工業株式会社 | アミド化合物の結晶 |
JP2012506386A (ja) * | 2008-10-21 | 2012-03-15 | メタボレックス, インコーポレイテッド | アリールgpr120受容体アゴニストおよびその使用 |
WO2012036293A1 (ja) | 2010-09-17 | 2012-03-22 | 武田薬品工業株式会社 | 糖尿病治療剤 |
WO2012074126A1 (en) | 2010-11-30 | 2012-06-07 | Takeda Pharmaceutical Company Limited | Bicyclic compound |
WO2012111849A1 (en) | 2011-02-17 | 2012-08-23 | Takeda Pharmaceutical Company Limited | Production method of optically active dihydrobenzofuran derivative |
WO2013061962A1 (ja) | 2011-10-24 | 2013-05-02 | 武田薬品工業株式会社 | 二環性化合物 |
US8450522B2 (en) | 2008-03-06 | 2013-05-28 | Amgen Inc. | Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders |
WO2013105676A1 (en) | 2012-01-12 | 2013-07-18 | Takeda Pharmaceutical Company Limited | Benzimidazole derivatives as mch receptor antagonists |
WO2013104257A1 (zh) | 2012-01-12 | 2013-07-18 | 江苏恒瑞医药股份有限公司 | 多环类衍生物、其制备方法及其在医药上的应用 |
WO2013122029A1 (ja) | 2012-02-13 | 2013-08-22 | 武田薬品工業株式会社 | 芳香環化合物 |
WO2013122028A1 (ja) | 2012-02-13 | 2013-08-22 | 武田薬品工業株式会社 | 芳香環化合物 |
WO2013125732A1 (en) | 2012-02-24 | 2013-08-29 | Takeda Pharmaceutical Company Limited | Aromatic ring compound |
WO2013147026A1 (ja) | 2012-03-29 | 2013-10-03 | 武田薬品工業株式会社 | 芳香環化合物 |
WO2013168760A1 (ja) | 2012-05-10 | 2013-11-14 | 武田薬品工業株式会社 | 芳香環化合物 |
WO2013168759A1 (ja) | 2012-05-10 | 2013-11-14 | 武田薬品工業株式会社 | 芳香環化合物 |
WO2013183784A1 (en) | 2012-06-05 | 2013-12-12 | Takeda Pharmaceutical Company Limited | Solid preparation |
WO2014011926A1 (en) | 2012-07-11 | 2014-01-16 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
WO2014022528A1 (en) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
US8748462B2 (en) | 2008-10-15 | 2014-06-10 | Amgen Inc. | Spirocyclic GPR40 modulators |
JP2014521744A (ja) * | 2011-08-17 | 2014-08-28 | イーライ リリー アンド カンパニー | 糖尿病の治療に有用な新規1,2,3,4−テトラヒドロキノリン誘導体 |
WO2014130608A1 (en) | 2013-02-22 | 2014-08-28 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2014142363A1 (en) | 2013-03-14 | 2014-09-18 | Takeda Pharmaceutical Company Limited | Spiro azetidine isoxazole derivatives and their use as sstr5 antagonists |
WO2015005489A1 (en) | 2013-07-09 | 2015-01-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
WO2015020184A1 (ja) | 2013-08-09 | 2015-02-12 | 武田薬品工業株式会社 | 芳香環化合物 |
WO2015051725A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
WO2015052910A1 (en) | 2013-10-07 | 2015-04-16 | Takeda Pharmaceutical Company Limited | Antagonists of somatostatin receptor subtype 5 (sstr5) |
WO2015062486A1 (en) * | 2013-10-31 | 2015-05-07 | Sunshine Lake Pharma Co., Ltd. | Biphenyl compounds and uses thereof |
WO2015095256A1 (en) | 2013-12-19 | 2015-06-25 | Merck Sharp & Dohme Corp. | Antidiabetic substituted heteroaryl compounds |
JP2015523339A (ja) * | 2012-05-30 | 2015-08-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新しいインダニルオキシフェニルシクロプロパンカルボン酸 |
WO2015122187A1 (en) | 2014-02-13 | 2015-08-20 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
WO2015122188A1 (en) | 2014-02-13 | 2015-08-20 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
WO2015176640A1 (en) | 2014-05-22 | 2015-11-26 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
JP2016503409A (ja) * | 2012-11-09 | 2016-02-04 | エルジー・ライフ・サイエンシーズ・リミテッドLG Life Sciences Ltd. | Gpr40受容体アゴニスト、この製造方法およびこれを活性成分として含有する医薬組成物 |
WO2016019863A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [7,6]-fused bicyclic antidiabetic compounds |
WO2016022448A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2016022446A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [5,6]-fused bicyclic antidiabetic compounds |
WO2016022742A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
JP2016505551A (ja) * | 2012-12-07 | 2016-02-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規インダニルオキシジヒドロベンゾフラニル酢酸 |
US20160280626A1 (en) * | 2013-12-04 | 2016-09-29 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
US9499467B2 (en) | 2011-04-08 | 2016-11-22 | Caldan Therapeutics Limited | Ortho-fluoro substituted compounds for the treatment of metabolic diseases |
JP2017052777A (ja) * | 2011-09-16 | 2017-03-16 | サノフイ | アニリン誘導体、それらの調製およびそれらの治療適用 |
WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
US10005720B2 (en) | 2013-04-05 | 2018-06-26 | North Carolina Central University | Compounds useful for the treatment of metabolic disorders and synthesis of the same |
WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
US10059667B2 (en) | 2014-02-06 | 2018-08-28 | Merck Sharp & Dohme Corp. | Antidiabetic compounds |
JP2018526405A (ja) * | 2015-09-09 | 2018-09-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | [{[2,3−ジヒドロ−1H−インデン−1−イル]アミノ}−2H,3H−フロ[3,2−b]ピリジン−3−イル]酢酸、それらの医薬組成物および使用 |
JP2018526352A (ja) * | 2015-08-07 | 2018-09-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | インダニルアミノピリジルシクロプロパンカルボン酸、医薬組成物及びこれらの使用 |
WO2018182050A1 (en) | 2017-03-31 | 2018-10-04 | Takeda Pharmaceutical Company Limited | Substituted cyclyl-acetic acid derivatives for the treatment of metabolic disorders |
WO2018181847A1 (ja) | 2017-03-31 | 2018-10-04 | 武田薬品工業株式会社 | 芳香環化合物 |
WO2018181864A1 (en) | 2017-03-31 | 2018-10-04 | Takeda Pharmaceutical Company Limited | Gip receptor activating peptide |
WO2018182051A1 (en) | 2017-03-30 | 2018-10-04 | Takeda Pharmaceutical Company Limited | Ip6k inhibitors |
WO2019134984A1 (en) | 2018-01-08 | 2019-07-11 | Celon Pharma S.A. | 3-phenyl-4-hexynoic acid derivatives as gpr40 agonists |
JP2019532110A (ja) * | 2016-10-25 | 2019-11-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベンジルアミノピリジルシクロプロパンカルボン酸、その医薬組成物および使用 |
US10519115B2 (en) | 2013-11-15 | 2019-12-31 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
JP2020502111A (ja) * | 2016-12-15 | 2020-01-23 | イルドン ファーマシューティカル カンパニー リミテッド | 新規フェニルプロピオン酸誘導体及びその用途 |
US10550127B1 (en) | 2017-02-08 | 2020-02-04 | Boehringer Ingelheim International Gmbh | Indanylaminoazadihydrobenzofuranylacetic acids, pharmaceutical compositions for the treatment of diabetes |
JP2020505400A (ja) * | 2017-01-26 | 2020-02-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベンジルアミノピリジルシクロプロパンカルボン酸、その医薬組成物及び使用 |
WO2020045326A1 (ja) | 2018-08-27 | 2020-03-05 | 株式会社スコヒアファーマ | 安息香酸エステル化合物 |
US10603317B2 (en) | 2017-01-26 | 2020-03-31 | Boehringer Ingelheim International Gmbh | Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
WO2020067557A2 (en) | 2018-09-24 | 2020-04-02 | Takeda Pharmaceutical Company Limited | Gip receptor agonist peptide compounds and uses thereof |
WO2020067575A1 (en) | 2018-09-24 | 2020-04-02 | Takeda Pharmaceutical Company Limited | Gip receptor agonist peptide compounds and uses thereof |
US10676458B2 (en) | 2016-03-29 | 2020-06-09 | Merch Sharp & Dohne Corp. Rahway | Antidiabetic bicyclic compounds |
US10793530B2 (en) | 2017-01-26 | 2020-10-06 | Boehringer Ingelheim International Gmbh | Benzylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
US10913720B2 (en) | 2017-01-26 | 2021-02-09 | Boehringer Ingelheim International Gmbh | Benzyloxypyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
WO2021193983A2 (en) | 2020-03-25 | 2021-09-30 | Takeda Pharmaceutical Company Limited | Qw dosing of gip receptor agonist peptide compounds and uses thereof |
WO2021193984A2 (en) | 2020-03-25 | 2021-09-30 | Takeda Pharmaceutical Company Limited | Qd dosing of gip receptor agonist peptide compounds and uses thereof |
US11225471B2 (en) | 2017-11-16 | 2022-01-18 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2022053013A1 (zh) | 2020-09-10 | 2022-03-17 | 上海爱博医药科技有限公司 | 苯并含氧杂环类化合物及其医药应用 |
WO2022241287A2 (en) | 2021-05-13 | 2022-11-17 | Carmot Therapeutics, Inc. | Modulators of g-protein coupled receptors |
US11535660B1 (en) | 2018-03-23 | 2022-12-27 | Cannot Therapeutics, Inc. | Modulators of G-protein coupled receptors |
US11583528B2 (en) | 2016-02-17 | 2023-02-21 | Children's Medical Center Corporation | FFA1 (GPR40) as a therapeutic target for neural angiogenesis diseases or disorders |
WO2023169456A1 (en) | 2022-03-09 | 2023-09-14 | Gasherbrum Bio , Inc. | Heterocyclic glp-1 agonists |
WO2023179542A1 (en) | 2022-03-21 | 2023-09-28 | Gasherbrum Bio , Inc. | 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes |
WO2023198140A1 (en) | 2022-04-14 | 2023-10-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
WO2024125602A1 (en) | 2022-12-15 | 2024-06-20 | Gasherbrum Bio, Inc. | Salts and solid forms of a compound having glp-1 agonist activity |
WO2024138048A1 (en) | 2022-12-22 | 2024-06-27 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
WO2024131869A1 (en) | 2022-12-22 | 2024-06-27 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
WO2024169952A1 (en) | 2023-02-16 | 2024-08-22 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200815377A (en) | 2006-04-24 | 2008-04-01 | Astellas Pharma Inc | Oxadiazolidinedione compound |
EP2222639A1 (en) * | 2007-11-21 | 2010-09-01 | Decode Genetics EHF | Biaryl pde4 inhibitors for treating pulmonary and cardiovascular disorders |
WO2010080976A1 (en) * | 2009-01-09 | 2010-07-15 | Sdg, Inc. (An Ohio Corporation) | Insulin therapies for the treatment of diabetes, diabetes related ailments, and/or diseases or conditions other than diabetes or diabetes related ailments |
GB0901834D0 (en) | 2009-02-04 | 2009-03-11 | Syngenta Ltd | Novel herbicides |
FR2965262A1 (fr) | 2010-09-24 | 2012-03-30 | Sanofi Aventis | Derives de nicotinamide, leur preparation et leur application en therapeutique |
CN103145663B (zh) * | 2013-03-01 | 2016-03-23 | 上海高准医药有限公司 | (s)-2-(2,3-二氢苯并呋喃-3-基)乙酸衍生物,其制备方法及其在医药上的应用 |
CN104507921B (zh) * | 2013-07-02 | 2017-02-22 | 四川海思科制药有限公司 | 苯并环丁烯类衍生物、其制备方法及其在医药上的应用 |
CN105246875A (zh) * | 2013-09-03 | 2016-01-13 | 四川海思科制药有限公司 | 茚满衍生物及其制备方法和在医药上的应用 |
CN103804270B (zh) * | 2014-01-23 | 2016-06-22 | 中国药科大学 | 5-(4-甲脒基苄氧基)色氨酸衍生物、其制法及应用 |
CN104326950A (zh) * | 2014-10-14 | 2015-02-04 | 中国药科大学 | 苯氧乙酸类衍生物、其制备方法及其作为药物的用途 |
EP3242867A4 (en) | 2014-12-26 | 2018-11-07 | Dow Global Technologies LLC | Organic compounds and electronic device comprising organic layer comprising organic compounds |
US11046670B2 (en) | 2015-10-19 | 2021-06-29 | Board Of Regents, The University Of Texas System | Piperazinyl norbenzomorphan compounds and methods for using the same |
EP3448520A4 (en) | 2016-04-29 | 2020-07-29 | Board Of Regents, The University Of Texas System | SIGMA RECEIVER BINDERS |
AU2017257151A1 (en) * | 2016-04-29 | 2018-11-15 | Board Of Regents, The University Of Texas System | Sigma receptor binders |
CN107162921B (zh) * | 2017-05-27 | 2019-12-13 | 中国药科大学 | 一类苯氧乙酸衍生物、其制备方法及其作为药物的用途 |
WO2019165043A2 (en) | 2018-02-22 | 2019-08-29 | Chemocentryx, Inc. | Indane-amines as pd-l1 antagonists |
EP3886854A4 (en) | 2018-11-30 | 2022-07-06 | Nuvation Bio Inc. | PYRROLE AND PYRAZOLE COMPOUNDS AND METHODS OF USE THERE |
KR20220034829A (ko) * | 2019-07-10 | 2022-03-18 | 케모센트릭스, 인크. | Pd-l1 억제제로서의 인단 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06239817A (ja) * | 1992-12-10 | 1994-08-30 | Dr Karl Thomae Gmbh | カルボン酸誘導体、これらの化合物を含む医薬組成物及びそれらの調製方法 |
US20020002203A1 (en) | 1999-04-05 | 2002-01-03 | City Of Hope | Novel breakers of advanced glycation endproducts |
WO2003099793A1 (en) | 2002-05-24 | 2003-12-04 | Takeda Pharmaceutical Company Limited | 1,2-azole derivatives with hypoglycemic and hypolipidemic activity |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8728051D0 (en) | 1987-12-01 | 1988-01-06 | Leo Pharm Prod Ltd | Chemical compounds |
GB9514160D0 (en) * | 1994-07-25 | 1995-09-13 | Zeneca Ltd | Aromatic compounds |
WO2000021927A2 (en) * | 1998-10-08 | 2000-04-20 | Smithkline Beecham Plc | Pyrrole-2,5-diones as gsk-3 inhibitors |
US6583183B2 (en) * | 1999-09-23 | 2003-06-24 | Pharmacia Corporation | Substituted n-phenyl-n-fused-benzyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity |
GB0008264D0 (en) * | 2000-04-04 | 2000-05-24 | Smithkline Beecham Plc | Novel method and compounds |
IL155035A0 (en) | 2000-09-27 | 2003-10-31 | Ajinomoto Kk | Benzodiazepine derivatives |
CN100436452C (zh) * | 2000-12-21 | 2008-11-26 | 沃泰克斯药物股份有限公司 | 可用作蛋白激酶抑制剂的吡唑化合物 |
DE60139025D1 (de) | 2000-12-28 | 2009-07-30 | Takeda Pharmaceutical | Alkansäurederivate, verfahren zu deren herstellung und deren verwendung |
WO2003072100A1 (en) | 2002-02-25 | 2003-09-04 | Eli Lilly And Company | Peroxisome proliferator activated receptor modulators |
EP1480642B1 (en) * | 2002-02-25 | 2008-11-26 | Eli Lilly And Company | Peroxisome proliferator activated receptor modulators |
JP2004277397A (ja) * | 2002-05-24 | 2004-10-07 | Takeda Chem Ind Ltd | 1,2−アゾール誘導体 |
WO2004026823A1 (en) | 2002-09-20 | 2004-04-01 | Pfizer Products Inc. | Amide and sulfonamide ligands for the estrogen receptor |
BR0315041A (pt) | 2002-10-04 | 2005-08-16 | Millennium Pharm Inc | Métodos para inibir crth2 em um indivìduo que necessita inibição de crth2; composto; e composição farmacêutica |
WO2004041266A1 (ja) | 2002-11-08 | 2004-05-21 | Takeda Pharmaceutical Company Limited | 受容体機能調節剤 |
US7820837B2 (en) * | 2003-05-30 | 2010-10-26 | Takeda Pharmaceutical Company Limited | Condensed ring compound |
RU2005141516A (ru) * | 2003-06-06 | 2007-07-20 | Ф.Хоффманн-Ля Рош Аг (Ch) | Производные анилина |
WO2005049573A1 (en) * | 2003-11-05 | 2005-06-02 | F. Hoffmann-La Roche Ag | Phenyl derivatives as ppar agonists |
ES2285554T3 (es) * | 2003-12-11 | 2007-11-16 | GALDERMA RESEARCH & DEVELOPMENT | Nuevos compuestos que son moduladores de receptores de tipo ppar y su uso en composiciones cosmeticas o farmaceuticas. |
BRPI0417543A (pt) | 2003-12-12 | 2007-03-27 | Wyeth Corp | quinolinas úteis no tratamento de doença cardiovascular |
RU2006126978A (ru) | 2003-12-25 | 2008-01-27 | Такеда Фармасьютикал Компани Лимитед (Jp) | Производные 3-(4-бензилоксифенил)пропановой кислоты |
EP1698624B1 (en) | 2003-12-26 | 2012-06-27 | Takeda Pharmaceutical Company Limited | Phenylpropanoic acid derivatives |
-
2005
- 2005-03-14 CA CA002560111A patent/CA2560111A1/en not_active Abandoned
- 2005-03-14 US US10/592,789 patent/US7786165B2/en not_active Expired - Fee Related
- 2005-03-14 WO PCT/JP2005/004872 patent/WO2005087710A1/ja not_active Application Discontinuation
- 2005-03-14 EP EP05721059A patent/EP1726580A4/en not_active Withdrawn
- 2005-03-14 JP JP2006511072A patent/JP4875978B2/ja not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06239817A (ja) * | 1992-12-10 | 1994-08-30 | Dr Karl Thomae Gmbh | カルボン酸誘導体、これらの化合物を含む医薬組成物及びそれらの調製方法 |
US20020002203A1 (en) | 1999-04-05 | 2002-01-03 | City Of Hope | Novel breakers of advanced glycation endproducts |
WO2003099793A1 (en) | 2002-05-24 | 2003-12-04 | Takeda Pharmaceutical Company Limited | 1,2-azole derivatives with hypoglycemic and hypolipidemic activity |
Non-Patent Citations (1)
Title |
---|
See also references of EP1726580A4 * |
Cited By (142)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7820837B2 (en) | 2003-05-30 | 2010-10-26 | Takeda Pharmaceutical Company Limited | Condensed ring compound |
US7816367B2 (en) | 2004-02-27 | 2010-10-19 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders |
JP2007525516A (ja) * | 2004-02-27 | 2007-09-06 | アムジエン・インコーポレーテツド | 代謝疾患の治療に使用するための、化合物、薬学的組成物及び方法 |
US7649110B2 (en) | 2004-02-27 | 2010-01-19 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders |
US7932289B2 (en) | 2004-07-27 | 2011-04-26 | Takeda Pharmaceutical Company Limited | Remedy for diabetes |
US7465804B2 (en) | 2005-05-20 | 2008-12-16 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders |
US7582803B2 (en) | 2005-09-14 | 2009-09-01 | Amgen Inc. | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders |
US7732626B2 (en) | 2006-06-27 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Fused cyclic compounds |
US8088821B2 (en) | 2006-06-27 | 2012-01-03 | Takeda Pharmaceutical Company Limited | Fused cyclic compounds |
RU2444521C2 (ru) * | 2006-06-27 | 2012-03-10 | Такеда Фармасьютикал Компани Лимитед | Конденсированные циклические соединения |
KR101058772B1 (ko) | 2006-06-27 | 2011-08-24 | 다케다 야쿠힌 고교 가부시키가이샤 | 융합 환형 화합물 |
CN102731451B (zh) * | 2006-06-27 | 2015-07-29 | 武田药品工业株式会社 | 稠环化合物 |
US8598226B2 (en) | 2006-06-27 | 2013-12-03 | Takeda Pharmaceutical Company Limited | Fused cyclic compounds |
WO2008001931A3 (en) * | 2006-06-27 | 2009-09-11 | Takeda Pharmaceutical Company Limited | Fused cyclic compounds |
EP2431367A3 (en) * | 2006-06-27 | 2012-07-04 | Takeda Pharmaceutical Company Limited | Fused cyclic compounds as GPR40 receptor modulators |
US8492430B2 (en) | 2006-06-27 | 2013-07-23 | Takeda Pharmaceutical Company Limited | Fused cyclic compounds |
CN103083307A (zh) * | 2006-06-27 | 2013-05-08 | 武田药品工业株式会社 | 稠环化合物 |
EP2743268A3 (en) * | 2006-06-27 | 2014-10-08 | Takeda Pharmaceutical Company Limited | Fused cyclic compounds as GPR40 receptor modulators |
EP2248812A3 (en) * | 2006-06-27 | 2011-03-16 | Takeda Pharmaceutical Company Limited | Fused cyclic compounds as gpr40 receptor modulators |
CN101616913B (zh) * | 2006-06-27 | 2013-01-23 | 武田药品工业株式会社 | 稠环化合物 |
JP2012062320A (ja) * | 2006-06-27 | 2012-03-29 | Takeda Chem Ind Ltd | 縮合環化合物 |
US7714008B2 (en) | 2006-09-07 | 2010-05-11 | Amgen Inc. | Heterocyclic GPR40 modulators |
US8003648B2 (en) | 2006-09-07 | 2011-08-23 | Amgen Inc. | Heterocyclic GPR40 modulators |
US7687526B2 (en) | 2006-09-07 | 2010-03-30 | Amgen Inc. | Benzo-fused compounds for use in treating metabolic disorders |
WO2008066097A1 (en) | 2006-12-01 | 2008-06-05 | Astellas Pharma Inc. | Carboxylic acid derivative |
US7572934B2 (en) | 2007-04-16 | 2009-08-11 | Amgen Inc. | Substituted biphenyl GPR40 modulators |
US8318781B2 (en) | 2007-04-26 | 2012-11-27 | Japan Science And Technology Agency | G-protein-conjugated receptor agonist |
WO2008139987A1 (ja) * | 2007-04-26 | 2008-11-20 | Japan Science And Technology Agency | Gタンパク質共役型レセプタ-作動剤 |
JP2010527974A (ja) * | 2007-05-25 | 2010-08-19 | アボット ゲーエムベーハー ウント カンパニー カーゲー | 代謝型グルタミン酸受容体2(mglu2受容体)の陽性調節剤としての複素環化合物 |
JP2010540482A (ja) * | 2007-09-27 | 2010-12-24 | エフ.ホフマン−ラ ロシュ アーゲー | ビアリールスルホンアミド誘導体 |
US8030354B2 (en) | 2007-10-10 | 2011-10-04 | Amgen Inc. | Substituted biphenyl GPR40 modulators |
WO2009054390A1 (ja) * | 2007-10-23 | 2009-04-30 | Astellas Pharma Inc. | チアゾリジンジオン化合物 |
WO2009054423A1 (ja) | 2007-10-24 | 2009-04-30 | Astellas Pharma Inc. | オキサジアゾリジンジオン化合物 |
US8450522B2 (en) | 2008-03-06 | 2013-05-28 | Amgen Inc. | Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders |
WO2010035806A1 (ja) | 2008-09-25 | 2010-04-01 | 武田薬品工業株式会社 | 固形医薬組成物 |
US8748462B2 (en) | 2008-10-15 | 2014-06-10 | Amgen Inc. | Spirocyclic GPR40 modulators |
JP2012506386A (ja) * | 2008-10-21 | 2012-03-15 | メタボレックス, インコーポレイテッド | アリールgpr120受容体アゴニストおよびその使用 |
WO2010050445A1 (ja) | 2008-10-27 | 2010-05-06 | 武田薬品工業株式会社 | 二環性化合物 |
WO2010076884A1 (ja) | 2008-12-29 | 2010-07-08 | 武田薬品工業株式会社 | 新規縮合環化合物およびその用途 |
WO2010123016A1 (ja) | 2009-04-22 | 2010-10-28 | アステラス製薬株式会社 | カルボン酸化合物 |
JP2012529422A (ja) * | 2009-06-09 | 2012-11-22 | 武田薬品工業株式会社 | 新規な縮合環化合物およびその用途 |
WO2010143733A1 (en) | 2009-06-09 | 2010-12-16 | Takeda Pharmaceutical Company Limited | Novel fused cyclic compound and use thereof |
WO2011013639A1 (ja) | 2009-07-28 | 2011-02-03 | 武田薬品工業株式会社 | 錠剤 |
WO2011136385A1 (en) | 2010-04-27 | 2011-11-03 | Takeda Pharmaceutical Company Limited | Bicyclic compound derivatives and their use as acc inhibitors. |
WO2011158880A1 (ja) | 2010-06-16 | 2011-12-22 | 武田薬品工業株式会社 | アミド化合物の結晶 |
WO2012036293A1 (ja) | 2010-09-17 | 2012-03-22 | 武田薬品工業株式会社 | 糖尿病治療剤 |
WO2012074126A1 (en) | 2010-11-30 | 2012-06-07 | Takeda Pharmaceutical Company Limited | Bicyclic compound |
WO2012111849A1 (en) | 2011-02-17 | 2012-08-23 | Takeda Pharmaceutical Company Limited | Production method of optically active dihydrobenzofuran derivative |
US9499467B2 (en) | 2011-04-08 | 2016-11-22 | Caldan Therapeutics Limited | Ortho-fluoro substituted compounds for the treatment of metabolic diseases |
JP2014521744A (ja) * | 2011-08-17 | 2014-08-28 | イーライ リリー アンド カンパニー | 糖尿病の治療に有用な新規1,2,3,4−テトラヒドロキノリン誘導体 |
JP2017052777A (ja) * | 2011-09-16 | 2017-03-16 | サノフイ | アニリン誘導体、それらの調製およびそれらの治療適用 |
WO2013061962A1 (ja) | 2011-10-24 | 2013-05-02 | 武田薬品工業株式会社 | 二環性化合物 |
WO2013104257A1 (zh) | 2012-01-12 | 2013-07-18 | 江苏恒瑞医药股份有限公司 | 多环类衍生物、其制备方法及其在医药上的应用 |
US9139548B2 (en) | 2012-01-12 | 2015-09-22 | Jiangsu Hengrui Medicine Co., Ltd. | Polycyclic derivatives, preparation process and pharmaceutical use thereof |
WO2013105676A1 (en) | 2012-01-12 | 2013-07-18 | Takeda Pharmaceutical Company Limited | Benzimidazole derivatives as mch receptor antagonists |
JP2015503595A (ja) * | 2012-01-12 | 2015-02-02 | ジエンス ヘンルイ メデイシンカンパニー リミテッドJiangsu Hengrui Medicine Co.,Ltd. | 多環式化合物誘導体、それらの製造方法および医薬用途 |
WO2013122029A1 (ja) | 2012-02-13 | 2013-08-22 | 武田薬品工業株式会社 | 芳香環化合物 |
WO2013122028A1 (ja) | 2012-02-13 | 2013-08-22 | 武田薬品工業株式会社 | 芳香環化合物 |
WO2013125732A1 (en) | 2012-02-24 | 2013-08-29 | Takeda Pharmaceutical Company Limited | Aromatic ring compound |
WO2013147026A1 (ja) | 2012-03-29 | 2013-10-03 | 武田薬品工業株式会社 | 芳香環化合物 |
WO2013168759A1 (ja) | 2012-05-10 | 2013-11-14 | 武田薬品工業株式会社 | 芳香環化合物 |
WO2013168760A1 (ja) | 2012-05-10 | 2013-11-14 | 武田薬品工業株式会社 | 芳香環化合物 |
JP2015523339A (ja) * | 2012-05-30 | 2015-08-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新しいインダニルオキシフェニルシクロプロパンカルボン酸 |
WO2013183784A1 (en) | 2012-06-05 | 2013-12-12 | Takeda Pharmaceutical Company Limited | Solid preparation |
WO2014011926A1 (en) | 2012-07-11 | 2014-01-16 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
WO2014022528A1 (en) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
US9527875B2 (en) | 2012-08-02 | 2016-12-27 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
JP2018184454A (ja) * | 2012-11-09 | 2018-11-22 | エルジー・ケム・リミテッド | Gpr40受容体アゴニスト、この製造方法およびこれを活性成分として含有する医薬組成物 |
JP2016503409A (ja) * | 2012-11-09 | 2016-02-04 | エルジー・ライフ・サイエンシーズ・リミテッドLG Life Sciences Ltd. | Gpr40受容体アゴニスト、この製造方法およびこれを活性成分として含有する医薬組成物 |
JP2016505551A (ja) * | 2012-12-07 | 2016-02-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規インダニルオキシジヒドロベンゾフラニル酢酸 |
WO2014130608A1 (en) | 2013-02-22 | 2014-08-28 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
US9840512B2 (en) | 2013-02-22 | 2017-12-12 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2014142363A1 (en) | 2013-03-14 | 2014-09-18 | Takeda Pharmaceutical Company Limited | Spiro azetidine isoxazole derivatives and their use as sstr5 antagonists |
US10005720B2 (en) | 2013-04-05 | 2018-06-26 | North Carolina Central University | Compounds useful for the treatment of metabolic disorders and synthesis of the same |
WO2015005489A1 (en) | 2013-07-09 | 2015-01-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
WO2015020184A1 (ja) | 2013-08-09 | 2015-02-12 | 武田薬品工業株式会社 | 芳香環化合物 |
WO2015052910A1 (en) | 2013-10-07 | 2015-04-16 | Takeda Pharmaceutical Company Limited | Antagonists of somatostatin receptor subtype 5 (sstr5) |
US9932311B2 (en) | 2013-10-08 | 2018-04-03 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
WO2015051725A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
WO2015062486A1 (en) * | 2013-10-31 | 2015-05-07 | Sunshine Lake Pharma Co., Ltd. | Biphenyl compounds and uses thereof |
US10519115B2 (en) | 2013-11-15 | 2019-12-31 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
US20160280626A1 (en) * | 2013-12-04 | 2016-09-29 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
US9957219B2 (en) | 2013-12-04 | 2018-05-01 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2015095256A1 (en) | 2013-12-19 | 2015-06-25 | Merck Sharp & Dohme Corp. | Antidiabetic substituted heteroaryl compounds |
EP3974413A1 (en) | 2013-12-19 | 2022-03-30 | Merck Sharp & Dohme Corp. | Antidiabetic substituted heteroaryl compounds |
US9834563B2 (en) | 2013-12-19 | 2017-12-05 | Merck Sharp & Dohme Corp. | Antidiabetic substituted heteroaryl compounds |
US10059667B2 (en) | 2014-02-06 | 2018-08-28 | Merck Sharp & Dohme Corp. | Antidiabetic compounds |
WO2015122187A1 (en) | 2014-02-13 | 2015-08-20 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
WO2015122188A1 (en) | 2014-02-13 | 2015-08-20 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
WO2015176640A1 (en) | 2014-05-22 | 2015-11-26 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
US10000454B2 (en) | 2014-05-22 | 2018-06-19 | Merck Sharp & Dohme | Antidiabetic tricyclic compounds |
US10100042B2 (en) | 2014-08-08 | 2018-10-16 | Merck Sharp & Dohme Corp. | [5,6]—fused bicyclic antidiabetic compounds |
US10131651B2 (en) | 2014-08-08 | 2018-11-20 | Merck Sharp & Dohme Corp. | [7,6]-fused bicyclic antidiabetic compounds |
US10968193B2 (en) | 2014-08-08 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2016022448A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
US10662171B2 (en) | 2014-08-08 | 2020-05-26 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2016022446A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [5,6]-fused bicyclic antidiabetic compounds |
WO2016019863A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [7,6]-fused bicyclic antidiabetic compounds |
WO2016022742A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
JP2018526352A (ja) * | 2015-08-07 | 2018-09-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | インダニルアミノピリジルシクロプロパンカルボン酸、医薬組成物及びこれらの使用 |
JP2018526405A (ja) * | 2015-09-09 | 2018-09-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | [{[2,3−ジヒドロ−1H−インデン−1−イル]アミノ}−2H,3H−フロ[3,2−b]ピリジン−3−イル]酢酸、それらの医薬組成物および使用 |
US11583528B2 (en) | 2016-02-17 | 2023-02-21 | Children's Medical Center Corporation | FFA1 (GPR40) as a therapeutic target for neural angiogenesis diseases or disorders |
US10676458B2 (en) | 2016-03-29 | 2020-06-09 | Merch Sharp & Dohne Corp. Rahway | Antidiabetic bicyclic compounds |
JP7050797B2 (ja) | 2016-10-25 | 2022-04-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベンジルアミノピリジルシクロプロパンカルボン酸、その医薬組成物および使用 |
JP2019532110A (ja) * | 2016-10-25 | 2019-11-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベンジルアミノピリジルシクロプロパンカルボン酸、その医薬組成物および使用 |
US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
US11225472B2 (en) | 2016-12-15 | 2022-01-18 | Il Dong Pharmaceutical Co., Ltd. | Phenyl propionic acid derivatives and uses thereof |
US11731961B2 (en) | 2016-12-15 | 2023-08-22 | Ildong Pharmaceutical Co., Ltd. | Phenyl propionic acid derivatives and uses thereof |
JP2020502111A (ja) * | 2016-12-15 | 2020-01-23 | イルドン ファーマシューティカル カンパニー リミテッド | 新規フェニルプロピオン酸誘導体及びその用途 |
US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
US10793530B2 (en) | 2017-01-26 | 2020-10-06 | Boehringer Ingelheim International Gmbh | Benzylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
JP7023969B2 (ja) | 2017-01-26 | 2022-02-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベンジルアミノピリジルシクロプロパンカルボン酸、その医薬組成物及び使用 |
US10603317B2 (en) | 2017-01-26 | 2020-03-31 | Boehringer Ingelheim International Gmbh | Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
US10913720B2 (en) | 2017-01-26 | 2021-02-09 | Boehringer Ingelheim International Gmbh | Benzyloxypyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
US10919859B2 (en) | 2017-01-26 | 2021-02-16 | Boehringer Ingelheim International Gmbh | Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
JP2020505400A (ja) * | 2017-01-26 | 2020-02-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベンジルアミノピリジルシクロプロパンカルボン酸、その医薬組成物及び使用 |
JP7049353B2 (ja) | 2017-02-08 | 2022-04-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糖尿病の治療のためのインダニルアミノアザジヒドロベンゾフラニル酢酸、医薬組成物 |
JP2020506205A (ja) * | 2017-02-08 | 2020-02-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糖尿病の治療のためのインダニルアミノアザジヒドロベンゾフラニル酢酸、医薬組成物 |
US10550127B1 (en) | 2017-02-08 | 2020-02-04 | Boehringer Ingelheim International Gmbh | Indanylaminoazadihydrobenzofuranylacetic acids, pharmaceutical compositions for the treatment of diabetes |
WO2018182051A1 (en) | 2017-03-30 | 2018-10-04 | Takeda Pharmaceutical Company Limited | Ip6k inhibitors |
WO2018182050A1 (en) | 2017-03-31 | 2018-10-04 | Takeda Pharmaceutical Company Limited | Substituted cyclyl-acetic acid derivatives for the treatment of metabolic disorders |
WO2018181864A1 (en) | 2017-03-31 | 2018-10-04 | Takeda Pharmaceutical Company Limited | Gip receptor activating peptide |
WO2018181847A1 (ja) | 2017-03-31 | 2018-10-04 | 武田薬品工業株式会社 | 芳香環化合物 |
US11225471B2 (en) | 2017-11-16 | 2022-01-18 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2019134984A1 (en) | 2018-01-08 | 2019-07-11 | Celon Pharma S.A. | 3-phenyl-4-hexynoic acid derivatives as gpr40 agonists |
US11535660B1 (en) | 2018-03-23 | 2022-12-27 | Cannot Therapeutics, Inc. | Modulators of G-protein coupled receptors |
WO2020045326A1 (ja) | 2018-08-27 | 2020-03-05 | 株式会社スコヒアファーマ | 安息香酸エステル化合物 |
WO2020067575A1 (en) | 2018-09-24 | 2020-04-02 | Takeda Pharmaceutical Company Limited | Gip receptor agonist peptide compounds and uses thereof |
WO2020067557A2 (en) | 2018-09-24 | 2020-04-02 | Takeda Pharmaceutical Company Limited | Gip receptor agonist peptide compounds and uses thereof |
WO2021193983A2 (en) | 2020-03-25 | 2021-09-30 | Takeda Pharmaceutical Company Limited | Qw dosing of gip receptor agonist peptide compounds and uses thereof |
WO2021193984A2 (en) | 2020-03-25 | 2021-09-30 | Takeda Pharmaceutical Company Limited | Qd dosing of gip receptor agonist peptide compounds and uses thereof |
WO2022053013A1 (zh) | 2020-09-10 | 2022-03-17 | 上海爱博医药科技有限公司 | 苯并含氧杂环类化合物及其医药应用 |
WO2022241287A2 (en) | 2021-05-13 | 2022-11-17 | Carmot Therapeutics, Inc. | Modulators of g-protein coupled receptors |
WO2023169456A1 (en) | 2022-03-09 | 2023-09-14 | Gasherbrum Bio , Inc. | Heterocyclic glp-1 agonists |
WO2023179542A1 (en) | 2022-03-21 | 2023-09-28 | Gasherbrum Bio , Inc. | 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes |
WO2023198140A1 (en) | 2022-04-14 | 2023-10-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
WO2024125602A1 (en) | 2022-12-15 | 2024-06-20 | Gasherbrum Bio, Inc. | Salts and solid forms of a compound having glp-1 agonist activity |
WO2024138048A1 (en) | 2022-12-22 | 2024-06-27 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
WO2024131869A1 (en) | 2022-12-22 | 2024-06-27 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
WO2024169952A1 (en) | 2023-02-16 | 2024-08-22 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
Also Published As
Publication number | Publication date |
---|---|
JPWO2005087710A1 (ja) | 2008-01-24 |
US20080269220A1 (en) | 2008-10-30 |
EP1726580A1 (en) | 2006-11-29 |
US7786165B2 (en) | 2010-08-31 |
EP1726580A4 (en) | 2008-02-13 |
CA2560111A1 (en) | 2005-09-22 |
JP4875978B2 (ja) | 2012-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005087710A1 (ja) | アミノフェニルプロパン酸誘導体 | |
JP4855777B2 (ja) | フェニルプロパン酸誘導体 | |
JP6121339B2 (ja) | 芳香環化合物 | |
JP4859665B2 (ja) | アルコキシフェニルプロパン酸誘導体 | |
US7456218B2 (en) | 3-(4-benzyloxyphenyl) propanoic acid derivatives | |
JP5657578B2 (ja) | 新規な縮合環化合物およびその用途 | |
CN110049984B (zh) | 苯基丙酸衍生物及其用途 | |
WO2004106276A1 (ja) | 縮合環化合物 | |
WO2013122028A1 (ja) | 芳香環化合物 | |
ZA200600819B (en) | Cycloalkylidene compounds as modulators of estrogen receptor | |
JP4805552B2 (ja) | 縮合環化合物 | |
JP4074616B2 (ja) | 3−(4−ベンジルオキシフェニル)プロパン酸誘導体 | |
KR20070018827A (ko) | 3-(4-벤질옥시페닐)프로판산 유도체 | |
MXPA06006597A (en) | 3-(4-benzyloxyphenyl)propanoic acid derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006511072 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10592789 Country of ref document: US Ref document number: 2005721059 Country of ref document: EP Ref document number: 2560111 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2005721059 Country of ref document: EP |